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Damage to both mitochondria and the endoplasmic reticulum (ER) involving ER stress 
and the unfolded protein response (UPR) are characteristic features in amyotrophic 
lateral sclerosis (ALS). However, how these two pathological features might be linked 
in a common disease pathway is unclear. Approximately 5-20% of the mitochondrial 
surface is closely apposed to ER and tethers linking the two organelles can be visualised 
via electron microscopy. These regions mediate a number of physiological processes 
including Ca2+ and phospholipid exchange between ER and mitochondria, ER and 
mitochondrial stress responses and apoptosis. Moreover, defects in ER-mitochondria 
associations are now known to contribute to neurodegenerative diseases. To properly 
investigate the role of ER-mitochondria associations in physiological processes and 
disease situations, the identity of the molecular tethers that physically link ER with 
mitochondria needs to be established. Previous work from our research group identified 
the outer mitochondrial membrane protein, protein tyrosine phosphatase-interacting 
protein 51 (PTPIP51) as a binding partner for the resident ER protein vesicle-associated 
membrane protein-associated protein-B (VAPB). As such, VAPB and PTPIP51 
represent plausible candidates for mediating ER-mitochondria associations. In order to 
test this possibility, ER and mitochondria associations were quantified following the 
experimental manipulation of VAPB and/or PTPIP51 expression. The results strongly 
support a role for VAPB and PTPIP51 in controlling ER-mitochondria associations. 
 
TAR DNA-binding protein-43 (TDP-43) is strongly linked to ALS and mutations in 
TARDBP, the gene encoding TDP-43, are the cause of some familial forms of the 
disease. The effects of TDP-43 expression on ER-mitochondria associations and 
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binding of VAPB to PTPIP51 were investigated. The results showed that both wild-type 
and ALS mutant TDP-43 disrupt ER-mitochondria associations and that this is 
accompanied by decreased binding of VAPB to PTPIP51. Mutations in the genes 
encoding fused in sarcoma (FUS) and Cu/Zn superoxide dismutase-1 (SOD1) also cause 
some familial forms of ALS and preliminary investigations revealed that FUS but not 
SOD1 also decreases VAPB-PTPIP51 interactions. 
 
Finally, the mechanisms that regulate binding of VAPB to PTPIP51 were investigated. 
Phosphorylation is known to influence protein-protein interactions and phosphorylation 
sites in VAPB and PTPIP51 were identified by mass spectrometry. However, mutation 
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1.1 Motor neuron diseases and amyotrophic lateral sclerosis 
Motor neuron diseases are a group of neurological disorders characterized by 
progressive muscle weakness and/or spasticity that are caused by selective degeneration 
of lower motor neurons (LMN) and/or upper motor neurons (UMN). These include 
amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), spinal bulbar 
muscular atrophy (SBMA), hereditary spastic paraplegia (HSP), primary lateral 
sclerosis (PLS) and lethal congenital contracture syndrome (LCCS) (Dion et al., 2009) 
(Table 1.1). 
 
The most prevalent motor neuron disease is ALS, a devastating adult-onset 
neurodegenerative disease initially described by the 19th century neurologist Jean-
Martin Charcot. The name stems from his observation of a characteristic “myelin 
pallor” in the lateral portions of the spinal cord, corresponding to the loss of descending 
UMN axons (“lateral sclerosis”). “Amyotrophy” refers to muscle fibre atrophy after 
losing the neuronal input from the anterior horn of the spinal cord. The disease affects 
both LMN and UMN and is usually fatal within 3 years from symptom onset when 
denervation of respiratory muscles occurs (Hardiman et al., 2011).  
 
1.1.1 Epidemiology 
ALS incidence averages 2.13 cases per 100,000 population and most reports suggest a 
uniform distribution across Western countries (Logroscino et al., 2011; Wolfson et al., 
2009). The overall lifetime risk of developing the disease is 1:400 and the mean age of 
onset is around 60 years with a slight male predominance (male:female ratio is 
approximately 1.5:1) (Alonso et al., 2009; Manjaly et al., 2010).  
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Disease Motor neuron 
involvement 
Clinical features 
ALS UMN+LMN Progressive muscle atrophy and spasticity 
HSP UMN Progressive spasticity in the lower extremity 
PLS UMN Spinal and bulbar spasticity 
SMA LMN Symmetrical muscle weakness and atrophy 
SBMA LMN Slowly progressive limb and bulbar muscle weakness 
and muscle atrophy 
LCCS UMN+LMN Fetal hydrops and akinesia, degeneration of anterior horn 
motor neurons and skeletal muscle atrophy 
 
Table 1.1 Classification of motor neuron diseases 
 
1.1.2 Clinical aspects and current treatments 
Since there is no established biological marker for ALS, the diagnosis is based almost 
entirely on characteristic clinical findings. In 1994, the World Federation of Neurology 
developed the “El Escorial” diagnostic criteria (Brooks, 1994) which were revised in 
2000 (Brooks et al., 2000) and 2006 to include electrophysiological criteria that 
facilitate a more secure diagnosis (de Carvalho et al., 2008) (Figure 1.1). Symptom 
onset is usually asymmetrical and the initial clinical presentation depends on the sites 
affected first in the neuraxis. The neurological examination usually reveals a 
combination of UMN and LMN dysfunction, for example spasticity combined with 
flaccid paralysis and fasciculation. The dysfunctions will spread to contiguous anatomic 
regions producing increasingly diffuse and symmetrical phenotypes. The progression 
rate is linear within each individual but it can vary from 1 year to over 10 years between 
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different patients (Ravits and La Spada, 2009). In addition to motor symptoms, half of 
the ALS patients develop various levels of cognitive, behavioural or executive function 
impairment (Lomen-Hoerth et al., 2003). Moreover, it is now recognized that 15% of 
ALS patients meet criteria for frontotemporal dementia (FTD), a condition 
characterized by personality change, poor insight and irritability (Ringholz et al., 2005). 
This is consistent with a long known neuropathological overlap between ALS and FTD 
(Wightman et al., 1992), a link strengthened by recent key findings (see for reviews 
(Morris et al., 2012; Rademakers et al., 2012)). These neuropathological findings, 
discussed in greater detail below (see Section 1.1.3), prompt the need for new 
diagnostic approaches and disease classification. 
 
Despite significant advances on the understanding of ALS disease mechanisms, the 
therapeutic options for ALS remain limited. The only approved disease modifying 
medication is riluzole, a compound with a modest effect on disease progression and 
survival (Bensimon et al., 1994; Miller et al., 2012). Measures aimed at symptom 
control and quality of life preservation include pain management, treatment of 
spasticity, enteral tube feeding and respiratory support for advanced stages (Hardiman et 
al., 2011). Several therapeutic compounds such as antioxidants, ciliary neurotrophic 
growth factor, insulin-like growth factor I or more recently lithium carbonate were 
tested in clinical trials but they have failed so far to show any significant benefits 


















Figure 1.1 The Awaji-shima diagnosis criteria (de Carvalho et al., 2008) 
 
1.1.3 Pathology of ALS 
The classic pathological hallmarks of ALS are the degeneration and loss of motor 
neurons together with astrocytosis and intracellular aggregates in degenerating motor 
neurons and glia. UMN pathology is characterized by the loss of Betz cells and 
astrocytosis in the motor cortex accompanied by axonal loss and myelin pallor within 
the descending pyramidal motor pathway (Hammer et al., 1979; Kamo et al., 1987; 
Oyanagi et al., 1995). LMN pathology affects the ventral horn of the spinal cord and the 
motor neurons in the brainstem. Autopsy findings include a reduced number of LMN 
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neurons are atrophic and contain 3 types of intraneuronal inclusions: Bunina bodies, 
neurofilament accumulations and ubiquitinated inclusions. 
 
Bunina bodies are cytoplasmic eosinophilic inclusions initially described by the Russian 
neuropathologist Bunina who suspected them to be the sign of a viral infection (Bunina, 
1962). Found mostly in the remaining LMN, Bunina bodies are present in 
approximately 85% of ALS cases and are generally considered a specific pathologic 
finding (Piao et al., 2003). They are thought to be of lysosomal origin and are seen more 
frequently in patients with shorter disease durations and patients with dementia and 
ALS (Okamoto et al., 2008). Cystatin C, transferrin and more recently peripherin have 
been identified as major components of these inclusions but despite numerous 
investigations, their origin and significance are still unclear (Mizuno et al., 2006; 
Mizuno et al., 2011; Okamoto et al., 1993). 
 
Another long known feature of ALS is the accumulation of phosphorylated 
neurofilaments and peripherin in affected motor neuron perikarya and their proximal 
axons (Carpenter, 1968; Corbo and Hays, 1992; Hirano et al., 1984; Munoz et al., 
1988). However, these inclusions are not specific to ALS, since aberrant accumulation 
of neurofilaments occurs in other neurodegenerative diseases including Parkinson’s 
disease, dementia with Lewy bodies, Alzheimer’s disease and progressive supranuclear 
palsy (Al-Chalabi and Miller, 2003). The association with other conditions suggests 
they might play a role in disease pathogenesis, a hypothesis supported by the finding 
that point mutations in the light neurofilament subunit gene cause forms of the sensory 
and motor neuropathy Charcot-Marie-Tooth disease (Mersiyanova et al., 2000). 
Interestingly, modulation of neurofilament expression in ALS transgenic mice can alter 
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the disease course and mutations of the neurofilament heavy chain gene have been 
proposed as risk factors for ALS (Al-Chalabi et al., 1999; Figlewicz et al., 1994; 
Tomkins et al., 1998). Furthermore, neurofilament accumulations have also been linked 
with slowed neurofilament transport through axons, which is caused by glutamate-
induced phosphorylation and rescued by riluzole (Ackerley et al., 2000; Stevenson et 
al., 2009). 
 
The third pathological hallmark of ALS is the presence of ubiquitin-positive inclusions 
in affected motor neurons (see Figure 1.2). These probably indicate the cell’s effort to 
label damaged proteins for proteasomal degradation (Leigh et al., 1988; Lowe et al., 
1989). Interestingly, ubiquitinated inclusions are also a common finding in tau-negative 
frontotemporal lobar degeneration (FTLD), a condition clinically overlapping with 
ALS, suggesting a common underlying pathophysiology (Shi et al., 2005). This link 
remained unknown until recently, when transactive response DNA binding protein 43 
(TDP-43) was identified as a major component of these inclusions in most ALS and 
FTLD cases (Arai et al., 2006; Neumann et al., 2006). This seminal discovery prompted 
the reconsideration of these disorders as a clinicopathological spectrum and led to the 
development of a new classification system for FTLD and ALS (Mackenzie et al., 
2010). Interestingly, TDP-43 pathology has also been detected in Alzheimer’s disease 
cases (Amador-Ortiz et al., 2007) and in disorders such as Huntington disease, 
corticobasal degeneration and dementia with Lewy bodies, suggesting it might play a 
more general role in the neurodegenerative process (Chen-Plotkin et al., 2010). 
 
However, a notable exception from TDP-43 pathology is familial ALS caused by 
mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene, characterized by ubiquitin 
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inclusions that are largely negative for TDP-43 but positive for SOD1, possibly 
indicating a different pathogenic mechanism (Mackenzie et al., 2007). TDP-43 
inclusions are also absent in a subset of familial ALS cases associated with mutations in 
the fused in sarcoma (FUS) gene, where intracytoplasmic FUS aggregates are observed 
(Kwiatkowski et al., 2009; Vance et al., 2009). FUS inclusions have subsequently been 
detected in many non-SOD1 ALS cases, indicating an involvement in the pathogenic 
cascade (Deng et al., 2010). 
 
Optineurin, another protein recently linked to ALS was reported to form inclusions in 
TDP-43, FUS and SOD1 cases and in several other neurodegenerative disorders (Ito et 
al., 2011b; Maruyama et al., 2010; Osawa et al., 2011). However, a different group 
identified it in only a minority of TDP-43 positive cases (Hortobagyi et al., 2012) 
making its significance difficult to assess. 
 
Finally, recent studies have shown that a large proportion of familial ALS and related 
FTLD are caused by a GGGGCC repeat expansion within the C9ORF72 gene (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Although ubiquitin and p62 positive TDP-
43 inclusions have been identified in these cases, some of the ubiquitin/p62 inclusions 
do not label for TDP-43, thus suggesting the presence of another pathological protein 
(Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; Stewart et al., 2012). 
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 Figure 1.2 Pathological protein aggregates in sporadic and familial ALS 
 
1.2 ALS genetics –overview 
 Although the cause of ALS is unknown, it is likely the result of a complex interplay 
between genetic and environmental factors. Most cases occur in an apparently random 
manner and are termed sporadic ALS, while around 5-10% of patients have a family 
history and show a Mendelian pattern of inheritance (Byrne et al., 2011). Familial ALS 
is genetically heterogeneous and a complete list of the causative mutations identified to 
date is available in the ALS Online Database (http://alsod.iop.kcl.ac.uk/). Interestingly, 
most mutations are also found in a subset of the apparently sporadic cases, indicating an 
underestimation of the genetic involvement in ALS (Andersen and Al-Chalabi, 2011). 
Since sporadic and familial ALS are clinically indistinguishable, motor neuron demise 
likely occurs through common molecular pathways and insights into the known gene 
mutations are believed to advance the understanding of sporadic disease. 
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The number of known ALS-associated mutations has increased dramatically since the 
first reports of families carrying pathogenic variants of SOD1 almost two decades ago 
(Rosen et al., 1993). Interestingly, mutations in C9ORF72, TDP-43, FUS, UBQLN2 
and valosin-containing protein (VCP) were found to be responsible for both ALS and 
FTLD cases and this is consistent with the previously documented overlap between the 
two disorders (Deng et al., 2011; Johnson et al., 2010; Kwiatkowski et al., 2009; Seelaar 
et al., 2007; Sreedharan et al., 2008; Vance et al., 2009). These compelling clinical, 
pathological and genetic findings have produced a paradigm shift in the understanding 
of ALS and FTLD, which are now considered part of a disease continuum. Another 
piece of the puzzle was the linkage to chromosome 9p observed in a subset families 
with ALS, FTLD or both (Morita et al., 2006; Valdmanis et al., 2007; Vance et al., 
2006). However, the underlying genetic defect remained unknown until two groups 
identified it as a GGGGCC repeat expansion in a non-coding region of the 
uncharacterized gene C9ORF72 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
The repeat expansion is accountable for 39% of familial ALS cases and 4-7% of 
sporadic cases, making it the most prevalent genetic cause of ALS to date (Majounie et 
al., 2012). 
 
The work in this thesis involves four proteins where mutants have been shown to cause 
ALS. These are SOD1, TDP-43, FUS and vesicle-associated membrane protein-
associated protein B (VAPB). These proteins and their links to ALS are thus described 
in more detail below.  
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1.2.1 SOD1 and ALS 
The first genetic defects associated with ALS were identified in the Cu/Zn superoxide 
dismutase (SOD1) gene in 1993 (Rosen et al., 1993). These account for approximately 
20% of familial ALS and a small percentage of the sporadic cases (Millecamps et al., 
2010) and until recently, SOD1 was believed to be the most common genetic cause for 
ALS . The identification of mutations in SOD1 facilitated the creation of the first 
transgenic ALS mouse models, which recapitulate the rapidly progressive motor neuron 
degeneration seen in human patients (Gurney et al., 1994). 
 
SOD1 is a ubiquitously expressed antioxidant enzyme, which converts superoxide 
radicals to hydrogen peroxide and molecular oxygen. The protein is encoded by a single 
gene on chromosome 21 and to date, 166 different mutations have been reported 
involving most of its 153 amino acids (Andersen and Al-Chalabi, 2011). It was first 
hypothesised that loss of its dismutase activity might lead to motor neuron degeneration, 
but a number ALS mutants have been shown to maintain a normal enzymatic activity 
(Borchelt et al., 1994). Moreover, analyses of transgenic mice that express mutant 
SOD1 have provided strong evidence that the toxicity is not via a loss of SOD1 activity 
(Bruijn and Cleveland, 1996). If loss of SOD1 activity was responsible for the observed 
ALS phenotype, then manipulating this activity would be predicted to alter disease 
onset and/or progression. However, crossing of mutant SOD1 mice with mice 
overexpressing wild-type SOD1 or in which the wild-type SOD1 gene has been ablated 
does not alter disease onset or progression (Bruijn et al., 1998). These results suggest 
that the toxicity of mutant SOD1 involves a novel toxic gain of function. The nature of 
this toxicity is still not clear but there is evidence for several mechanisms. These include 
oxidative damage, accumulation of intracellular aggregates, mitochondrial dysfunction, 
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growth factor deficiency, astroglial cell pathology, glutamate excitotoxicity, ER stress 
and damage to axonal transport (see for review (Rothstein, 2009)). 
 
Although SOD1 is ubiquitously expressed, its pathogenic effect was thought to occur 
strictly within motor neurons. This view was challenged by analyses of transgenic mice 
with mutant SOD1 expression restricted to neurons or astrocytes, which failed to 
develop disease (Gong et al., 2000; Pramatarova et al., 2001). Furthermore, pathogenic 
SOD1 expression in motor neurons surrounded by a wild-type environment prolonged 
their survival, while normal motor neurons surrounded by mutant SOD1 nonneuronal 
cells developed ALS pathology (Clement et al., 2003; Yamanaka et al., 2008). These 
studies have provided evidence that motor neuron degeneration is a non-cell 
autonomous process or in other words, SOD1 toxicity in nonneuronal cells contributes 
to the pathogenic cascade. To identify the contributing cells, mice expressing a deletable 
SOD1 gene were designed. Diminishing mutant SOD1 levels within motor neurons 
increased survival by delaying disease onset and early progression. Conversely, 
excising the mutant SOD1 gene in microglia or astrocytes had little effect on the early 
disease, but sharply slowed disease progression and increased overall survival (Beers et 
al., 2006; Boillee et al., 2006; Yamanaka et al., 2008). Surprisingly, selective reduction 
of mutant SOD1 in Schwann cells had the opposite effect, significantly accelerating the 
late phase of the disease (Lobsiger et al., 2009). 
 
Finally, skeletal muscle pathology in ALS was long considered a secondary event. 
However, mutant SOD1 expression restricted to skeletal muscle is sufficient to cause 
muscle atrophy and motor neuron degeneration (Dobrowolny et al., 2008; Wong and 
Martin, 2010). 
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 Despite the significant progress made since its discovery, the exact pathogenic 
mechanisms underlying SOD1 toxicity as well as the initial toxic events have yet to be 
established. 
 
1.2.2 TDP-43 and ALS 
Our understanding of ALS pathology was significantly advanced after TDP-43 was 
identified as the major component of ubiquitin inclusions in most ALS and FTLD cases 
(Arai et al., 2006; Neumann et al., 2006). This result highlighted a possible role for 
TDP-43 in disease pathogenesis, confirmed by the finding that missense mutations in 
TARDBP, the gene encoding TDP-43, cause familial forms of ALS (Kabashi et al., 
2008; Sreedharan et al., 2008). To date, over 44 mutations in TARDBP have been found 
and these account for approximately 5% of familial ALS cases (Millecamps et al., 
2010). These are characterized by earlier, predominantly upper limb onset and longer 
disease duration compared to sporadic ALS (Corcia et al., 2012). 
 
TARDBP encodes TDP-43, a highly conserved, ubiquitously expressed 414 amino acid 
protein, initially identified to bind TAR DNA, a regulatory element of HIV-1 (Ou et al., 
1995). The protein is predominantly localized to the nucleus and contains two RNA 
recognition motifs and a glycine rich domain which facilitates binding to nucleic acids 
and ribonuclear proteins (Wang et al., 2004). The C-terminal glycine-rich domain 
harbours the majority of ALS associated mutations, which induce fragmentation and 
mislocalization of TDP-43 to the cytoplasm, where it forms ubiquitinated aggregates 
(Neumann et al., 2006). Moreover, nuclear TDP-43 depletion in cells with cytoplasmic 
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aggregates has been observed and lead to the hypothesis that TDP-43 toxicity may be 
caused by a loss of its nuclear function. 
 
TDP-43 functions include regulation of mRNA alternative splicing and transcription 
(Ayala et al., 2008; Buratti and Baralle, 2008), mRNA stabilization and transport 
(Volkening et al., 2009) and formation of RNA stress granules (Colombrita et al., 
2009). A recent study characterizing the RNA targets of TDP-43 found several mRNA 
isoforms that encode proteins relevant for neurological diseases and normal 
development (Tollervey et al., 2011). TDP-43 knockout mice die early in the embryonic 
stage and suggest a critical developmental role for this protein (Sephton et al., 2010). To 
circumvent this, conditional knockout mice have been created and a recent report 
describes an ALS-like phenotype in mice with post-natal TDP-43 inactivation targeted 
to the spinal cord motor neurons (Wu et al., 2012). 
 
Overexpression of wild-type TDP-43 has consistently been found to be toxic in most 
transgenic mouse models (Shan et al., 2010; Tsai et al., 2010; Wils et al., 2010; Xu et 
al., 2010). The observed phenotypes include motor abnormalities, growth retardation, 
cognitive impairment or early lethality and can vary greatly according to the promoter 
used and the TDP-43 expression levels (Da Cruz and Cleveland, 2011). Mice 
overexpressing ALS-associated TDP-43 mutants have also been created and they 
exhibit a similar progressive motor phenotype and reduced survival (Stallings et al., 
2010; Wegorzewska et al., 2009; Xu et al., 2011b). Both wild-type and mutant 
transgenic mice are characterized by a selective loss of neurons in the frontal cortex and 
the anterior horn of the spinal cord, accompanied by ubiquitin aggregates and reactive 
gliosis (Da Cruz and Cleveland, 2011). Although these clinical and pathological 
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features are reminiscent of both ALS and FTD, it is difficult to differentiate between 
mutant and wild-type TDP-43 toxicity. Moreover, it is currently unclear whether TDP-
43 is inducing motor neuron degeneration through a loss of function, through a toxic 
gain of function or both. 
 
1.2.3 FUS and ALS 
Shortly after the discovery of TDP-43 involvement in ALS, mutations in the fused in 
sarcoma (FUS) gene, encoding another RNA/DNA binding protein, were identified in 
ALS families (Kwiatkowski et al., 2009; Vance et al., 2009). So far, 42 different FUS 
pathogenic mutations have been reported and these account for 4-6% of familial ALS 
cases (Andersen and Al-Chalabi, 2011). The associated phenotype is consistent with a 
predominantly LMN involvement, early disease onset and rapid progression 
(Millecamps et al., 2010). 
 
FUS, also known as translocated in liposarcoma (TLS), is a ubiquitously expressed 526 
amino acid protein originally described as a component of fusion oncogenes in human 
cancer (Rabbitts et al., 1993). It contains an N-terminal Gln-Gly-Ser-Tyr-rich domain, a 
Gly-rich domain, an RNA recognition motif, multiple Arg-Gly-Gly repeats and a C-
terminal zinc finger motif (Lagier-Tourenne and Cleveland, 2009). Most pathogenic 
mutations are missense and cluster in the extreme C-terminus of the protein, a highly 
conserved region functioning as a nuclear localization signal (Mackenzie et al., 2010; 
Zakaryan and Gehring, 2006). Although the protein resides mainly in the nucleus, 
analyses of brains and spinal cords from patients with FUS mutations reveals loss of 
nuclear FUS and ubiquitinated cytoplasmic inclusions positive for FUS, but negative for 
TDP-43 (Tateishi et al., 2010; Vance et al., 2009). 
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 FUS is an RNA binding protein with structure and functions similar to TDP-43, raising 
the possibility that RNA misprocessing is a key feature in motor neuron degeneration. 
The protein shuttles between the nucleus and the cytoplasm (Zinszner et al., 1997) and 
is involved in cell proliferation, DNA repair, alternative splicing, transcription 
regulation, RNA and microRNA processing (Janknecht, 2005; Lagier-Tourenne et al., 
2010; Law et al., 2006). The FUS gene knockout in inbred mice causes perinatal death 
accompanied by major B lymphocyte defects (Hicks et al., 2000), while only male 
sterility was reported in FUS deficient mice on an outbred background (Kuroda et al., 
2000). 
 
Transgenic rats overexpressing ALS-associated mutant FUS develop progressive 
paralysis secondary to axonal degeneration and a significant loss of neurons in the 
frontal cortex and hippocampus recapitulating features of ALS and FTD (Huang et al., 
2011). Similar to TDP-43, expression of human wild-type FUS in rats is sufficient to 
induce cognitive deficits and mild neuronal loss at a more advanced age (Huang et al., 
2011). In both cases, neuronal loss is accompanied by FUS distribution to the 
cytoplasm, ubiquitin aggregation and reactive gliosis in the brain and spinal cord. 
Interestingly, a compound blocking glial inflammation managed to preserve the 
cognitive function of mutant FUS transgenic rats (Huang et al., 2012). 
 
In a recent study, mice expressing wild-type FUS develop progressive paralysis and 
death in a dose dependent manner and are characterized by loss of spinal motor neurons, 
muscle atrophy, astrogliosis and ubiquitin-negative cytoplasmic FUS inclusions 
(Mitchell et al., 2012). Although mutant FUS transgenic mice are not available yet, 
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these results suggest FUS could induce disease through a toxic gain of function in the 
cytoplasm. 
 
1.2.4 VAPB and ALS 
A dominant missense mutation causing a proline to serine substitution at residue 56 in 
the VAPB gene was initially identified in eight Brazilian families with phenotypes 
ranging from typical ALS to late-onset SMA (Nishimura et al., 2004). A further 
mutation causing a threonine to isoleucine change at position 46 has also been 
associated with ALS (Chen et al., 2010) (Figure 1.3). Interestingly, transgenic mice 
expressing VAPB P56S develop cytoplasmic TDP-43 accumulations in the spinal cord, 
but fail to develop overt motor neuron disease (Tudor et al., 2010). 
 
There are two VAP isoforms in mammals termed VAPA and VAPB that are encoded by 
different genes and which share approximately 63% sequence identity; both are 
expressed in most tissues and cell types including the nervous system (Amarilio et al., 
2005; Gkogkas et al., 2008; Kim et al., 2010a; Nishimura et al., 1999; Skehel et al., 
2000; Teuling et al., 2007). VAPB comprises an N-terminal major sperm protein (MSP) 
domain, named for its similarity to the nematode MSP, a central coiled-coil domain and 
a C-terminal transmembrane domain which anchors it in the ER membrane (Nishimura 
et al., 1999; Skehel et al., 2000; Soussan et al., 1999) (Figure 1.3). 
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 Figure 1.3 Schematic representation of VAPB structure showing protein domains and 
the localization of ALS-associated pathogenic mutations within the MSP domain 
 
The function of VAPB is not properly understood and it has been implicated in a variety 
of cellular processes. These include ER to Golgi transport (Amarilio et al., 2005), lipid 
transport and metabolism (Peretti et al., 2008), bouton formation at the neuromuscular 
junction and microtubule organisation (Pennetta et al., 2002), the unfolded protein 
response (UPR) in response to ER stress (Gkogkas et al., 2008; Kanekura et al., 2006; 
Langou et al., 2010; Suzuki et al., 2009) and signalling via ephrin receptors (Han et al., 
2012; Tsuda et al., 2008). Finally, VAPB has recently been shown to play a role in Ca2+ 
homeostasis (De Vos et al., 2012). To carry out these putative functions, VAPB 
interacts with several proteins including soluble N-ethylmaleimide-sensitive factor-
attached protein receptor (SNARE) proteins (Skehel et al., 1995), two phenylalanines 
(FF) in acidic tract (FFAT) motif-containing proteins (Amarilio et al., 2005), 
microtubules (Pennetta et al., 2002; Skehel et al., 2000), protein tyrosine phosphatase-
interacting protein 51 (PTPIP51) (De Vos et al., 2012), activating transcription factor 6 
(ATF6) (Gkogkas et al., 2008) and viral proteins (Hamamoto et al., 2005). 
 
VAPB was originally identified as binding partner for the synaptic vesicle SNARE 
protein vesicle-associated membrane protein (VAMP)/synaptobrevin in Aplysia 
californica and this suggests a role in vesicle trafficking (Skehel et al., 1995). Aside 
from this, several other lines of evidence indicate that VAPB is involved in the transport 
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of vesicles between ER and Golgi and in intra-Golgi transport. Transport through the 
Golgi apparatus and from the Golgi to ER is mediated by coat protein I (COPI)-coated 
vesicles (Letourneur et al., 1994; Orci et al., 1997). Vesicle transport from ER to Golgi 
is mediated by coat protein II (COPII)-coated vesicles via the ER-Golgi intermediate 
compartment (ERGIC) (Barlowe et al., 1994; Campbell and Schekman, 1997). VAPB 
co-localizes with COPI vesicles, ERGIC and the COPII vesicle marker secretion-
defective 23 (Sec23) (Moumen et al., 2011; Tran et al., 2012). In addition, VAPB also 
interacts with the FFAT motif-containing N-terminal domain-interacting receptor (Nir) 
proteins Nir2 and Nir3 (Amarilio et al., 2005; Loewen et al., 2003), and overexpression 
of VAPB and Nir2 causes remodelling of the ER and blocks protein export from the ER 
to the Golgi apparatus (Amarilio et al., 2005). Together, these findings support a role 
for VAPB in the regulation of vesicle trafficking. 
 
There is also evidence that VAPB is involved in lipid metabolism. Thus, VAPB binds to 
the FFAT motif-containing lipid transferring, binding and sensing proteins Nir2, 
oxysterol binding protein and ceramide transfer protein (Amarilio et al., 2005; Kawano 
et al., 2006; Loewen et al., 2003). The VAPB-FFAT motif interaction is essential for 
lipid transfer between the ER and Golgi, and also for lipid metabolism (Loewen et al., 
2003; Peretti et al., 2008). The VAPB homologue in yeast also binds to the FFAT motif 
containing protein overproducer of inositol 1 which functions to regulate transcription 
of genes involved in phospholipid synthesis (Gavin et al., 2002; Loewen et al., 2003). 
 
VAPB has also been implicated in microtubule organisation and in particular, 
microtubule regulation of bouton formation at the neuromuscular junction. Thus, VAPB 
interacts either directly or indirectly with microtubules (Amarilio et al., 2005; Pennetta 
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et al., 2002; Skehel et al., 2000). Via its interaction with microtubules, VAPB influences 
the neuromuscular junction structure in Drosophila melanogaster (Pennetta et al., 2002) 
and also ER structure in mammals (Amarilio et al., 2005). Also, via its binding to Nir3, 
VAPB modulates microtubule stability and overexpression of VAPB can induce 
rearrangement of the ER and microtubule networks (Amarilio et al., 2005). 
 
There is also strong evidence that VAPB plays a role in the UPR following ER stress. 
Increased protein trafficking through the ER or insults that affect protein folding in the 
ER lumen can lead to ER stress. To sense ER and respond to ER stress, eukaryotic 
organisms have evolved the UPR which activates pathways that include transcriptional 
changes to adjust the ER protein folding capacity and rectify the stress (Bernales et al., 
2006; Lin et al., 2008). There are three major branches to the UPR which involve 
different ER resident proteins. These proteins are inositol-requiring protein 1 (IRE1), 
double stranded RNA activated protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) and ATF6 (see Figure 1.3 page 58). These proteins all contain domains that 
protrude into the ER lumen so as to sense ER stress and also have cytosolic effector 
domains (Bernales et al., 2006; Lin et al., 2008). 
 
Although a number of lines of evidence suggest that VAPB functions in the UPR, the 
precise details are unclear. Thus, in some reports overexpression of VAPB promotes 
UPR and loss of VAPB blocks activation of UPR (Kanekura et al., 2006; Langou et al., 
2010; Moumen et al., 2011). Moreover, this role of VAPB in the UPR has been shown 
to involve IRE1 and X-box binding protein-1 (XBP1) signalling (Kanekura et al., 2006; 
Suzuki et al., 2009). By contrast, others have shown that VAPB binds to ATF6 and 
overexpression of VAPB blocks UPR via an effect on ATF6 (Gkogkas et al., 2008). 
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 Studies primarily conducted in Drosophila and C. elegans have provided evidence that 
VAPB is cleaved and a region containing the MSP and coiled-coil domains is then 
secreted to function as a ligand for some growth factor receptors (Han et al., 2012; 
Tsuda et al., 2008). These secreted VAPB domains function as ligands for ephrin 
receptors (EphR), sensory axon guidance-3 receptor Roundabout (SAX-3 Robo) 
receptors and caterpillar-like receptor-1 leukocyte common antigen-related-like (CLR-1 
Lar) receptors (Han et al., 2012; Tsuda et al., 2008). EphR, SAX-3 Robo and CLR-1 
Lar are located in neuronal growth cones and are involved in axon guidance (Chang et 
al., 2004; Sun et al., 2000; Wang and Anderson, 1997). Furthermore, Han and co-
workers have demonstrated that the secreted MSP domain of VAPB influences 
mitochondrial localization in striated muscles via SAX-3, Robo and CLR-1 Lar 
receptors (Han et al., 2012). 
 
Finally, recent work has provided evidence that VAPB is involved in intracellular Ca2+ 
homeostasis (De Vos et al., 2012; Langou et al., 2010). In particular VAPB has been 
shown to bind to the outer mitochondrial membrane protein PTPIP51 to regulate Ca2+ 
exchange between ER and mitochondria (De Vos et al., 2012). Both ER and 
mitochondria are Ca2+ stores and following release from the ER, Ca2+ can be taken up 
by mitochondria. The VAPB-PTPIP51 interaction has been shown to regulate Ca2+ 
exchange from ER to mitochondria after induction of inositol 1,4,5-trisphosphate 
receptor (IP3R)-mediated Ca2+ release from ER stores (De Vos et al., 2012). 
 
Since the functions of VAPB are not properly understood, the mechanisms by which 
ALS-associated VAPB P56S causes disease are also not clear. However, VAPB P56S 
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has been shown to aggregate and induce the formation of abnormal ER-derived 
inclusions (Fasana et al., 2010; Langou et al., 2010; Nishimura et al., 2004; Teuling et 
al., 2007; Tudor et al., 2010). The biological consequences of these inclusions and their 
relationship to the neurodegenerative process are unclear. In particular, the effect of 
VAPB P56S on UPR has generated conflicting results. Thus, in some reports, 
expression of VAPB induces UPR and VAPB P56S inhibits this process (Chen et al., 
2010; Kanekura et al., 2006; Suzuki et al., 2009). In another, expression of VAPB and 
VAPB P56S both inhibit UPR but VAPB P56S is more potent in this effect (Gkogkas et 
al., 2008). Finally, other studies have shown that VAPB and/or VAPB P56S can induce 
ER stress and UPR (Langou et al., 2010; Tsuda et al., 2008). Studies on the effect of 
VAPB P56S on Ca2+ homeostasis have provided more consistent results with two 
groups showing that VAPB P56S elevates intracellular Ca2+ levels (De Vos et al., 2012; 
Langou et al., 2010). Whether VAPB P56S induces disease via a loss or gain of 
function is thus unclear. VAPB P56S may inhibit VAPB function by sequestering wild-
type VAPB to the inclusions and preventing its interaction with other proteins 
(Kanekura et al., 2006; Mitne-Neto et al., 2007; Ratnaparkhi et al., 2008; Suzuki et al., 
2009; Teuling et al., 2008). Alternatively, VAPB P56S could be a toxic gain-of-function 
mutant because VAPB P56S overexpression has been shown to induce the UPR 
(Gkogkas et al., 2008; Tsuda et al., 2008). Support for a loss of function comes from the 
finding that VAPB levels are reduced in ALS spinal cord and also in motor neurons 
derived from induced pluripotent stem cell of patients that harbour the VAPB P56S 
mutation (Anagnostou et al., 2010; Mitne-Neto et al., 2007). 
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1.3 Neurodegeneration mechanisms in ALS  
Several mechanisms have been proposed to induce motor neuron degeneration in ALS 
and these have recently been reviewed (Ferraiuolo et al., 2011). They include 
glutamatergic excitotoxicity, oxidative stress, pathological protein aggregation, 
mitochondrial dysfunction, damage to RNA processing, axonal transport dysfunction 
and ER stress. None of these mechanisms are mutually exclusive and it is plausible that 
they all contribute to the disease process to some extent. In addition, it has become clear 
that ALS is not just a disease of motor neurons, but that other cell types such as 
astrocytes and microglia actively participate in the disease process (for review see 
(Ferraiuolo et al., 2011)). In the following section of this thesis, I discuss the evidence 
supporting the different pathogenic mechanisms. 
 
1.3.1 Excitotoxicity 
Glutamate is the major excitatory neurotransmitter in the central nervous system. After 
its release from the presynaptic terminal, it binds to and activates ionotropic and 
metabotropic receptors (Nicoletti et al., 2011; Traynelis et al., 2010). Glutamate is then 
re-internalized into either glia or neurons by re-uptake systems (Kanai and Hediger, 
2004), of which the astroglial excitatory amino acid transporter 2 (EAAT2) is the most 
common (Danbolt, 2001). Excessive activation of glutamate receptors is capable of 
inducing neuronal damage through a process called excitotoxicity, which can elicit an 
excessive Ca2+ influx and the activation of cell death programmes (Berliocchi et al., 
2005). Excitotoxicity is a well established pathogenic component in many neurological 




An early hint of glutamate metabolism disruption was the observation of elevated 
glutamate levels in the cerebrospinal fluid (CSF) of ALS patients (Rothstein et al., 
1990). Subsequently, a decreased EAAT2 activity was detected in ALS brain and spinal 
cord, raising the possibility that the increased glutamate levels reflected defective 
clearance of glutamate (Rothstein et al., 1992).  
 
Interestingly, the intrinsic properties of motor neurons make them especially vulnerable 
to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor 
mediated excitotoxicity (Carriedo et al., 1996; Van Den Bosch et al., 2000). First, motor 
neurons show a relative deficiency in the glutamate receptor-2 (GluR2) subunit, which 
normally regulates the AMPA receptor’s permeability to Ca2+ (Van Damme et al., 
2002). Therefore, motor neurons have a high number of Ca2+–permeable AMPA 
receptors. Second, motor neurons express low levels of Ca2+  buffering proteins (Ince et 
al., 1993), which makes them rely heavily on the mitochondrial Ca2+  buffering capacity 
(Alexianu et al., 1994). Thus, upon repeated AMPA stimulation, mitochondrial Ca2+ 
buffering is saturated, leading to a persistent elevation in baseline cytosolic Ca2+ 
(Grosskreutz et al., 2007). Furthermore, excessive Ca2+ entry into motor neurons and 
mitochondrial Ca2+ overload can lead to loss of mitochondrial membrane potential and 
the generation of reactive oxygen species (ROS) (Carriedo et al., 2000). Finally, there is 
considerable evidence for altered mitochondrial function in ALS (see Section 1.3.4), 
which could also increase the susceptibility of motor neurons to excitotoxicity. 
 
Mutations in alsin, a guanine nucleotide exchange factor, cause autosomal recessive 
juvenile onset ALS, infantile-onset HSP, and juvenile PLS (Eymard-Pierre et al., 2002; 
Gros-Louis et al., 2003; Otomo et al., 2003). Alsin was found to interact with glutamate 
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receptor interacting protein 1 (GRIP1), a protein responsible for GluR2 shuttling to the 
synapse. When deficient, alsin alters the distribution of GRIP1 and reduces the amount 
of GluR2, rendering motor neurons more vulnerable to excitotoxicity (Lai et al., 2006). 
 
Finally, riluzole, the only disease modifying agent approved for the treatment of ALS 
has anti-glutamatergic properties. Thus, riluzole blocks presynaptic glutamate release 
and modulates N-methyl-D-aspartate (NMDA) and AMPA receptors (Albo et al., 2004; 
Bensimon et al., 1994; Debono et al., 1993; Lacomblez et al., 1996). However, other 
anti-glutamate compounds such as topiramate and lamotrigine have failed in clinical 
trials, suggesting the neuroprotective effect of riluzole might also depend on other 
pathways (Cudkowicz et al., 2003; Ryberg et al., 2003). 
 
1.3.2 Oxidative stress 
The aerobic metabolism is constantly generating potentially toxic by-products in the 
form of reactive oxygen species (ROS). Cellular ROS arise mostly due to an incomplete 
reduction of molecular oxygen during oxidative phosphorylation. However, under 
normal conditions the cell’s antioxidant mechanisms are constantly scavenging the ROS 
and preventing or repairing the damage they cause. Oxidative stress occurs when the 
balance between ROS production and the physiologic antioxidant defence is perturbed 
(Halliwell, 1994). 
 
Several lines of evidence suggest oxidative stress is involved in ALS pathogenesis. 
Initially, evidence of oxidative damage was identified in post-mortem ALS spinal cord 
and motor cortex (Ferrante et al., 1997; Shaw et al., 1995). This was confirmed by 
biological samples from ALS patients which showed oxidative damage to lipids, DNA 
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and protein (Bogdanov et al., 2000; Simpson et al., 2004; Smith et al., 1998). The 
oxidation of mRNA, leading to decreased expression of key proteins is also an 
important feature in patients and mutant SOD1 mice (Chang et al., 2008). The link 
between ALS and oxidative stress was strengthened after the discovery of causative 
ALS mutations in the antioxidant enzyme SOD1 and mutant SOD1 transgenic mice 
recapitulate the oxidative damage characteristic of human ALS (Andrus et al., 1998; 
Casoni et al., 2005; Liu et al., 1998; Zimmerman et al., 2007). More recently, ALS 
mutant TDP-43 has been shown to induce oxidative injury in motor neuron cell lines 
(Duan et al., 2010). It is now widely accepted that loss of SOD1 dismutase activity does 
not occurr in all ALS mutants and is not sufficient to cause disease. However, genes 
involved in the antioxidant response, including nuclear factor erythroid 2-related factor 
2 (NRF2) are down-regulated in cells expressing mutant SOD1 (Kirby et al., 2005). 
NRF2 induces gene expression in response to oxidative stress and also maintains the 
basal expression of antioxidant enzymes (Nguyen et al., 2009). In addition, decreased 
levels of NRF2 have been reported in the CNS of ALS patients (Sarlette et al., 2008). 
 
An important source of ROS in ALS is represented by microglia. Activated microglia 
increase the production of superoxide through the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase as a form of defence against pathogens (Bedard and 
Krause, 2007). Mutant SOD1 expressed in microglia binds to the NADPH oxidase 
activator Rac1 and blocks the enzyme in an active state, generating harmful amounts of 
superoxide ions (Harraz et al., 2008). Moreover, the activation of NADPH oxidase was 
also detected in the spinal cords of sporadic ALS patients (Wu et al., 2006) and the 
administration of apocynin, a NADPH oxidase inhibitor, increased survival in SOD1 
transgenic mice (Harraz et al., 2008). Interestingly, mutant SOD1 can also induce 
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activation of microglia following its secretion from neighbouring neurons or astrocytes 
(Zhao et al., 2010) and extracellular SOD1 has been detected in the CSF of ALS 
patients and transgenic mice (Turner and Talbot, 2008; Urushitani et al., 2006). 
 
Ageing is an important risk factor for developing ALS and ROS production is known to 
increase with age. This is unlikely to be the causative event, but in the presence of other 
pathogenic insults, it could be enough to tip the homeostatic balance and initiate an 
irreversible cycle of cellular injury. Although antioxidant therapies have extended 
survival in transgenic animal models (see for review (Turner and Talbot, 2008)), most 
human trials have failed so far (Barber and Shaw, 2010).  
 
1.3.3 Pathological protein aggregation 
The accumulation of ubiquitinated proteins in motor neurons is a hallmark pathology of 
ALS (see for review (Ince et al., 2011)). The major component of the ubiquitinated 
inclusions was recently identified as TDP-43, a DNA/RNA binding protein (Neumann 
et al., 2006). Although TDP-43 resides predominantly in the nucleus in physiological 
conditions, pathological TDP-43 is cleaved and redistributed to the cytoplasm, where it 
becomes abnormally phosphorylated and ubiquitinated (Neumann et al., 2006). Since 
TARDBP mutations are capable of causing familial and sporadic ALS (Kabashi et al., 
2008; Sreedharan et al., 2008), it has been speculated that abnormal aggregation of 
TDP-43 contributes to the disease process. 
 
The classical ALS pathology also features accumulations of other proteins. These 
include phosphorylated neurofilaments, which accumulate in axons and cell bodies and 
could have detrimental effects on axonal homeostasis (see for review (Al-Chalabi and 
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Miller, 2003)) and misfolded SOD1 which is also present in ALS spinal cords (Shibata 
et al., 1996) and in SOD1 transgenic animals (Bruijn et al., 1998). Antibodies 
selectively detecting misfolded SOD1 have been created (Rakhit et al., 2007) and these 
label mutant SOD1 inclusions in familial ALS and an oxidized form of wild-type SOD1 
in a subset of sporadic ALS cases (Bosco et al., 2010). Finally, mutations in FUS, a 
nuclear protein, induce its aberrant localization to the cytoplasm, where it forms 
inclusions (Kwiatkowski et al., 2009; Vance et al., 2009). Recently, the number of FUS 
inclusions has been shown to increase with disease duration (Suzuki et al., 2012). 
 
Other recently identified causative ALS mutations support a role for abnormal protein 
aggregation in disease pathogenesis. Mutations in the valosin-containing protein (VCP) 
gene on chromosome 9 have been found in patients with familial ALS (Johnson et al., 
2010). VCP is an abundantly expressed adenosine triphosphate (ATP)ase  involved in a 
wide variety of cellular processes including ER and mitochondrial protein degradation, 
endosomal sorting, the ubiquitin proteasome system, ER and Golgi reassembly, nuclear 
envelope formation and the cell cycle (Acharya et al., 1995; Cao et al., 2003; Dai and 
Li, 2001; Latterich et al., 1995; Rabouille et al., 1995; Ritz et al., 2011; Xu et al., 
2011a). Pathogenic VCP mutations have been found to impair the clearance of 
aggregated proteins (Ju et al., 2008), perturb endolysosomal sorting (Ritz et al., 2011) 
and induce autophagosome accumulation (Ju et al., 2009). Interestingly, VCP can escort 
ubiquitinated proteins to the proteasome for degradation by binding to Derlin-1, thus 
playing a central role in ER-associated protein degradation (ERAD) (Ye et al., 2005). 
 
Mutations in ubiquilin 2 (UBQLN2) cause X-chromosome linked dominantly inherited 
ALS with or without FTD (Deng et al., 2011). The gene encodes a ubiquitin-like protein 
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which interacts with polyubiquitin chains and proteasome subunits, and is thought to 
regulate protein degradation (Ko et al., 2004). Mutant UBQLN2 perturbs the ubiquitin 
proteasome system suggesting a mechanism linked to impaired protein clearance in 
ALS (Deng et al., 2011).  
 
1.3.4 Mitochondrial dysfunction 
Mitochondria are organelles essential for energy production, Ca2+ buffering and 
mediating apoptosis. Abnormalities in mitochondrial morphology, such as 
mitochondrial swelling or vacuolization have long been observed in ALS motor neurons 
(Sasaki and Iwata, 2007). Moreover, these changes correlate with functional alterations 
such as defects in ATP production and the electron transport chain, and reduced Ca2+ 
buffering capacity (Carrì et al., 1997; Fujita et al., 1996; Siklos et al., 1996; Wiedemann 
et al., 2002). 
 
Mitochondrial abnormalities and functional deficits have been consistently reported in 
mutant SOD1 transgenic mice and mutant SOD1 expressing cells (Dal Canto and 
Gurney, 1995; Kong and Xu, 1998; Liu et al., 2004; Pasinelli et al., 2004; Sotelo-
Silveira et al., 2009; Vande Velde et al., 2011; Wong et al., 1995). A proportion of 
mutant SOD1 is present on the outer mitochondrial membrane, in the intermembrane 
space and mitochondrial matrix, suggesting that it may directly damage mitochondria 
(Higgins et al., 2002; Liu et al., 2004; Mattiazzi et al., 2002; Pasinelli et al., 2004; 
Vande Velde et al., 2008; Vijayvergiya et al., 2005). This abnormal localization of 
mutant SOD1 is specific for spinal cord mitochondria and is not found in brain or liver, 
indicating its direct relevance for disease (Mattiazzi et al., 2002; Pasinelli et al., 2004; 
Vande Velde et al., 2008). 
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 Some specific molecular targets for mutant SOD1 toxicity have been identified. One of 
them is the outer mitochondrial membrane voltage-dependent anion channel 1 
(VDAC1), which directly binds mutant SOD1 (Israelson et al., 2010). VDAC1 regulates 
the ion and metabolite flux between mitochondria and cytosol and plays a key role in 
the mitochondrial permeability transition pore apoptotic pathway (McCommis and 
Baines, 2012). Interaction of mutant SOD1 with VDAC1 impairs channel conductance 
and adenosine diphosphate (ADP) import across the outer mitochondrial membrane 
(Israelson et al., 2010). This can lead to reduced ATP production and may explain the 
perturbation of ATP synthesis observed in mutant SOD1 models (Carrì et al., 1997; 
Damiano et al., 2006). VDAC1 is involved in Ca2+ exchange between ER and 
mitochondria via its interaction with inositol-1,4,5-triphosphate receptors (IP3R) 
(Rapizzi et al., 2002; Szabadkai et al., 2006) and mutant SOD1 binding to VDAC1 may 
also underlie the aberrant Ca2+ handling and impaired Ca2+ buffering observed in mutant 
SOD1 models (Grosskreutz et al., 2007; Jaiswal and Keller, 2009). Aberrant 
mitochondrial Ca2+ handling has also been described in VAPB-related ALS (De Vos et 
al., 2012; Langou et al., 2010) and ALS patients (Siklos et al., 1996) but it is not clear 
whether this involves VDAC1. Nevertheless, impaired mitochondrial Ca2+ handling and 
increased cytosolic Ca2+ are common findings in ALS that could be primary pathogenic 
events or act indirectly by inducing defects in axonal transport (MacAskill and Kittler, 
2010; Wang and Schwarz, 2009) or by rendering motor neurons vulnerable to 
excitotoxicity (see Section 1.3.1). 
 
Another target of mutant SOD1 is the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) 
in spinal cord mitochondria, which is sequestered into SOD1 aggregates (Pasinelli et al., 
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2004). Bcl-2 depletion from motor neurons could be the underlying cause of 
cytochrome c release and caspase activation in mutant SOD1 models (Kirkinezos et al., 
2005; Takeuchi et al., 2002). 
 
1.3.5 Axonal transport dysfunction 
The proper transport of protein and organelle cargoes along the cytoskeleton is a vital 
process for virtually all mammalian cells. This process is particularly important in 
neurons, since they are polarized cells with axons and dendrites usually extending over 
great distances. Since most neuronal proteins are synthesised in the cell body and then 
transported to their final destination, neurons require highly efficient transport of 
cargoes to the distal regions of axons and dendrites to permit functioning of synapses. 
Likewise, trophic factors need to be shipped from the synapse to the cell body. 
Transport from cell body to the axon terminal is termed anterograde axonal transport 
and transport from the axon terminal to the cell body is termed retrograde axonal 
transport. 
 
Most long range transport through axons is mediated by kinesin and dynein molecular 
motors that move along microtubules. Within axons, microtubules are mostly orientated 
with their plus ends (the ends to which tubulin subunits are added) towards the synapse. 
Most kinesins move towards the plus end of microtubules (anterograde transport) 
whereas dynein moves towards the minus end of microtubules (retrograde transport) 
(Hirokawa and Noda, 2008). 
 
A number of lines of evidence suggest that defective axonal transport contributes to 
neurodegenerative diseases including ALS (for review see (De Vos et al., 2008)). 
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Firstly, mutations in dynactin, a component of the dynein motor, can cause a familial 
form of ALS (Munch et al., 2004; Puls et al., 2003) and mutant dynactin damages 
dynein function (Levy et al., 2006). 
 
Secondly, the presence of protein/organelle accumulations in ALS such as 
neurofilament and mitochondria in the proximal axon suggest that axonal transport is 
disrupted (Ackerley et al., 2004; Carpenter, 1968; Hirano et al., 1984; Ince et al., 1998; 
Sasaki and Iwata, 2007). Thirdly, damage to axonal transport has been described in 
ALS transgenic animals and cellular models. Defective axonal transport of components 
of the cytoskeleton, mitochondria and vesicles are observed in mutant SOD1 mice that 
develop ALS (Bilsland et al., 2010; De Vos et al., 2007; Kieran et al., 2005; Williamson 
and Cleveland, 1999; Zhang et al., 1997). Also overexpression of neurofilaments can 
model ALS in mice and damage to axonal transport is seen in these models (Collard et 
al., 1995; Millecamps et al., 2006).  
 
Finally, disrupting molecular motor function can model ALS in transgenic mice. The 
Legs-at-odd-angles and Cramping 1 mutant mice develop a progressive locomotor 
phenotype including motor neuron cell loss, and the genetic defect in these animals has 
been shown to involve the dynein gene (Hafezparast et al., 2003). Furthermore, 
overexpression of dynamitin (which disrupts dynein function) causes motor neuron 
disease in transgenic mice (LaMonte et al., 2002). 
 
In contrast, some evidence suggests that damage to axonal transport of mitochondria 
might not be mechanistic in the ALS disease process. Syntaphilin is a protein that 
anchors mitochondria to microtubules in axons and syntaphilin knockout mice show 
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increased mitochondrial movement (Kang et al., 2008). Crossing mutant SOD1 mice 
with syntaphilin knockout mice increases axonal transport of mitochondria but it does 
not slow disease progression (Zhu and Sheng, 2011). However, there is evidence that 
damage to mitochondrial transport is anterograde specific in ALS (De Vos et al., 2007; 
Morotz et al., 2012) and loss of syntaphilin increases overall transport so does not 
properly correct the defect. Others have also reported that SOD1 G85R transgenic mice 
develop ALS despite having no axonal transport defects (Marinkovic et al., 2012). 
However, this finding is in disagreement with studies from other groups (Williamson 
and Cleveland, 1999) and the weight of evidence supports a role for defective axonal 
transport in ALS. 
 
1.3.6 Damage to mRNA metabolism 
Defective splicing of mRNA for the glial glutamate transporter EAAT2 in ALS patients 
was one of the first pieces of evidence linking RNA processing defects to excitotoxicity 
and motor neuron degeneration (Lin et al., 1998). Moreover, mRNA oxidation in motor 
neurons is a common finding in ALS patients and SOD1 transgenic mice (Chang et al., 
2008). More recently, the importance of RNA metabolism has been highlighted by the 
discovery that mutations in genes encoding Senataxin, an RNA helicase, Angiogenin, a 
ribonuclease and RNA/DNA interacting proteins TDP43 and FUS all cause familial 
forms of ALS (Chen et al., 2004; Greenway et al., 2006; Kwiatkowski et al., 2009; 
Sreedharan et al., 2008; Vance et al., 2009). 
 
TDP-43 is a predominantly nuclear protein that regulates mRNA expression, splicing, 
translation and gene transcription (Cohen et al., 2011). Expression of mutant TDP-43 in 
cells leads to an abnormal localization to the cytoplasm, particularly in stress granules 
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(Liu-Yesucevitz et al., 2010). Certain conditions such as oxidative stress or ischemia 
trigger a global translational silencing and the formation of stress granules, cytoplasmic 
aggregates which transiently sequester mRNA and RNA binding proteins and can 
modulate the signalling balance between apoptosis and survival (Thomas et al., 2011). 
More than 6000 TDP-43 RNA targets have now been identified and these include 
several that are linked to ALS such as FUS, EAAT1, progranulin and TDP-43 itself 
(Polymenidou et al., 2011; Sephton et al., 2011; Tollervey et al., 2011). 
 
In a similar manner to TDP-43, ALS mutant FUS shows abnormal cytoplasmic 
localization and can induce the formation of FUS containing cytoplasmic stress granules 
(Dormann et al., 2010; Ito et al., 2011a; Kwiatkowski et al., 2009; Vance et al., 2009). 
FUS is also a component of mRNA transporting granules and might contribute to 
mRNA shuttling to synapses for local translation (Kanai et al., 2004). Recently, FUS 
has been shown to facilitate exon 10 skipping in the gene encoding Tau (Ishigaki et al., 
2012). This generates 3-repeat Tau, an isoform which is relatively increased in 
neurodegenerative disorders (Yoshida, 2006). In addition, TDP-43 and FUS interact to 
regulate mRNA expression of histone deacetylase 6 (HDAC6) (Kim et al., 2010b), a 
protein involved in autophagy and stress granule formation (d'Ydewalle et al., 2012). 
 
Lastly, a GGGGCC hexanucleotide repeat expansion in a non-coding region of 
C9ORF72 is currently the most common genetic defect in both ALS and FTD (Cooper-
Knock et al., 2012; DeJesus-Hernandez et al., 2011; Majounie et al., 2012; Renton et 
al., 2011). In one scenario, the expanded hexanucleotide repeats can act through a toxic 
gain of function at the mRNA level and form intranuclear accumulations that sequester 
mRNA binding proteins to disrupt mRNA metabolism. Indeed, C9ORF72 RNA foci 
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have been identified in the spinal cords and frontal cortex of patients carrying the 
expansion (DeJesus-Hernandez et al., 2011). This toxic mRNA disease mechanism has 
been described in other forms of neurodegeneration such as myotonic dystrophies and 
ataxias (Todd and Paulson, 2010). 
 
1.3.7 ER stress and the unfolded protein response (UPR) 
In order to survive, all living cells must carry out a quality control programme which 
regulates protein biosynthesis, folding, translocation, assembly/disassembly, and 
clearance (degradation). This complex regulatory network requires the coordinated 
action of chaperones and proteolytic systems and is called protein homeostasis or 
proteostasis (see for reviews (Bar-Lavan et al., 2012; Hartl et al., 2011)). Molecular 
chaperones prevent protein aggregation by stabilizing or helping proteins acquire their 
final conformation (Hartl et al., 2011). When the chaperone machinery is overwhelmed, 
two major systems mediate the complete degradation of abnormal proteins: the 
proteasome and the lysosome (Wong and Cuervo, 2010). The proteasome selectively 
recognizes substrates tagged with ubiquitin, which are mostly short-lived proteins. 
Autophagy denotes the delivery of cytosolic components and organelles (dubbed 
mitophagy in case of mitochondria) to the lysosome, where they undergo catalytic 
degradation. 
 
Under normal conditions, proteins fold in the ER lumen and are prepared for delivery to 
the cell compartment where they are needed. Finely tuned molecular sensors in the ER 
lumen are capable of detecting a deficit in the ER folding capacity (i.e. ER stress) and 
activate signalling pathways collectively termed the UPR (see for reviews (Hetz, 2012; 
Lin et al., 2008)). The UPR tries to decrease the load of misfolded proteins and restore 
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proteostasis by (i) attenuation of translation, (ii) induction of chaperones to aid protein 
folding, and (iii) upregulation of degradation pathways such as ERAD and autophagy to 
completely remove misfolded proteins (see Figure 1.3). However, if ER stress persists 
and elicits a prolonged induction of UPR, the cell initiates apoptosis (Nakagawa et al., 
2000; Nishitoh et al., 2002). 
 
Several lines of evidence suggest an important role for ER stress in the pathogenic 
cascade of ALS. Firstly, ER stress and activation of the UPR has been described in 
mutant SOD1 transgenic mice and in cell lines that express mutant SOD1 (Atkin et al., 
2006; Kikuchi et al., 2006; Nishitoh et al., 2008; Saxena et al., 2009; Tobisawa et al., 
2003). Furthermore, the induction of UPR stress sensor kinases, chaperones and 
apoptotic mediators have been detected in the CSF of ALS patients and in postmortem 
sporadic ALS motor neurons (Atkin et al., 2008; Sasaki, 2010). Interestingly, in mutant 
SOD1 expressing mice, the upregulation of the ER resident misfolded protein sensor 
glucose-regulated protein 78/immunoglobulin heavy-chain binding protein 
(GRP78/BiP), which is indicative of UPR activation, appears to be specific for the fast-
fatigable motor neurons, which are most susceptible to disease in ALS and was 
observed as early as postnatal day 5 (Saxena et al., 2009). It is not clear how mutant 
SOD1 induces ER stress but there is evidence that mutant SOD1 aggregates accumulate 
in the ER lumen and on the cytosolic surface of the ER where they interact with BiP and 
Derlin-1 (Kikuchi et al., 2006; Nishitoh et al., 2008). Binding of mutant SOD1 to 
Derlin-1 inhibits ERAD and increases ER stress and UPR (Nishitoh et al., 2008). The 
aberrant interaction between mutant SOD1 and BiP may also lead to an uncontrolled 
and prolonged UPR by preventing BiP interaction with ER stress sensors (Kikuchi et 
al., 2006). Mutant SOD1 also upregulates protein-disulfide isomerase (PDI), an ER-
 55 
resident chaperone which colocalizes with SOD1 aggregates and is suggested to have a 
protective role in SOD1 models (Atkin et al., 2006). Prolonged ER stress and UPR have 
deleterious effects on homeostasis and eventually activate apoptosis via cysteinyl 
aspartate-specific protease-12 (caspase-12) and apoptosis signal-regulating kinase 1 
(ASK1) (Nakagawa et al., 2000; Nishitoh et al., 2002). Both caspase-12 and ASK1 are 
activated in ALS mutant SOD1 expressing transgenic mice suggesting that UPR 
dependent apoptosis might contribute to neurodegeneration in ALS (Atkin et al., 2006; 
Holasek et al., 2005; Wengenack et al., 2004; Wootz et al., 2004). 
 
A second line of evidence implicating ER stress in ALS comes from the finding that 
mutations in the gene encoding VAPB cause a form of familial ALS; VAPB functions 
in mediating the UPR in response to ER stress (Gkogkas et al., 2008; Kanekura et al., 
2006; Suzuki et al., 2009). However, there are some inconsistencies regarding the role 
of VAPB in the UPR. Thus, in some reports, expression of VAPB induces UPR and 
ALS mutant VAPB inhibits this process (Chen et al., 2010; Kanekura et al., 2006; 
Suzuki et al., 2009). In another, expression of VAPB and ALS mutant VAPB both 
inhibit UPR but mutant VAPB is more potent in this effect (Gkogkas et al., 2008). 
Finally, other studies have shown that VAPB and/or mutant VAPB can induce ER stress 
and UPR (Langou et al., 2010; Tsuda et al., 2008). 
 
Finally, there is evidence that ALS mutant TDP-43 and FUS can induce ER stress and 
UPR. TDP-43 is cleaved into toxic ubiquitinated hyperphosphorylated 25 kDa 
fragments (Neumann et al., 2006) and chemical induction of ER stress promotes  
TDP-43 cleavage via caspase-12 (Suzuki et al., 2011). Also expression of mutant FUS 
induces ER stress and mutant FUS interacts with and upregulates PDI (Farg et al., 
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2012). Together, these findings support a role for ER stress and UPR induction in the 
ALS pathogenic cascade. 
 
 
Figure 1.4 The vertebrate UPR 
When unfolded proteins accumulate in the ER, the stress sensors PERK, IRE1 and 
ATF6 initiate signalling cascades known as the UPR. Initially, activated PERK inhibits 
translation via EIF2α to reduce protein influx in the ER. Subsequently, regulated mRNA 
splicing and transcriptional activation act on specialized target genes. These genes 
encode proteins involved in protein folding, autophagy, ERAD and redox mechanisms, 
in an attempt to re-establish protein homeostasis. If ER homeostasis cannot be restored 
from the combined action of the three pathways, the cell undergoes apoptosis. RIDD -
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Regulated IRE1-dependent decay; ATF4 -Activating transcription factor 4; JNK - c-Jun 
N-terminal kinase. 
 
1.4 The ER-mitochondria axis and neurodegenerative diseases 
As detailed above, defects in a number of apparently disparate cellular functions can be 
seen in ALS. Understanding how these different pathological changes might be linked 
in a common pathway remains a major challenge for comprehending ALS disease 
processes. Recently, several studies have highlighted the role of ER-mitochondria 
communications in neurodegenerative diseases such as ALS (see for reviews (Cali et al., 
2011; Giorgi et al., 2012; Lautenschlaeger et al., 2012; Rowland and Voeltz, 2012; 
Schon and Area-Gomez, 2012)). 
 
Both ER and mitochondria play pivotal roles in a number of essential cellular functions. 
Thus, the ER is involved in protein synthesis, lipid metabolism and Ca2+ homeostasis, 
while mitochondria function in energy metabolism, Ca2+ homeostasis, lipid synthesis 
and apoptosis. These functions require a dynamic spatial organization that permits 
relaying of signals between different organelles. In particular, mitochondria and ER 
display close associations with between 5 and 20% of the mitochondrial surface closely 
apposed (10-25 nm distance) to ER membranes (Csordas et al., 2006; Rizzuto et al., 
1998). These ER membrane domains are known as mitochondria-associated ER 
membranes (MAM). A large body of evidence demonstrates that mitochondria 
communicate directly with ER through MAM to facilitate a number of intracellular 
signaling processes. These include Ca2+ and phospholipid exchange, ER and 
mitochondrial stress responses, and apoptosis (Giorgi et al., 2009; Hayashi et al., 2009; 
Pinton et al., 2008; Rowland and Voeltz, 2012). 
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 A number of ALS associated insults are now known to target either MAM proteins, or 
mitochondrial proteins at the MAM interface. Thus, VAPB is a known MAM protein 
and ALS mutant VAPB disrupts ER structure and ER to mitochondria Ca2+ exchange 
(De Vos et al., 2012; Fasana et al., 2010; Kim et al., 2010a; Langou et al., 2010; 
Nishimura et al., 2004; Teuling et al., 2007; Tudor et al., 2010). Also, MAM is involved 
in ER stress and the UPR (Simmen et al., 2010; Verfaillie et al., 2012) and ALS mutant 
SOD1, TDP-43 and FUS all induce prolonged UPR (Farg et al., 2012; Saxena et al., 
2009; Suzuki et al., 2011; Tong et al., 2012). Likewise, mutant SOD1 damages VDAC1 
(Israelson et al., 2010) which is located in the outer mitochondrial membrane and 
interacts with IP3Rs in MAM via BiP (Rapizzi et al., 2002; Szabadkai et al., 2006). 
 
Such perturbations to ER-mitochondria communications are predicted to induce some 
of the other pathogenic features of ALS. For example, altered Ca2+ exchange between 
ER and mitochondria is likely to impact on axonal transport of mitochondria since Ca2+ 
regulates this process (Chang et al., 2006; Macaskill et al., 2009; Rintoul et al., 2003; 
Saotome et al., 2008; Wang and Schwarz, 2009). Indeed, ALS mutant VAPB disrupts 
axonal transport and this is linked to ER-mitochondria Ca2+ exchange (De Vos et al., 
2012; Morotz et al., 2012). Thus, a number of ALS associated insults can be linked to 
the ER-mitochondria axis and damage to this axis is likely to induce some of the 
pathogenic features of ALS. 
 
Alterations to ER-mitochondria associations are predicted to have particularly 
detrimental effects to neurons. Tightening of contacts is likely to increase Ca2+ 
signalling between the two organelles, leading to mitochondria Ca2+ overload. This in 
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turn stimulates opening of the mitochondrial permeability transition pore and induction 
of apoptosis (Csordas et al., 2006; Rowland and Voeltz, 2012). By contrast, loosening 
of contacts will affect Ca2+-dependent regulation of the tricarboxylic acid cycle and 
ATP synthesis in mitochondria (Csordas et al., 2006; Rowland and Voeltz, 2012). 
Mitochondria are enriched in synapses where they are required for generating ATP to 
maintain ionic potential and for regulating Ca2+ homeostasis. Thus, any damage to 
mitochondria or reduction in their ability to generate ATP is likely to have detrimental 
effects at the synapse. Synaptic loss is a key and early feature of ALS (Dadon-Nachum 
et al., 2011; De Vos et al., 2008). 
 
1.4.1 Neurodegenerative diseases and alterations to ER-mitochondria associations   
Studies such as those described above which highlight how neurodegenerative disease 
insults might target MAM and mitochondria proteins at the MAM interface have 
prompted examinations of ER-mitochondria connections in some disease states. To 
date, direct studies on the effects of neurodegenerative disease insults on ER-
mitochondria contacts are restricted to Alzheimer’s disease and Parkinson’s disease. 
 
Mutations in the genes encoding presenilins cause some forms of familial Alzheimer’s 
disease. The presenilins (presenilin-1 and presenilin-2) are part of the γ-secretase 
complex that processes the amyloid precursor protein (APP) to release amyloid β-
peptide (Aβ) that is deposited in the brains of Alzheimer’s disease patients. Alterations 
to processing of APP and production of Aβ are believed to be major events in 
Alzheimer’s disease. The presenilins are resident ER proteins (see for reviews (De 
Strooper and Annaert, 2010; Ho and Shen, 2011; Selkoe and Wolfe, 2007)). Moreover, 
both presenilin-1 and presenilin-2 are enriched in MAM (Area-Gomez et al., 2009). 
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Recently, the effects of Alzheimer’s disease mutant presenilins on ER-mitochondria 
contacts have been studied although the results are a little conflicting. In one study, 
presenilin-2 but not presenilin-1 increases ER-mitochondria contacts whereas in the 
other, presenilin-1 increases ER-mitochondria contacts (Area-Gomez et al., 2012; 
Zampese et al., 2011). The presenilin-induced changes to ER-mitochondria contacts 
have been shown to induce alterations to both Ca2+ and lipid metabolism (Area-Gomez 
et al., 2012; Zampese et al., 2011). 
 
α-synuclein is a major component of Lewy bodies that are a pathological feature of 
Parkinson’s disease and some forms of dementia. Mutations in the α-synuclein gene 
cause familial forms of Parkinson’s disease (see for reviews (Goedert et al., 2012; Lee 
and Trojanowski, 2006)). Damage to mitochondria is strongly linked to Parkinson’s 
disease and some other mutant genes that cause familial Parkinson’s disease encode 
mitochondrial proteins (see for reviews (Exner et al., 2012; Youle and van der Bliek, 
2012)). A proportion of α-synuclein localizes to mitochondria (Cole et al., 2008; Devi 
et al., 2008; Shavali et al., 2008) and recently, α-synuclein has been shown to increase 
ER-mitochondria contacts and to influence mitochondrial Ca2+ levels (Cali et al., 2012). 
 
Finally, mutations in the Mitofusin-2 gene cause some Charcot-Marie-Tooth disease 
type 2A (Barisic et al., 2008) and there is evidence that mitofusin-2 forms some of the 
molecular tethers that directly link ER and mitochondria (de Brito and Scorrano, 2008). 
 
1.4.2 ER-mitochondria tethering proteins  
Despite the importance of ER-mitochondria interactions to fundamental biological 
processes, the mechanisms that control these interactions and in particular, the 
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molecular identity of the tethers that physically connect ER and mitochondria are poorly 
understood. Electron tomography studies reveal that ER and mitochondria are linked by 
structures of different length (10 nm at smooth ER and 25 nm at rough ER) and this 
suggests that a number of proteins can physically connect these organelles (Csordas et 
al., 2006). 
 
In yeast, proteins of the ER-mitochondria encounter structure (ERMES) act as a 
molecular tether between ER and mitochondria but ERMES orthologs in higher 
eukaryotes have not so far been identified (Kornmann et al., 2009). In a major study, 
mitofusin-2 was shown to link ER and mitochondria in mammalian cells (de Brito and 
Scorrano, 2008) but these findings have not been properly replicated. Indeed, strong 
evidence has just been presented that mitofusin-2 does not play any role in juxtaposing 
ER and mitochondria (Cosson et al., 2012). 
 
Phosphofurin acidic cluster sorting protein-2 (PACS-2) is a sorting protein believed to 
be involved in mediating vesicle sorting and trafficking and which is associated with 
both ER and mitochondria (Simmen et al., 2005). Silencing of PACS-2 uncouples ER 
from mitochondria but since this involves mitochondrial fragmentation and altered 
morphology, it has been concluded that this effect on ER-mitochondria associations is 
probably indirect (Simmen et al., 2005). 
 
IP3R in MAM and VDAC in mitochondria physically interact via the molecular 
chaperone BiP and this prompted the suggestion that these molecules represent ER-
mitochondria tethers (Rapizzi et al., 2002; Szabadkai et al., 2006). However, IP3R 
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knockout cells have intact ER-mitochondria interactions ruling out a major role for 
these proteins as structural linkers (Csordas et al., 2006). 
 
Recently, work from our research group identified the mitochondrial protein, PTPIP51 
as a binding partner for the resident ER protein VAPB (De Vos et al., 2012). VAPB is 
anchored in the ER via a C-terminal membrane-spanning domain and its N-terminus 
projects into the cytoplasm (Kagiwada et al., 1998). PTPIP51 is anchored in the outer 
mitochondrial membrane via an N-terminal mitochondrial targeting sequence such that 
its C-terminus projects into the cytoplasm (De Vos et al., 2012). As such, VAPB and 
PTPIP51 represent candidate proteins for the structural tethers connecting ER with 
mitochondria that can be visualised by electron microscopy. 
 
VAPB is described in detail above (see Section 1.2.4). PTPIP51 is a relatively poorly 
studied protein that is also known as family with sequence similarity 82 member A2 
(FAM82A2), human cerebral protein-10 and regulator of microtubule dynamics  
protein-3 (RMD-3). PTPIP51 binds to protein tyrosine phosphatase-1B (PTP1B) and T-
cell protein tyrosine phosphatase (Brobeil et al., 2010; Stenzinger et al., 2005) but the 
functional significance of these interactions is unclear. PTPIP51 also binds 14-3-3 
proteins (Brobeil et al., 2012; Petri et al., 2011; Yu et al., 2008) but again, it is not clear 
how these interactions impact upon cellular function. RMD-3 is a putative homologue 
of PTPIP51 in C. elegans and another RMD family member, RMD-1 functions in 
chromosome segregation (Oishi et al., 2007). However, in mammalian cells PTPIP51 is 
an outer mitochondrial protein of unclear function that has been implicated in the 
regulation of cell morphology, motility and apoptosis and which contains an N-terminal 
transmembrane domain and a central coiled-coil domain (Brobeil et al., 2011; De Vos et 
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al., 2012; Lv et al., 2006; Yu et al., 2008). Both VAPB and PTPIP51 are ubiquitously 
expressed although their expression levels vary in different tissues (Lv et al., 2006; 
Skehel et al., 2000; Stenzinger et al., 2005). 
 
1.5 Aims of the thesis 
As detailed above, the finding that VAPB and PTPIP51 interact raised the possibility 
that these proteins represent at least some of the molecular tethers visualised in electron 
microscopy studies that physically link ER and mitochondria. Moreover, since mutant 
VAPB causes some forms of ALS, it is possible that defects in ER-mitochondria 
tethering and especially any involving VAPB and PTPIP51 might feature in ALS. The 
aims of this thesis were to investigate further these possibilities and specifically, to test 
two related hypotheses. The first is that the VAPB-PTPIP51 interaction mediates ER-
mitochondria associations. The second is that ALS associated TDP-43 disrupts ER-
mitochondria associations and that this disruption is linked to changes in the VAPB-
PTPIP51 interaction. In addition, studies were commenced to investigate how mutant 
SOD1 and FUS influence the VAPB-PTPIP51 interaction and to test whether 













CHAPTER 2: MATERIALS AND METHODS 
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Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich Co. (UK). 
All solutions and buffers were prepared using ultrapure water (resistivity ≥ 18.2 MΩ-
cm) from an ELGA Purelab Ultra purification system (Veolia Water Systems Ltd., UK). 
When required, solutions were sterilised either by autoclaving or by filtration through a 
0.2 μm pore size syringe filter (Nalgene).  
 
In the text, some commonly used organic compounds are referred to using their non-
systematic instead of systematic names, according to the guidelines of the International 
Union of Pure and Applied Chemistry: e.g., bromophenol blue was used instead of 4'-
(1,1-dioxido-3H-2,1-benzoxathiole-3,3-diyl)bis(2,6-dibromophenol) (Panico, 1993). All 
units are written according to the guidelines of the Bureau International des Poids et 
Mesures (International Bureau of Weights and Measures) (BIPM, 2006).  
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2.1 Materials 
2.1.1 Stock solutions 
Acrylamide-bis-acrylamide (30%, 37:5:1 stabilised solution; Geneflow, UK) 
Ammonium persulphate (APS; 10% (w/v); Geneflow, UK) 
Ampicillin (amp; 100 mg/ml, filter sterilised) 
β-mercaptoethanol (100%) 
Bovine serum albumin (BSA; 5% (w/v))  
Brilliant Blue G-Colloidal Coomassie 
Citric acid (1 M) 
4′, 6-diamidino-2-phenylindole (DAPI; 0.5 mg/ml in DMSO) 
Dimethyl sulphoxide (DMSO; 100%) 
Dithiothreitol (DTT; 1 M) 
Ethanol (70% v/v) 
Ethidium bromide (10 mg/ml) 
Ethylenediaminetetraacetic acid (EDTA; 0.5 M) 
Ethylene glycol-bis (β-aminoethylether) N,N,N’,N’-tetraacetic acid (EGTA; 0.5 M) 
Fetal bovine serum (100%; Sera Laboratories) 
Glacial acetic acid (100%)  
Glycerol (10%, 50% and 100% v/v, autoclaved) 
Glutaraldehyde (50%, distilled/EM grade; TAAB) 
Hydrogen chloride (HCl; 1 M) 
Hydrogen peroxide (30% w/w) 
Kanamycin (100 mg/ml, filter sterilised) 
K-HEPES ((4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid); 1 M; buffered with 
KOH to pH 7.4) 
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L-glutamine (200 mM; Invitrogen) 
Magnesium chloride (MgCl2; 1 M) 
Methanol (100%)  
Paraformaldehyde (PFA; 4% w/v in PBS) 
Penicillin (10,000 IU/ml) and streptomycin (10 mg/ml; PAA Laboratories) 
Pervanadate (100X) 
Phenylmethysulphonyl fluoride (PMSF; 100 mM in isopropanol) 
Phosphate-buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM potassium chloride, 
137 mM sodium chloride, pH 7.4 tablets) 
Sodium azide (10% w/v) 
Sodium dodecyl sulphate (SDS; 10% (w/v)) 
Sodium chloride (NaCl; 5 M) 
Sodium hydroxide (NaOH; 10 M) 
Sodium orthovanadate (Na3VO4; 200 mM, activated, pH 10.0) 
N,N,N',N'-Tetramethylethylenediamine (TEMED; 100%) 
Tris (hydroxymethyl) amino methane (Tris-HCl, buffered with HCl to pH 6.8-8.8)  
Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, buffered with HCl to pH 7.6) 
Trypsin-EDTA solution (1x; 0.05% trypsin, 0.02% EDTA in PBS; PAA Laboratories) 
Tris-citrate (1 M Tris; buffered with citric acid to pH 7.4) 




2.1.2 General molecular biology reagents 
2.1.2.1 Plasmids 
See Tables 2.1 and 2.2 below 
Table 2.1 Vectors 
Vector Vector Use Manufacturer 
pCI-neo Mammalian expression vector Promega 
pEGFP-C1 Mammalian expression vector Clontech 
pECFP-N1 Mammalian expression vector Clontech 
pIRES2-AcGFP Mammalian expression vector Clontech 
 
Table 2.2 Mammalian expression plasmids 
Protein expressed Vector backbone Reference or source of plasmid 
PTPIP51-HA+ phosphomutants pCI-neo (De Vos et al., 2012) 
Myc-VAPB+ phosphomutants pCI-neo (De Vos et al., 2012) 
EGFP pEGFP-C1 Clontech 
ECFP pECFP-N1 Kurt De Vos (IoP) 
ECFP-VAPB pECFP-N1 Kurt De Vos (IoP) 

















pEGFP-C1 Emma Gray (IoP) 
 
2.1.2.2 Oligonucleotides 
All the mutagenic oligonucleotides I used in these studies are listed in Table 2.3. 
PTPIP51S44A/S46A/S50A, PTPIP51S44D/S46D/S50D, PTPIP51S212A/S221A/S225A, 
PTPIP51S212A/S221A/S225D, PTPIP51S44A/S46A/S50A/S212A/S221A/S225A and 
PTPIP51S44D/S46D/S50D/S212D/S221D/S225D were obtained by mutating serine to alanine or 
aspartate respectively. In order to generate PTPIP51 constructs with all 6 
phosphorylation sites mutated to alanine or aspartate, PTPIP51S212A/S221A/S225A and 
PTPIP51S212D/S221D/S225D were used as a template in a mutagenesis reaction with the 
primers for serine positions 44, 46 and 50.  VAPBT150A/S158A, VAPBT150D/S158D, 
VAPBS146A/T150A/S156A/S158A/S159A/S160A and VAPBS146D/T150D/S156D/S158D/S159D/S160D were 
obtained by mutating serine or threonine to alanine and aspartate respectively.  
 
Table 2.3 Mutagenic primers 



















































2.1.2.3 Growth of E. coli for DNA purification: media 
Luria Bertani (LB) broth (powder; Invitrogen), 20 g/L sterilised by autoclaving 
LB agar (powder; Invitrogen), 32 g/L sterilised by autoclaving 
LB-amp broth (LB broth; ampicillin 100 µg/ml) 
LB-kan broth (LB broth; kanamycin 80 µg/ml) 
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LB-amp/LB-kan agar (LB agar; ampicillin 100 µg/ml or kanamycin 80 µg/ml added 
when agar is less than 55°C) 
Bacteria containing plasmids of interest were stored at -70°C in sterile 25% glycerol 
(v/v) solution in LB-amp or LB-kan broth. 
 
2.1.2.4 Plasmid DNA preparation from E. Coli 
Plasmids were isolated using a QIAprep® Spin Miniprep Kit (Qiagen Ltd, Hilden, 
Germany); the following reagents are provided with the kit: 
Resuspension buffer P1 supplemented with RNase A 
Lysis buffer P2 
Neutralisation buffer N3 
Wash buffer PB 
Wash buffer PE supplemented with ethanol (70% (v/v) final ethanol concentration) 
Elution buffer TE (10 mM Tris-HCl pH 8.0) 
 
2.1.2.5 Agarose gel electrophoresis of nucleic acids 
Solution for loading DNA samples in agarose gels (6X solution) 
0.25% Bromophenol blue (w/v) 
40% Sucrose (w/v) 
 
Tris-Acetate-EDTA (TAE) running buffer (50X solution) 
2 M Tris  
5.7 % glacial acetic acid (v/v) 
50 mM EDTA 
pH to 8 
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 Nucleic acid size markers 
Phage λ DNA digested with Hind III (sizes in base pairs): 23,131; 9419; 6434; 4335; 
2322; 2023; 564; 125. 
1 kb DNA ladder (NEB; sizes in kilo bases): 10; 8; 6; 5; 4; 3; 2; 1.5; 1; 0.5. 
 
2.1.2.6 Site-directed mutagenesis  
Site-directed mutagenesis was performed using the QuikChange XL mutagenesis kit 
(Stratagene). XL10-Gold® ultracompetent cells were provided with the kit. The 
following materials are supplied with the QuikChange XL PCR-based site-directed 
mutagenesis kit:  
Oligonucleotide control primer #1 (100 ng/μl):  
5’-CCATGATTACGCCAAGCGCGCAATTAACCCTCAC-3’  
Oligonucleotide control primer #2 (100 ng/μl):  
5’-GTGAGGGTTAATTGCGCGCTTGGCGTAATCATGG-3’  
pWhitescript™ 4.5 kb control template (5 μg/μl)  
pUC18 transformation control plasmid (0.1 ng/μl in TE buffer)  
QuickSolution 
PfuTurbo® DNA polymerase 
Dpn I restriction enzyme 
XL10-Gold® ultracompetent cells 
XL10-Gold® β-mercaptoethanol mix 




10X mutagenesis buffer 
200 mM Tris-HCl (pH 8.8)  
100 mM KCl  
100 mM (NH4)2SO4 
20 mM MgSO4 
1% Triton X-100 (v/v)  
1 mg/ml BSA  
 
2.1.3 Protein analysis 
2.1.3.1 Protein sample preparation 
1X SDS sample buffer 
50 mM Tris-HCl pH 6.8 
2% SDS (w/v) 
0.1% Bromophenol blue (w/v) 
10% Glycerol (v/v) 
100 mM DTT 
 
5X SDS sample buffer 
250 mM Tris-HCl pH 6.8 
10% SDS (w/v) 
0.5% Bromophenol blue (w/v) 
50% Glycerol (v/v) 
500 mM DTT 
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2.1.3.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Resolving gel 
375 mM Tris-HCl pH 8.8 
8-12% Acrylamide (v/v) 
0.1% SDS (w/v) 
0.1% APS (w/v) 
0.05% TEMED 
 
Stacking gel  
125 mM Tris-HCl pH 6.8 
5 % Acrylamide (v/v) 
0.1% SDS (w/v) 
0.1% APS 
0.1 % TEMED 
 
Running Buffer 
25 mM Tris 
250 mM Glycine 
0.1% SDS (w/v) 
 
Electrophoresis markers 
PageRuler™ Prestained Protein Ladder (Fermentas); 3-color ladder with 10 protein 
bands, sizes in kDa: 170; 130; 100; 70; 55; 40; 35; 25; 15; 10. 
Precision Plus Protein Standards (Biorad); high molecular weight, sizes in kDa: 250; 
150; 100; 75; 50; 37, 25; 20; 15; 10. 
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 2.1.3.3 Immobilisation of proteins on nitrocellulose membranes 
Blotting (transfer) buffer 
25 mM Tris 
192 mM Glycine 
20% Methanol (v/v) 
TBS-Tween (Tris-HCl buffered saline; Tween-20) 
TBS pH 7.6 
0.1% Tween-20 (v/v) 
 
2.1.3.4 Antibody probing of membrane-bound proteins 
Blocking buffer 
0.1% (v/v) Tween-20 
5% (w/v) dried skimmed milk in TBS 
 
TBS-Tween 
0.1% (v/v) Tween-20 in TBS 
 
Enhanced chemiluminescence (ECL) development reagent kit (GE Healthcare)  
The following reagents are provided with the kit: 
Detection solution A (luminol solution) 
Detection solution B (peroxide solution) 
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2.1.3.5 Protein staining 
Colloidal Coomassie 
16% Brilliant Blue G-Colloidal Coomassie (v/v) 
20% Methanol (v/v) 
 
Destain I 
7% Glacial acetic acid (v/v) 
25% Methanol (v/v) 
 
Destain II 
2% Glacial acetic acid (v/v) 
25% Methanol (v/v) 
 
Ponceau S red solution for staining of immunoblots 
0.2% Ponceau S (w/v) in 7% glacial acetic acid (v/v) 
 
2.1.4 Immunoprecipitation reagents 
Immunoprecipitation lysis buffer 
50 mM Tris-citrate pH 7.4 
150 mM NaCl 
1% (v/v) Triton X-100 
5 mM EGTA  
5 mM EDTA 




0.1% (v/v) Triton X-100 in PBS 
 
2.1.5 Antibodies 
2.1.5.1 Primary antibodies 
For a list of primary antibodies used in these studies see Table 2.4 
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GFP Abcam Polyclonal, rabbit 1:5000 (IB) 
HA Sigma Polyclonal, rabbit 
1:5000 (IB) 
1:300 (IP) 
9B11 (myc-tag) Cell Signaling Monoclonal, mouse 
1:5000 (IB) 
1:300 (IP) 
Actin (AC-40) Sigma Monoclonal, mouse 1:5000 (IB) 
α-tubulin 
(DM1A) 
Sigma Monoclonal, mouse 1:40,000 (IB) 






Polyclonal, rabbit 1:200 (IF) 
FAM82A2 Atlas Antibodies Polyclonal, rabbit 1:1000 (IB) 
PTPIP51 
(#skr10) 
In house;  
(De Vos et al., 2012) 
Polyclonal, rabbit 1:200 (IF) 
VAPB (#SK83) 
In house;  
(Tudor et al., 2010) 
Polyclonal, rat 1:2000 (IB) 
VAPB (#3503) 
In house;  
(Tudor et al., 2010) 
Polyclonal, rabbit 1:200 (IF) 
Mitofusin2 Sigma Polyclonal, rabbit 1:5000 (IB) 
Phospho-
tyrosine (4G10) 




IB-immunoblot, IF-immunofluorescence, IP-immunoprecipitation 
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2.1.5.2 Secondary antibodies 
For a list of secondary antibodies used in these studies see Table 2.5 






Anti-mouse Ig conjugated 
to horseradish peroxidase 
Dako Polyclonal, rabbit 1:5000 (IB) 
Anti-rabbit Ig conjugated 
to horseradish peroxidase 
Dako Polyclonal, goat 1:5000 (IB) 




Polyclonal, goat 1:5000 (IB) 
Anti-mouse IgG coupled 
with Alexa Fluor 488 
Invitrogen Polyclonal, goat 1:500 (IF) 
Anti-mouse IgG coupled 
with Alexa Fluor 568 
Invitrogen Polyclonal, goat 1:500 (IF) 
Anti-rabbit IgG coupled 
with Alexa Fluor 647 
Invitrogen Polyclonal, goat 1:500 (IF) 
Anti-mouse IgG coupled 
with Alexa Fluor 350 
Invitrogen Polyclonal, goat 1:500 (IF) 
IB-immunoblot, IF-immunofluorescence 
 
2.1.6 Fluorescence microscopy 
Fixing solution 
4% paraformaldehyde in PBS (v/v) 0.1% glutaraldehyde (v/v) 
 
Quenching solution 




0.25% Triton X-100 in PBS (v/v) 
 
Blocking/antibody incubation solution 
3% BSA in PBS (w/v) 
 
Mowiol-DABCO mounting medium 
10% (w/v) Mowiol® 4-88 (Calbiochem) 
25% (w/v) glycerol 
100 mM Tris-HCl pH 8.5 
2.5% (w/v) DABCO (1,4-diazobicyclo[2.2.2]octane) 
 
2.1.7 Duolink® in situ Proximity Ligation Assay (PLA) 
The following reagents are provided with the Duolink® in situ PLA™ kit (Olink 
Bioscience, Uppsala, Sweden):  
PLA probes MINUS and PLUS (secondary antibodies conjugated with a PLA 
nucleotide) 
Antibody Diluent 
Detection Reagent Orange (579 nm emission) 
Ligation solution (5x) – Contains oligonucleotides that hybridize to the PLA probes and 
all components needed for ligation except the Ligase 
Ligase (1 U/μl) 
Amplification solution (5x) – Contains all components needed for Rolling Circle 
Amplification (RCA) except the Polymerase. Included are also oligonucleotide probes 
labeled with a fluorophore that hybridize to the RCA product 
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Polymerase (10 U/μl) 
Wash Buffers A and B 
 
2.1.8 Electron microscopy 
Fixing solution 
2.5% glutaraldehyde in 0.1M cacodylate buffer pH 7.2 
 
Post-fixation solution 
1% osmium tetroxide in 0.1M cacodylate buffer 
 
Staining solutions 
saturated uranyl acetate in 50% ethanol 
0.1N lead citrate in NaOH 
 
2.1.9 Mammalian cell culture 
Chinese Hamster Ovary (CHO) cell medium 
Nutrient Mixture Ham F-12 (HAM) with L-glutamine 
10% fetal bovine serum (v/v)  
100 U/ml Penicillin  
100 μg/ml Streptomycin  
 
CV-1, HEK293 and NSC34 cell medium 
DMEM with 4.5 g/L glucose and L-glutamine 
10% fetal bovine serum (v/v)  
100 U/ml Penicillin  
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100 μg/ml Streptomycin  
 
1X Trypsin-EDTA solution 
0.25% Trypsin 
1 mM EDTA 
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2.2 Methods 
2.2.1 General microbiology methods 
2.2.1.1 Storage and growth of E. coli for DNA purification 
E. coli containing plasmids of interest were stored at -70 °C in sterile 25% (v/v) 
glycerol solution in LB broth containing the appropriate antibiotic for the plasmid 
vector.  
 
To grow bacteria for DNA purification, E. coli containing the plasmid of interest were 
streaked out on LB agar plates (see section 2.1.2.3) containing the appropriate antibiotic 
for the plasmid vector and grown for 16 hours at 37°C. Single bacterial colonies were 
picked and grown in 5 ml LB-ampicillin broth or LB-kanamycin broth (see section 
2.1.2.3) for approximately 16 hours at 37°C while shaking at 220 rpm. For larger 
culture volumes, 1 ml of confluent E. coli culture was added for each 100 ml of LB 
broth and cultured for a further 16 hours. 
 
2.2.1.2 Preparation of plasmid DNA 
The QIAfilter Plasmid Maxi and QIAgen Miniprep Kits (Qiagen Ltd.) were used 
according to manufacturer’s instructions. These kits are based on the alkaline lysis 
method of DNA recovery (Sambrook et al., 1989). Typically 200 ml of culture was used 
for the Maxi Kit, resulting in approximately 500 μg of pure plasmid DNA and 5 ml of 




2.2.1.3 Quantitation of nucleic acids 
Spectrophotometric quantitation of plasmid DNA was performed using a NanoDrop 
1000 (Thermo Scientific) spectrophotometer. The absorbance of samples at 260 nm and 
280 nm was recorded. An optical density (OD) reading of 1 at a wavelength of 260 nm 
corresponds to a concentration of 50 µg/ml for double stranded DNA. Proteins are 
known to strongly absorb at a wavelength of 280 nm thus the ratio of OD readings at 
260 and 280 nm (OD260/280) gives an indication of purity of the sample. Pure DNA has 
an OD260/280 value of 1.8 (Sambrook et al., 1989).   
 
Plasmid DNA concentrations were also roughly quantified using ethidium bromide 
fluorescent quantitation. This method relies on the ability of ethidium bromide to bind 
to DNA. UV-induced fluorescence emitted by DNA-linked ethidium bromide is 
proportional to the total mass of DNA. The amount of DNA in a sample could then be 
quantified by visual comparison with the UV-induced fluorescence of a known quantity 
of a DNA standard or series of standards. This technique has a detection limit of as little 
as 5 ng of DNA.   
 
2.2.1.4 Restriction enzyme digestion of plasmid DNA 
Plasmid DNA was digested using the appropriate restriction enzyme and corresponding 
buffer according to the manufacturer’s instructions (Invitrogen). 10 units of enzyme 
were used per μg of DNA (1 unit is usually the amount of enzyme required to cleave  
1 µg of DNA in 1 hour at 37°C in the appropriate buffer). The volume of enzyme never 
exceeded 10% (v/v) of final reaction volume and the incubation time with the enzyme 
was 2 hours at 37°C. A typical diagnostic reaction contained 500 ng plasmid, 1 µl (10 
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units) restriction enzyme, 2 µl of 10x buffer in a final volume of 20 µl; all of the 
reaction was loaded and analysed by agarose gel electrophoresis. 
 
2.2.1.5 Agarose gel electrophoresis of plasmid DNA 
Agarose (ultra pure, electrophoresis grade, Invitrogen) was dissolved in boiling TAE 
buffer (see section 2.1.2.5) in a final concentration of 0.6-1.5% (w/v) and cast on a gel 
bed with a suitable comb using a horizontal gel apparatus (Hybaid). On setting, gels 
were placed in an electrophoresis tank containing TAE buffer to a level just above the 
gel surface. DNA samples containing DNA loading buffer (see Section 2.1.2.5) were 
loaded into the sample wells and were run at 100 V. Gels were stained with 10 μg/ml 
ethidium bromide to visualise DNA. Gels were then placed on a 3UV transilluminator 
emitting ultra violet light (λ=302 nm), visualised on a Sony video monitor and 
videographed using a Sony video graphic printer.   
 
To determine the size of the separated DNA, nucleic acid size markers were used: 
Phage λ DNA digested with Hind III, 1 kb DNA ladder.  
 
2.2.1.6 PCR-based site-directed mutagenesis 
PTPIP51-HA and myc-VAPB alanine/aspartate mutant constructs were generated using 
the mutagenic primers listed in Section 2.1.2.2 and a QuikChange XL site-directed 
mutagenesis kit (Stratagene) according to the manufacturer’s instructions (see Section 
2.1.2.6).   
 
The QuikChange XL site-directed mutagenesis system is designed to produce 
mutations in double stranded plasmids using primers containing the entire mutation and 
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the high fidelity, thermostable PfuTurbo® DNA polymerase in PCR. Experimental 
reactions and control reactions, to test mutation efficiency using pWhitescript™ control 
plasmid, were set up as shown below and used for PCR as shown in Table 2.6. The 
pWhitescript™ mutagenesis control plasmid contains a stop codon instead of a 
glutamine codon in the gene of β-galactosidase thus β-galactosidase is inactive in cells 
containing this plasmid. Competent cells containing this plasmid appear white on LB-
ampicillin agar plates pre-spread with X-gal (5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside) and IPTG (isopropyl-1-thio-β-D-galactopyranoside) because the 
inactive β-galactosidase enzyme is unable to cleave X-gal to galactose and an insoluble 
blue product. During the mutagenesis the control primers mutate the stop codon back to 
glutamine in the β-galactosidase gene. The active β-galactosidase is able to cleave X-gal 
and the appearing blue products are obvious markers of the successful mutagenesis.  
 
Reactions were performed in 0.2 ml PCR tubes (Thermo Fisher). Reactions were mixed 
gently by pipetting and then placed in a T3 Thermocycler (Biometra) for the PCR 
(cycling parameters are shown in Table 2.6). The lowest number of amplification cycles 
was used to minimise the possibility of errors by the DNA polymerase whilst at the 
same time generating enough amplified product for DNA purification. A sample of each 
PCR product was analysed for size, quality and quantity by restriction enzyme digestion 
and agarose gel electrophoresis alongside appropriate DNA markers (see Section 
2.2.1.5). 
 
Control reaction (reagents, except H2O were supplied with the kit):  
2 μl (10 ng) of pWhitescript™ control template DNA  
5 μl of 10x mutagenesis buffer (see Section 2.1.2.6) 
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1 μl of dNTP mix  
1.25 μl (125 ng) of oligonucleotide control primer #1 
1.25 μl (125 ng) of oligonucleotide control primer #2 
3 μl QuickSolution 
36.5 μl H2O to final volume of 50 μl  
1 μl (2.5 U/μl) PfuTurbo® DNA polymerase  
 
Experimental reaction (reagents, except DNA template, oligonucleotides and H2O, were 
supplied with the kit):  
5 μl of 10x mutagenesis buffer  
10 ng DNA template 
1 μl dNTP mix  
125 ng of each oligonucletide 
3 μl QuickSolution 
H2O to a final volume of 50 μl  
1 μl (2.5 U/μl) PfuTurbo® DNA polymerase 
 
Table 2.6 PCR-based site-directed mutagenesis cycling parameters 
Step Cycles Temperature (°C) Time 
1 1 95 1 minute 
2 18 
95 50 seconds 
60 50 seconds 
68 1 minute/kb of plasmid length 
3 1 68 7 minutes 
 
 88 
 2.2.1.7 Digesting the PCR product 
Following PCR, the reactions were placed on ice, 1 μl (10 U/μl) of the Dpn I restriction 
enzyme (supplied with the kit) was added and the reaction was incubated at 37°C for 1 
hour. The Dpn I endonuclease (target sequence 5’-Gm6ATC-3’) is specific for 
methylated and hemimethylated DNA and is used to digest parental DNA and to select 
for mutation-containing amplified DNA. 
 
2.2.1.8 Transformation into XL10-Gold® ultracompetent cells 
2 μl of XL10-Gold® β-mercaptoethanol mix (provided with the kit) was added to 45 μl 
thawed XL10-Gold® ultracompetent cells (provided with the kit) and the reaction 
incubated on ice for 10 minutes. 2 μl of the Dpn I-treated DNA was transferred to the 
competent cells and the reaction incubated on ice for 30 minutes. A second control was 
set up to verify transformation efficiency: 0.1 ng of pUC18 transformation control 
plasmid (provided with the kit) was added to 45 µl XL10-Gold® ultracompetent cells 
and incubated on ice for 30 minutes. The cells were then heat pulsed for 30 seconds at 
42°C, and then placed on ice for 2 minutes. Following the heat pulse, 0.5 ml of super 
optimal broth with catabolite repression (S.O.C.) medium (Invitrogen) was added to the 
cells. Following incubation at 37°C for 1 hour with shaking at 220 rpm, the samples 
were spread on LB-kanamycin agar plates. The transformed control pWhitescript™ and 
pUC18 cells were plated on LB-ampicillin agar plates pre-spread with 40 μl of X-gal 
(20 mg/ml in DMSO) and 20 μl of 100 mM IPTG for colour selection. The plates were 
incubated at 37°C for 16 hours. The successfully mutagenised pWhitescript™ control 
colonies appeared as blue colonies. The number of pUC18 control colonies was greater 
than 100 colonies and most of them displayed the blue phenotype. The number of the 
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colonies for the experimental reaction was about 50 colonies. Plasmid DNAs were 
sequenced by Eurofins MWG Operon, UK to confirm the mutagenesis.   
 
2.2.2 Protein analysis 
2.2.2.1 Protein concentration determination (Bradford Assay) 
Determination of protein concentration was carried out using a Bio-Rad protein assay 
kit according to the manufacturer’s instructions (Bio-Rad, UK). The assay is using the 
colorimetric reaction described by Bradford (Bradford, 1976). The assay is based on the 
observation that the maximum absorbance for an acidic solution of Coomassie Brilliant 
Blue G-250 shifts from 465 nm to 595 nm when binding to protein occurs. In brief, 
eight dilutions were prepared from a freshly prepared BSA standard and four dilutions 
from each protein sample with the Bradford reagent. 50 µl of each dilution was 
transferred to a 96 well microtiter plate and absorbance readings were recorded at a 
wavelength of 595 nm using a VICTOR3 multilabel plate reader (Perkin Elmer). 
Sample protein concentrations were calculated using the recorded absorbance values 
and a standard curve drawn from the freshly prepared BSA standard.  
 
2.2.2.2 SDS-PAGE of protein samples 
For SDS-PAGE analyses of cell lysates, cells were washed in PBS, lysed on ice in 
appropriate amounts of 1x SDS sample buffer (final concentration 2 % SDS; see section 
2.1.3.1) and then heated on a heat block for 5 minutes at 100 ºC. The protein samples 
were then separated by SDS-PAGE using the Mini-PROTEAN 3 gel electrophoresis 
system (Bio-Rad) with a discontinuous buffer system. Depending on the size of the 
proteins of interest, 8, 10 or 12% (v/v) acrylamide gels (see Section 2.1.3.2) were run at 
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a voltage of 100 V, until the dye front reached the bottom of the gel or proteins were 
separated as necessary.  
 
To follow the progress of protein separation and to determine protein size, Precision 
Plus Protein Standards (Biorad) were used (see Section 2.1.3.2). 
 
2.2.2.3 Immunoblotting (Western Blotting) 
After SDS-PAGE, proteins were transferred from gels to a Protran nitrocellulose 
membrane (0.45 μm pore size; Whatman) using the wet method with the following filter 
sandwich: 
Cathode – sponge / extra thick cellulose blot paper (Whatman) / SDS-PAGE gel / 
nitrocellulose membrane / extra thick cellulose blot paper / sponge – Anode. 
 
This sandwich was assembled whilst totally immersed in transfer buffer (see Section 
2.1.3.3), secured in cassettes and placed in a Mini Trans-Blot electrophoretic transfer 
cell (Biorad), and run at 100 V for 60 minutes or at 30 V for 16 h.  Membranes 
containing transferred proteins were referred to as “blots”. Blots were incubated with 
Ponceau S solution (see Section 2.1.3.5) for 1 to 2 minutes to determine the efficiency 
of protein transfer. Blots were then rinsed for 1 to 2 minutes with ultrapure water to 
destain.  
 
2.2.2.4 Antibody probing of membrane-bound proteins 
Blots were incubated in blocking buffer (see Section 2.1.3.4) for 30 minutes at 20°C to 
reduce non-specific antibody binding. Blots were then incubated with an appropriate 
dilution of primary antibody in blocking buffer for 16 h at 4 °C (table 2.4 gives the 
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details of all primary antibodies used). Blots were then washed (3 x 10 minutes) in 
TBS-Tween (see Section 2.1.3.4) and an appropriate dilution of horseradish peroxidase-
coupled secondary antibody in TBS-Tween was added for 1 hour at 20°C.  Secondary 
antibodies were used depending on the species in which the primary antibody was 
raised (for details see Table 2.5). Following washing with TBS-Tween (3 x 10 minutes), 
immunoreactive species were visualised using enhanced chemiluminescence (ECL) 
development reagents (see Section 2.1.3.4) and Hyperfilm-ECL (GE Healthcare), 
according to the manufacturer’s instructions. ECL protein signal visualisation is based 
on antibody bound horseradish peroxidase catalysed oxidation of luminol in the 
presence of hydrogen peroxide in alkaline conditions. Oxidised luminol is in an 
increased energy state and when luminol returns to ground state it emits the energy as 
light. In ECL detection the light output of luminol is enhanced by the presence of 
chemical enhancers (Whitehead et al., 1979). The light emission maximum of luminol is 
at 428 nm which is easily detectable by blue light sensitive autoradiography films. To 
visualise nitrocellulose membrane-bound proteins, detection solution A (luminol 
solution) and detection solution B (peroxide solution) were mixed in a 1:1 ratio in a 
final volume of 0.125 ml/cm2 nitrocellulose membrane and incubated with the blot for 3 
minutes at 20 ºC. Following incubation, blots were placed in an X-ray film cassette and 
Hyperfilm-ECL was placed on top of the membrane in a dark room, and exposed for a 
time varying between 5 seconds and 1 hour. The Hyperfilm-ECL was developed using a 
Konica Minolta SRX-101A developer.  
 
Developed films were scanned using an Epson Perfection V700 Photo scanner (Seiko 
Epson Corp.). Signals on films were background-corrected and quantified using ImageJ 
developed by Wayne Rasband (NIH, Bethesda, USA; http://rsb.info.nih.gov/ij/) (Staal 
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et al., 2004). Each of the background-corrected OD signals was compared to an OD 
calibration curve obtained from a calibrated OD step tablet (Kodak) to ensure that 
signals were obtained within the linear range of the film. Only the signals within the 
linear OD range were used for statistical analysis.  
 
In experiments investigating the effects of TDP-43, FUS and SOD1 on binding of 
PTPIP51 to VAPB (Chapter 4), signals from co-immunoprecipitating VAPB were 
normalized to immunoprecipitated PTPIP51-HA signals. The individual values were 
then compared to control EGFP signals; control signals were assigned a reference value 
of 1. In experiments investigating the effects of mutated phosphorylation sites in 
PTPIP51 (Chapter 5), signals from co-immunoprecipitating VAPB were normalized to 
immunoprecipitated PTPIP51-HA signals. The individual values from the mutants were 
then compared to wild-type PTPIP51 signals.  Finally, in experiments investigating the 
effects of mutated phosphorylation sites in VAPB (Chapter 5), signals from co-
immunoprecipitating PTPIP51 were normalized to immunoprecipitated myc-VAPB 
signals. The individual values from the mutants were then compared to wild-type VAPB 
signals. Statistical analyses were performed using GraphPad Prism 5 software 
(GraphPad Software Inc., San Diego, CA). The statistical tests performed are detailed in 
the figure legends.   
 
2.2.2.5 Immunoprecipitation 
All steps of immunoprecipitation (IP) experiments were performed at 4°C or on ice. 
Cells were harvested by trypsinisation and washed once in PBS. 1/20 of the sample was 
removed (“Input”) and lysed in 5X SDS sample buffer (see Section 2.1.3.1). The rest of 
the sample was incubated in immunoprecipitation lysis buffer (see Section 2.1.4) for 1 
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hour after which the lysates were centrifuged at 100,000xg for 40 minutes to pellet 
insoluble particles. Supernatants were transferred to fresh tubes and were precleared by 
incubation with 25 μl of Protein G-sepharose beads (50% (v/v) in PBS-Triton) (see 
Section 2.1.4) for 30 minutes. Following centrifugation at 2,000xg for 30s to settle the 
beads, supernatants were transferred to fresh tubes and total protein concentrations were 
quantified by Bradford assay (see Section 2.2.2.1). The protein concentration was 
adjusted to 1 μg/μl if needed and equal amounts of protein (500 μg) for each sample 
were then used for immunoprecipitation. The appropriate primary antibody was added 
(see Table 2.4) and the samples were incubated with mild mixing on a rotary shaker for 
16 hours at 4°C. After the addition of 30 μl Protein G-sepharose beads (50% (v/v) in 
PBS-Triton), the samples were incubated for a further 2 hours on a rotary shaker before 
centrifuging at 2,000xg for 30 s to pellet the beads. The pelleted beads were retained 
and washed four times with 1 ml PBS-Triton. The bound proteins were then eluted from 
the beads by incubation in 50 μl of 1X SDS sample buffer, heated at 100°C for 5 
minutes and used for SDS-PAGE.  
 
2.2.2.6 Mass spectrometry studies 
Mass spectrometry studies were performed in collaboration with the Proteomics Facility 
at the Institute of Psychiatry. Identification of phosphorylation sites from transfected 
cells was performed essentially as described previously for other proteins (Standen et 
al., 2003). Briefly, VAPB and PTPIP51 were immunoprecipitated from transfected 
CHO cells using the myc- or the HA-tags. The two proteins were resolved by SDS-
PAGE, the gels stained with Colloidal Coomassie (see section 2.1.3.5) and the band 
corresponding to VAPB or PTPIP51 excised, reduced with 10 mM dithiothreitol (30 
minutes at 56°C) and derivatised with 55 mM iodoacetamide (20 minutes in the dark at 
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20°C). The proteins were then digested with trypsin (Roche Molecular Biochemical) for 
4 hours at 37°C. Digested peptides were extracted from the gel pieces with two wash 
cycles of 50 mM NH4HCO3 and acetonitrile, lyophilised and resuspended in 20 µl of  
50 mM NH4HCO3. 
 
Peptide digests were analysed by liquid chromatography tandem mass spectrometry 
(LC/MS/MS). Chromatographic separations were performed using an Ultimate LC 
system (Dionex, UK). Peptides were resolved by reversed-phase chromatography on a 
75 µm, C18 PepMap column. A gradient of acetonitrile in 0.05% formic acid was 
delivered over 60 minutes to elute the peptides at a flow rate of 200 nl/min. Peptides 
were ionised by electrospray ionisation using a Z-spray source fitted to a QTof-micro 
(Waters Corp.). The instrument was set to run in automated switching mode, selecting 
precursor ions based on their intensity and charge state, for sequencing by collision-
induced fragmentation. The MS/MS analyses were conducted using collision energy 
profiles that were chosen based on the mass-to-charge ratio (m/z) and the charge state of 
the peptides. 
 
The mass spectral data was processed into peak lists containing the m/z value of each 
precursor ion and the corresponding fragment ion m/z values and intensities. Data were 
searched against a custom-built database using the Mascot searching algorithm (Matrix 
Science, UK). Peptides and phospho-peptides of VAPB and PTPIP51 were identified by 
matching the MS/MS data against mass values generated from the theoretical 
fragmentation of peptides based on the search criteria set. Specifically, tryptic cleavage 
with up to 3 missed cleavages, carbamidomethyl modification of cysteine residues, 
oxidised methionine, N-acetylation of the protein and phosphorylation of 
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serine/threonine and tyrosine residues. All the amino acid modifications were selected 
as variable modifications in the software. The exact location of phosphorylation within 




All steps of the procedure were performed at 20 ºC. CV1 cells grown on glass 
coverslips were washed once with PBS (see Section 2.1.1) to remove culture medium 
and incubated in fixing solution (see Section 2.1.6) for 10 minutes. Cells were then 
washed twice with PBS to remove the fixing solution and quenching solution (see 
Section 2.1.6) was added for 15 minutes to remove excess paraformaldehyde and reduce 
autofluorescence. Following quenching, the cells were washed once with PBS, 
permeabilised for 3 minutes and blocked with blocking solution (see Section 2.1.6) for 
30 minutes to reduce non-specific binding  for 30 minutes. Incubation with primary 
antibodies in blocking solution was then carried out for 1 hour. All primary antibodies 
that were used during the experiments are listed in Table 2.4. The cells were then 
washed five times with PBS for 5 minutes before being incubated with the secondary 
antibody in blocking solution for 45 minutes. Fluorescent labelled secondary antibodies 
were chosen depending on the species in which the primary antibody was raised and the 
fluorophore (for details see Table 2.5).  
 
Following incubation with the secondary antibody the cells were washed three times 
with PBS. Nucleic acids were stained with 50 μg 4′,6-Diamidino-2-phenylindole 
(DAPI; see Section 2.1.1) for 5 minutes, followed by a further 5-6 washes in PBS. 
Finally, coverslips were mounted onto slides using Mowiol-DABCO mounting medium 
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(see Section 2.1.6).  Conventional images were captured using Leica LAS AF software 
on a Leica DM5000 B microscope equipped with a Leica DFC360 FX camera and 
10x/0.30NA, 40x/0.75NA or 63x/1.25NA HCX-PL-FLUOTAR objectives (all from 
Leica Microsystems CMS GmbH, Mannheim, Germany). Confocal images were 
captured using a Zeiss LSM 510 META confocal microscope at the appropriate 
excitation wavelengths with a 63x/1.4NA Zeiss Plan-APOCHROMAT objective (Carl 
Zeiss AG, Oberkochen, Germany). 
 
Co-localization of PDI (an ER marker) with TOM20 (a mitochondrial marker) was 
identified and quantified using ImageJ with the Intensity Correlation Analysis plug-in 
on whole cells. Intensity correlation analysis represents a robust method for 
quantitatively determining the relative co-localization of dye signals obtained from 
advanced microscopy. Conventional dye overlay methods that are often used in double 
immunofluorescence microscopy are limited in that they can report incorrect  
co-localization of two proteins. By contrast, intensity correlation analysis determines 
whether the pixel intensities from two signals vary in synchrony, making it a powerful 
method for judging whether two proteins co-localize. The values obtained from the 
analyses are reported as an intensity correlation quotient (ICQ), which is a statistically 
testable, single value assessment of the relationship between two stained protein pairs 
(Li et al., 2004). For dependent staining (co-localization) 0<ICQ≤+0.5, for random 
staining ICQ=0, and for segregated staining 0>ICQ≥-0.5 (no co-localization). 
Comparison of means was carried out using a one-way ANOVA combined with the 
Tukey post-hoc analysis to adjust for multiple comparisons. 
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2.2.3.2 In situ Proximity Ligation Assay™ (PLA™) 
Interactions between PTPIP51 and VAPB were visualized and quantified using a 
proximity ligation assay (Soderberg et al., 2006). For these experiments, a commercial 
kit (Olink Bioscience, Uppsala, Sweden) was used according to the manufacturer’s 
instructions. In this assay, fixed cells are probed with primary antibodies and then 
secondary antibodies coupled with complementary oligonucleotides are applied. If the 
distance between the two antibody-coupled oligonucleotides is less than 40 nm, they 
can interact through subsequent addition of two further oligonucleotides and join to 
form a closed circle. This can then be amplified by rolling-circle amplification with 
DNA polymerase to produce a concatemeric DNA strand onto which the detection 
probes hybridise.  
 
CV1 cells grown on glass coverslips were fixed, probed with VAPB and PTPIP51 
primary antibodies followed by Duolink secondary antibodies. All following 
incubations were performed using the reagents provided in the Duolink kit (Section 
2.1.7). Complementary PLA probes raised in the appropriate species were mixed with 
the Duolink Antibody Diluent and incubated with the samples in a pre-heated humidity 
chamber for 1 h at 37°C. The coverslips were then washed twice for 5 minutes with 
Wash Buffer A and incubated with the Ligation solution in a pre-heated humidity 
chamber for 30 minutes at 37°C. The reagents used in the amplification step are light 
sensitive and all the subsequent procedures were performed avoiding direct exposure to 
light. After two 2 minutes washes with Wash Buffer A, the coverslips were incubated 
with the Amplification-Polymerase solution in a pre-heated humidity chamber for 100 
minutes at 37°C. After two 10 minute washes in Wash Buffer B, the coverslips were air-
dried, mounted, and viewed using a Leica DM5000 fluorescence microscope (Leica 
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Microsystems GmbH, Wetzlar, Germany). Images were captured using a 63x/1.25NA 
HCX-PL-FLUOTAR oil immersion lens and PLA signals were analyzed using the 
Particle analysis function of ImageJ (National Institute of Mental Health, Bethesda, 
Maryland, USA). 
 
2.2.3.3 Transmission electron microscopy 
NSC34 cells grown on 60 mm Petri dishes were washed once with 0.1 M cacodylate 
buffer and then fixed with 2.5% glutaraldehyde in cacodylate buffer (see Section 2.1.8) 
for 3 hours at 20°C. The cells were then gently removed from the surface of the dish 
with a plastic scraper and centrifuged at 800xg for 10 minutes to form a pellet. The cell 
pellet was washed in 0.1 M cacodylate buffer pH 7.2 and then post-fixed for 1 hour in 
1% osmium tetroxide in 0.1M cacodylate buffer. Following a wash in 0.1 M cocodylate 
buffer, the samples were block stained for 1 hour with 1% uranyl acetate in water before 
dehydration through a graded series of alcohols and embedding in Taab resin. 70 nm 
sections were cut on a Leica Ultracut E microtome and stained with lead citrate (0.1N).  
 
Samples were viewed on a Tecnai 12 electron microscope (FEI) fitted with an AMT 
camera and digital images were captured at a magnification of 2900x, 4800x and 6800x. 
The mitochondrial perimeter, the length of ER apposed to mitochondria and the lengths 
of tethers connecting mitochondrial outer membranes to ER membranes were 
determined in a blind manner using the ImageJ software (NIH, Bethesda, USA; 
http://rsb.info.nih.gov/ij/).   
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2.2.4 Mammalian cell culture and transfection methods 
2.2.4.1 NSC34, CV-1, CHO and HEK293 cell culture 
The cells were maintained in monolayer culture in DMEM/HAM media containing 10% 
FBS and supplements (see Section 2.1.9) at 37°C under an atmosphere of 5% CO2. 
Cells were passaged when they formed an approximately 80% confluent layer in the 
culture vessel. Medium was removed and cells were washed once with sterile PBS (see 
Section 2.1.1). To dislodge cells from the surface of the vessel, enough trypsin-EDTA 
solution (see Section 2.1.9) was added to cover the monolayer (e.g. 1 ml trypsin-EDTA 
solution for a 25 cm2 flask) and the cells were incubated at 37°C for 2-3 minutes. Full 
media (e.g. 4 ml for a 25 cm2 flask) was then added to inactivate the trypsin, and cells 
were pipetted up and down to triturate them. Finally, the cell suspension was distributed 
into vessels for further culturing.  
 
2.2.4.2 Transient transfection 
Transient transfection of CV-1 cell cultures 
CV-1 cells were transfected using ExGen 500 (Thermo Scientific), a polyethylenimine 
based transfection reagent. Polyethylenimine is a cationic polymer with high proton 
buffer capacity (“proton sponge effect”). The mechanism of polyethylenimine based 
transfection has been described (Boussif et al., 1995; Sonawane et al., 2003). The 
positively charged polyethylenimine polymer interacts with negatively charged DNA 
and forms small particles (polyplexes). Polyplexes settle on and bind to anionic cell 
surface residues and are taken up by the cells via endocytosis (Boussif et al., 1995). The 
“proton sponge effect” of polyethylenimine neutralises the acidic pH of the 
endosome/lysosome and this results in a charge driven chloride influx into the 
endosome. The chloride influx causes osmotic swelling and disruption of the endosome 
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and allows the escape of the polyplexes from the endosome (Sonawane et al., 2003). 
The DNA then dissociates from the polyplex and translocates to the nucleus.  
 
Transfections were conducted according to the manufacturer’s instructions. Cells were 
plated on 13 mm diameter coverslips in 24 well plates (Greiner Bio-One) the day before 
transfection so that they reached approximately 50% confluence on the day of 
transfection. For each transfection, the amounts of reagents were vortexed as indicated 
in Table 2.7 for 10 s. The transfection solution was then incubated for 10 minutes at 
20°C and added drop-wise to the cells. The cells were analysed 24-48 hours post-
transfection. 
 
Table 2.7 Amounts of reagents for ExGen 500 based transient transfection 
Plate Format DNA/well (µg) ExGen 500/well (µl) 150 mM NaCl/well (µl) 
24 well plate 0.5 2.1 25 
12 well plate 1 4.3 50 
 
 
Lipid based transfection of CHO cell cultures 
CHO cells were transfected with Lipofectamine (Invitrogen) according to the 
manufacturer's instructions, using 10 μg plasmid DNA and 40 μl Lipofectamine™ per 
10 cm diameter Petri dish. The cells were plated out the day before the transfection 
experiment so that they reached 50-80% confluency on the day of transfection, and were 
harvested for analysis 24 hours post-transfection. 
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Lipid based transfection of HEK293 cell cultures 
HEK293 cells were transfected with FuGENE-6 (Promega) at a 3:1 ratio  
(FuGENE-6:DNA) according to manufacturer’s instructions, using 1 μg of plasmid 
DNA and 3 μl FuGENE-6 for a well in a 6 well plate. The cells were plated 24 hours 
prior to transfection so that they reached 50% confluency on the day of transfection, and 
were harvested for immunoprecipitation experiments 24-48 hours post-transfection. 
 
Lipid based transfection of NSC34 cell cultures 
NSC34 cells were transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer's instructions, using 20 μg plasmid DNA and 80 μl Lipofectamine 2000 
per 175 cm3 flask. The cells were plated out 24 hours before the transfection experiment 
so that they reached 25-30% confluency on the day of transfection, and were harvested 
for analysis 24 hours post-transfection. 
 
2.2.4.3 Delivery of siRNA to cell cultures 
Small interfering RNA (siRNA) duplexes (VAPB, PTPIP51 and non-targeting control) 
were purchased from Dharmacon and Origene and were described previously (De Vos 
et al., 2012). Duplexes were diluted in 1x resuspension buffer purchased from 
Dharmacon (60 mM KCl, 6 mM HEPES pH 7.5, and 200 mM MgCl2) and stored as  
100 μM aliquots at -20ºC. 
 
Human VAPB siRNA sequence (Dharmacon): 
UGUUACAGCCUUUCGAUUAUU 
Human PTPIP51 siRNA sequence (Dharmacon): 
CCUUAGACCUUGCUGAGAUUU 
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Mouse VAPB siRNA sequence (Dharmacon): 
UGUUACAGCCUUUCGAUUAUU 
Mouse PTPIP51 siRNA sequence (Origene): 
GGAUGACAACGCUGGCAAAGGGUCT 
 
Delivery of siRNAs to CV1 cells 
VAPB and PTPIP51 were knocked down in CV1 cells using Lipofectamine™ 2000 
(Invitrogen) according to manufacturer’s instructions, and using the amount of reagents 
indicated in Table 2.8. Cells were plated out the day before so they reached 30% 
confluency on the day of transfection. Transfection reagent and culture medium were 
removed 24 hours post-transfection and replaced with fresh culture medium. Cells were 
used for analysis 96 hours post-transfection. 
 
Table 2.8 Delivery of human VAPB and PTPIP51 siRNA to CV1 cells 
Plate Format siRNA concentration (nM) Lipofectamine 2000/well (μl) 
12 well 100 2 
24 well 100 1 
 
 
Delivery of siRNAs to NSC34 cells 
Mouse VAPB and PTPIP51 respectively were knocked down in NSC34 cells using 
Lipofectamine™ 2000 (Invitrogen) according to manufacturer’s instructions, and using 
the amount of reagents indicated in Table 2.9. Cells were plated 24 hours before so they 
reached 30% confluency on the day of transfection. Transfection reagent and culture 
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medium were removed 24 hours post-transfection and replaced with fresh culture 
medium. Cells were harvested 96 hours post-transfection. 
 
Table 2.9 Delivery of mouse VAPB and PTPIP51 siRNA to NSC34 cells 
Plate Format siRNA concentration (nM) Lipofectamine 2000/well (μl) 
60 mm 50 20 
12 well 50 4 
 
 
2.2.5 Treatment of HEK293 cells with the tyrosine phosphatase inhibitor 
pervanadate 
Pervanadate was prepared as a 100X stock by mixing 50 µl 200 mM sodium 
orthovanadate with 1.6 µl of 30% (w/w) hydrogen peroxide in 948 µl of water. The 
reaction was left for 5 minutes at 20°C, producing 10 mM sodium orthovanadate and  
16.3 mM hydrogen peroxide (Derkinderen et al., 2005; Huyer et al., 1997). The excess 
hydrogen peroxide was removed by adding 200 µg/ml catalase (Sigma) and incubating 
for an additional 5 minutes at 20°C. The reaction mix was diluted 1:100 with fresh cell 
culture medium and the cells were treated for 20 minutes. 
 
2.2.6 Fluorescence-activated cell sorting (FACS) of NSC34 cells 
NSC34 cells were grown in 175 cm3 flasks, transfected with plasmid DNA using 
Lipofectamine 2000 and incubated for 24 hours. Following trypsinisation, the cells were 
counted, filtered through a 40 µm BD Falcon™ cell strainer and resuspended in PBS at 
a concentration of 8-10 million/ml in 5 ml BD Falcon™ round-bottom tubes. All the 
following steps of the sorting procedure were performed at 4°C.  
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 The cells expressing ECFP, ECFP-tagged or AcGFP constructs (positive fraction) and 
the untransfected cells (the negative fraction) were analyzed and sorted based on their 
fluorescence, using a BD FACSAria™ cell sorter employing a 100 µm nozzle and 
applying 13.7x104 Pa (20 psi) sheath pressure. For detecting EGFP fluorescence, cells 
were excited using a blue laser (488 nm), a 505 Long pass filter and a 525/550 band 
pass filter. Sterile PBS was used as sheath fluid. The sample was maintained at 4°C and 
was sorted at a rate of less than 5000 events/second and at a flow rate of less than 6. The 
positive cells were collected in PBS with 5% FCS and underwent a post-sorting purity 
testing that involved re-analysing a proportion of the cells. Only the samples achieving 
a purity of over 98% were processed further. A proportion were also plated on 
coverslips and analysed by fluorescence microscopy to further confirm the purity of 
transfected cells in the final sorted population. Cells were then harvested and processed 


























As detailed in Section 1.4, up to approximately 20% of the mitochondrial surface is 
closely apposed to ER membranes. These regions facilitate a variety of signalling 
processes between the two organelles including Ca2+ and phospholipid exchange 
(Csordas et al., 2006; Hayashi et al., 2009; Lebiedzinska et al., 2009; Rizzuto et al., 
2009; Rizzuto et al., 1998; Rusinol et al., 1994). 
 
Tethers that link ER to mitochondria have been visualized in electron microscopy 
studies. These range from approximately 10 nm to 25 nm in length, suggesting that a 
number of different molecules are responsible for physically connecting ER and 
mitochondria (Csordas et al., 2006). However, the nature of these tethers is still not 
clear. Several molecules such as Drp1 (Pitts et al., 1999) and PACS2 (Simmen et al., 
2005) have been shown to indirectly regulate ER-mitochondria contacts. Interaction 
between IP3 receptors on the ER and voltage dependent anion channel-1 (VDAC1) on 
mitochondria via the molecular chaperone Binding immunoglobulin Protein (BiP) has 
been proposed to link ER to mitochondria (Szabadkai et al., 2006), but IP3 receptor 
deficient cells show normal ER-mitochondria interactions suggesting other molecules 
are responsible for the physical linkage (Csordas et al., 2006). In yeast, proteins of the 
ER-mitochondria encounter structure (ERMES) act as a molecular tether between ER 
and mitochondria but orthologs of these proteins in higher eukaryotes have not been 
identified so far (Kornmann et al., 2009). In mammalian cells, mitofusin-2 dimers have 
been shown to link ER and mitochondria (de Brito and Scorrano, 2008). However, other 
groups could not replicate this finding, which involved mainly light microscopy studies. 
Moreover, a recent study involving electron microscopy of mitofusin-2 knockout cells 
has revealed that loss of mitofusin-2 actually increases ER-mitochondria contacts 
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(Cosson et al., 2012). Thus, the identity of the molecular tethers that physically connect 
ER and mitochondria in mammalian cells is not properly known.  
 
Previous work from our research group demonstrated that outer mitochondrial 
membrane protein PTPIP51 interacts with integral ER protein VAPB (De Vos et al., 
2012). PTPIP51 is anchored in the outer mitochondrial membrane via an N-terminal 
transmembrane domain with the remaining C-terminus projecting into the cytoplasm 
(De Vos et al., 2012). VAPB is anchored in the ER via its C-terminal membrane 
spanning domain with its N-terminus projecting into the cytosol (Kagiwada et al., 
1998). As such, VAPB and PTPIP51 are plausible candidates that might represent at 
least some of the linkers visualized by electron microscopy which act as ER-
mitochondria tethers.  
 
In this chapter, the role of VAPB and PTPIP51 in mediating ER-mitochondria 
interactions was tested. If PTPIP51 and VAPB form some of the physical links between 
ER and mitochondria, then modulating the expression of these proteins is predicted to 
alter ER-mitochondria associations. The expression levels of VAPB and PTPIP51 were 
thus modulated and ER-mitochondria associations then monitored by electron and light 
microscopy. VAPB and PTPIP51 expression were reduced via siRNAs and elevated via 
transfection.  
 
For the electron microscopy studies, the NSC34 motor neuron cell line was used. This 
cell line was chosen as some of the later studies (see Chapter 4) involved analysing the 
effects of proteins associated with familial ALS on ER-mitochondria associations and 
the VAPB-PTPIP51 interaction. NSC34 cells were developed by fusing mouse 
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embryonic motor neurons with mouse neuroblastoma cells (Cashman et al., 1992) and 
exhibit morphological and physiological features of spinal motor neurons (Matusica et 
al., 2008). Thus, they represent a suitable model for studying how insults associated 
with ALS might affect ER-mitochondria associations.  
 
For the confocal light microscopy studies, CV1 cells were utilised. This is an 
established cell line initially extracted from Cercopithecus aethiops kidney fibroblasts 
(Jensen et al., 1964). CV1 cells have a highly spread morphology and are suitable for 
analysing the distribution of intracellular organelles (e.g. see (De Vos et al., 2012)).  
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3.2 Results 
3.2.1 VAPB and PTPIP51 mediate ER-mitochondria associations in electron 
microscopy studies using NSC34 cells 
To investigate the role of VAPB and PTPIP51 in mediating ER-mitochondria 
interactions, expression of VAPB and PTPIP51 were first modulated and ER-
mitochondria associations then quantified by electron microscopy in NSC34 cells. This 
involved capturing images of mitochondria in appropriately manipulated cells and then 
calculating the % of the mitochondrial surface closely apposed (less than 25 nm) to ER. 
The quantification was performed using the ImageJ software (http://rsb.info.nih.gov/ij/) 
(see Section 2.2.3.3).  
 
First, VAPB and PTPIP51 expression was reduced using siRNAs. Consistent with a 
previous study (De Vos et al., 2012), siRNA knockdown of VAPB did not influence the 
expression of PTPIP51 and knockdown of PTPIP51 did not influence the expression of 
VAPB (Figure 3.1). Moreover, the expression levels of mitofusin-2 (another protein 
suggested to mediate ER-mitochondria interaction (de Brito and Scorrano, 2008)) were 
not affected by the siRNA knockdown of either VAPB or PTPIP51. In control siRNA 
treated cells, approximately 12% of the mitochondrial surface was closely associated 
with ER (Figure 3.2). However, siRNA knockdown of either VAPB or PTPIP51 
significantly reduced these values to 8% (VAPB siRNA) and 6% (PTPIP51 siRNA). 
Loss of PTPIP51 was the more potent in disrupting ER-mitochondria interactions 
(Figure 3.2). 
 
Next, the expression of VAPB and PTPIP51 was elevated via transfection. Cells were 
transfected with either ECFP control vector, ECFP-VAPB (Morotz et al., 2012) or 
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PTPIP51 that was expressed using a bicistronic internal ribosome entry site (IRES) 
vector with AcGFP. To monitor the effect of VAPB and PTPIP51 co-expression, the 
cells were transfected with ECFP-VAPB and HA tagged PTPIP51. Since these transient 
transfections achieved a transfection efficiency of only 30-50%, the ECFP/AcGFP tags 
were further utilized to isolate transfected cells using a BD® FACS Aria cell sorter. The 
cell sorting achieved over 98% positive cells (Figure 3.3). This was further confirmed 
by monitoring ECFP, ECFP-VAPB and PTPIP51 expression in the sorted cells by 
fluorescence and immunofluorescence microscopy. This staining confirmed the 
efficiency of the sorting procedure (see for example staining for ECFP-VAPB and 
PTPIP51 in ECFP-VAPB/PTPIP51-HA co-transfected cells in Figure 3.4).  
 
As expected, the proportion of the mitochondrial surface closely associated with ER in 
control cells expressing ECFP alone was not significantly different to that in cells 
treated with control siRNA (Figure 3.5A). However, expression of either VAPB or 
PTPIP51 markedly increased the percentage of mitochondrial surface in touch with ER 
to approximately 18% or 26% respectively (Figure 3.5A).  Interestingly, overexpression 
of PTPIP51 was more potent than VAPB at promoting ER-mitochondria interactions 
and this is consistent with the siRNA studies where loss of PTPIP51 was more effective 
at disrupting ER-mitochondria interactions (Figure 3.2 and 3.5A).  
 
The effect of overexpressing both VAPB and PTPIP51 was also investigated and here a 
dramatic increase in ER-mitochondria interactions was observed. In these co-transfected 
cells, approximately 60% of the mitochondrial surface was closely associated with ER 
(Figure 3.5A and 3.5B). 
 
 111 
3.2.2 VAPB and PTPIP51 mediate ER-mitochondria co-localization in confocal 
light microscopy studies using CV1 cells 
For these investigations, CV1 cells were utilized due to their flattened and spread 
morphology which facilitates such morphological analyses. Other groups have utilized 
confocal microscopy to study ER-mitochondria interactions (e.g. (Area-Gomez et al., 
2012; de Brito and Scorrano, 2009; Rizzuto et al., 1998)). In this set of experiments, ER 
was detected by immunostaining for the integral ER protein, protein disulfide isomerase 
(PDI) and mitochondria were detected by immunostaining for translocase of outer 
mitochondrial membrane 20 (TOM20). The co-localization of PDI and TOM20 was 
quantified using intensity correlation analysis (ICA) and data presented as relative 
intensity correlation quotients (ICQ) (Li et al., 2004). ICA is one of the most rigorous 
methods for studying co-localization of proteins by confocal microscopy since it 
compares the scatter plots of two stains against the product of the pixel intensity 
difference for each of the two stains from their respective means. Thus, unlike other 
methods which simply compare co-localization of pixels, ICA determines whether the 
pixel intensities from two signals vary in synchrony. 
 
First, the cells were transfected with control siRNA, PTPIP51 siRNA or VAPB siRNA 
and ER and mitochondria co-localization monitored by immunostaining. The  
co-localization of PDI and TOM20 was significantly decreased after either VAPB or 
PTPIP51 depletion (Figure 3.6) and this was consistent with the electron microscopy 
results (Figure 3.2). However, unlike the electron microscopy studies, there was no 
significant difference between loss of VAPB and loss of PTPIP51. This may be 
explained by the reduced resolution of the light microscope compared to the electron 
microscope which results in a corresponding decrease in sensitivity. 
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 Secondly, VAPB and/or PTPIP51 were overexpressed in the CV1 cells. Cells were 
transfected with ECFP control, ECFP-VAPB, hemagglutinin-tagged PTPIP51 
(PTPIP51-HA) or ECFP-VAPB+PTPIP51-HA. Transfection of VAPB or PTPIP51 both 
increased co-localization of ER and mitochondria and in agreement with the electron 
microscopy studies, this phenotype was particularly striking in VAPB+PTPIP51  
co-transfected cells (Figure 3.7). In these co-transfected cells, a dramatic reorganization 
of the ER was observed so that it co-aligned with mitochondria (Figure 3.7). 
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 Figure 3.1 siRNA knockdown of VAPB or PTPIP51  
Immunoblots showing siRNA knockdown of VAPB or PTPIP51 in NSC34 cells. 
siRNA knockdown of VAPB does not affect expression of PTPIP51, siRNA 
knockdown of PTPIP51 does not affect expression of VAPB and siRNA knockdown of 
either VAPB or PTPIP51 do not affect expression of mitofusin 2 (MFN2). Also shown 
is an immunoblot of tubulin as a loading control. Bar charts show PTPIP51 or VAPB 
expression levels following quantification of signals from immunoblots normalized to 
tubulin. Statistical significance was determined by a paired t-test. n=4; error bars are 
SEM; ***p<0.001. 
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 Figure 3.2 siRNA knockdown of VAPB or PTPIP51 reduces ER-mitochondria 
associations  
Representative electron micrographs of ER-mitochondria contacts in control siRNA 
(CTRL), VAPB or PTPIP51 siRNA treated cells. Arrowheads show ER-mitochondria 
contact sites. Scale bar=100 nm. Bar chart shows percentage of mitochondrial surface 
closely apposed to ER in the different samples. Statistical significance was determined 
by one-way ANOVA followed by Tukey’s multiple comparison test. n=34-40 cells and 
341-623 mitochondria; error bars are SEM; **p<0.01, ***p<0.001. 
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 Figure 3.3 FACS post-sorting analyses demonstrating high purity of ECFP/AcGFP 
positive samples 
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NSC34 cells transfected with ECFP control vector (A), ECFP-VAPB (B), PTPIP51 in 
IRES vector with AcGFP (C) or ECFP-VAPB + PTPIP51-HA (D) were sorted using 
ECFP or AcGFP. The scatter plots (A-a, B-a, C-a, D-a) illustrate high cell viability and 
low amounts of cell debris in the sorted population. The area charts (A-b, B-b, C-b, D-
b) display an ECFP/AcGFP positive cell population (CFP/GFP+) distinct from the very 
few negative cells (CFP/GFP-). The tables (A-c, B-c, C-c, D-c) show the percentage of 
viable cells in the sorted population and the percentage of ECFP/AcGFP positive cells 
within the live population. 
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 Figure 3.4 Confirmation of cell sorting purification of ECFP-VAPB and PTPIP51-HA 
expressing cells. 
NSC34 cells co-transfected with ECFP-VAPB and PTPIP51-HA were sorted, plated 
onto coverslips and immunostrained for PTPIP51 using the HA epitope tag. VAPB was 
visualized via the ECFP tag. Low magnification images show phase contrast (to 
visualize cells), ECFP-VAPB and PTPIP51-HA signals. Scale bar=100 µm. 
Immunoblots revealed that VAPB and PTPIP51 were overexpressed by approximately 
3-5 fold in the transfected cells (data not shown but see (Morotz et al., 2012)). 
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 Figure 3.5 Overexpression of VAPB and/or PTPIP51 increases ER-mitochondria 
associations  
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(A) Representative electron micrographs of ER-mitochondria contacts in NSC34 cells 
transfected with control ECFP vector (CTRL), ECFP-VAPB (VAPB), PTPIP51 or 
ECFP-VAPB + PTPIP51 (VAPB+PTPIP51). Arrowheads show ER-mitochondria 
contact sites. Scale bar=100 nm. Bar chart shows percentage of mitochondrial surface 
closely apposed to ER in the different samples. Statistical significance was determined 
by one-way ANOVA followed by Tukey’s multiple comparison test. n=30-35 cells and 
358-623 mitochondria; error bars are SEM; *p<0.05, ***p<0.001. (B) Lower 
magnification electron micrograph of cell transfected with VAPB and PTPIP51 to show 
numerous mitochondria with closely apposed ER. Scale bar=500 nm. 
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 Figure 3.6 siRNA knockdown of VAPB or PTPIP51 reduces co-localization of ER and 
mitochondria 
Confocal immunostaining of CV-1 cells transfected with control siRNA (CTRL), 
VAPB siRNA or PTPIP51 siRNA and immunostained for ER (using mouse PDI 
antibody) and mitochondria (using rabbit TOM-20 antibody) as indicated. Zoom shows 
high magnification of boxed area with co-localized pixels. Scale bars are 20 µm and 4 
µm (zoom). Bar chart shows ICQ values (with control siRNA represented as 100%) in 
the different transfections. Statistical significance was determined by one-way ANOVA 




 Figure 3.7 Overexpression of VAPB, PTPIP51 and VAPB with PTPIP51 all increase 
co-localization of ER and mitochondria 
Confocal immunostaining of CV-1 cells transfected with control ECFP vector (CTRL), 
ECFP-VAPB (VAPB), PTPIP51-HA (PTPIP51) or ECFP-VAPB+PTPIP51-HA 
(VAPB+PTPIP51) and immunostained for ER (using mouse PDI antibody) and 
mitochondria (using rabbit TOM-20 antibody) as indicated. In ECFP-VAPB+PTPIP51-
HA co-transfected cells, only ECFP-VAPB labeling is shown but duplicate coverslips 
were immunostained for PTPIP51-HA and this demonstrated that approximately 95% of 
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cells expressed both transfected proteins (data not shown). This data is consistent with 
many previous reports which show that most co-transfected cells express both plasmids 
(e.g. (Ackerley et al., 2000). Zoom shows high magnification of boxed area with co-
localized pixels. Scale bars are 20 µm and 4 µm (zoom). Bar chart shows ICQ values 
(with ECFP control represented as 100%) in the different transfections. Statistical 
significance was determined by 1-way ANOVA with Tukey’s post-hoc test. n=34-52 
cells; error bars are SEM; ***p<0.001. 
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3.3 Discussion 
Despite their fundamental importance to a variety of physiological processes, the 
mechanisms that mediate and regulate ER-mitochondria interactions are still not 
properly understood. In particular, the identity of the molecular tethers that physically 
connect ER and mitochondria are not fully characterised. Mitofusin-2 has been shown 
to tether ER to mitochondria (de Brito and Scorrano, 2008) but more recent work 
involving electron microscopy studies of ER-mitochondria associations in mitofusin-2 
knockout cells have challenged this finding (Cosson et al., 2012). 
 
Recent work in our research group identified an interaction between the resident ER 
protein VAPB and the mitochondrial protein PTPIP51. VAPB is anchored in the ER via 
a C-terminal membrane-spanning domain such that its N-terminus projects into the 
cytoplasm (Kagiwada et al., 1998) and PTPIP51 is an outer mitochondrial membrane 
protein whose C-terminus projects into the cytoplasm (De Vos et al., 2012). Therefore, 
VAPB and PTPIP51 represent plausible candidate tethers at the ER-mitochondria 
interface.  
 
In this chapter, modulating VAPB and PTPIP51 expression was shown to significantly 
affect ER-mitochondria associations in both electron and confocal microscopy analyses. 
Both approaches have been previously utilised to visualise ER-mitochondria 
interactions (Csordas et al., 2010; Rizzuto et al., 1998). However, electron and confocal 
microscopy can produce conflicting results (Cosson et al., 2012; de Brito and Scorrano, 
2008) and it has been suggested that electron microscopy is more suitable for 
investigating ER-mitochondria juxtaposition because of its higher resolution (Cosson et 
al., 2012; Rowland and Voeltz, 2012).  
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 Interestingly, electron and confocal studies have produced complementary results in this 
chapter. siRNA knockdown of VAPB or PTPIP51 reduced ER-mitochondria 
associations, whereas overexpression of VAPB and/or PTPIP51 markedly increased 
ER-mitochondria associations using both microscopy methods. Indeed, VAPB and 
PTPIP51 co-expression produced a remarkable phenotype detectable by both electron 
and confocal microscopy in which the ER and mitochondria redistribute to form close 
associations. Alterations to ER-mitochondria interactions are known to affect Ca2+ 
exchange between these organelles and it has previously been demonstrated that 
modulating VAPB and PTPIP51 expression induces such changes in Ca2+ transmission 
(De Vos et al., 2012). Together, these findings support the conclusion that VAPB and 
PTPIP51 form at least one of the molecular scaffolds that mediate ER-mitochondria 
associations. 
 
The ER-mitochondria interface is also involved in regulating cell survival and increased 
interactions between the two organelles may promote mitochondrial Ca2+ overload and 
apoptosis (Csordas et al., 2006; Rowland and Voeltz, 2012). Interestingly, one of the 
initial studies investigating PTPIP51 function reports cytochrome c release and caspase 
activation in PTPIP51 overexpressing cells (Lv et al., 2006). Thus, the markedly 
increased ER-mitochondria association induced by PTPIP51 overexpression in this 
study might provide a mechanism for the proapoptotic effect of overexpressing 
PTPIP51. 
 
The findings that VAPB and PTPIP51 regulate ER-mitochondria associations have 
implications for a number of physiological processes. Key functions such as 
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phospholipid synthesis and trafficking, Ca2+ transmission, mitochondrial transport and 
biogenesis have been proposed to be regulated by ER-mitochondria associations 
(Rowland and Voeltz, 2012).  
 
Thus, phospholipid synthesis is regulated by the ER-mitochondria encounter structure 
(ERMES) in yeast (Kornmann et al., 2009), although a tethering complex controlling 
lipid metabolism in higher eukaryotes has not been identified. Nonetheless, the 
mitochondrial protein Miro1 is the animal homologue of the ERMES subunit Gem1 
(Kornmann et al., 2011) and controls mitochondrial morphology and movement along 
microtubules through a Ca2+ sensor (Fransson et al., 2006; Macaskill et al., 2009; Wang 
and Schwarz, 2009). Interestingly, Miro1 also interacts with the proposed ER-
mitochondria tethering protein mitofusin-2, providing another link between the ER-
mitochondria interface and mitochondrial dynamics (Misko et al., 2010). Furthermore, 
dynamin-related protein 1, a protein controlling mitochondrial division, is also localized 
at ER-mitochondria contact sites (Friedman et al., 2011) and can fragment the 
mitochondrial network, block interorganellar Ca2+ currents and protect against apoptosis 
(Szabadkai et al., 2004). 
 
Ca2+ transmission between ER and mitochondria is mediated by IP3 receptors (ER 
membrane) and VDAC1 (mitochondrial membrane) ion channels, which can modulate 
apoptotic responses (Rizzuto et al., 1998; Szabadkai et al., 2006). Both pro- and anti-
apoptotic Bcl-2 family members can regulate the ER Ca2+ levels by altering IP3 
receptor phosphorylation or by directly interacting with the IP3 receptors (Oakes et al., 
2005; White et al., 2005). Promielocytic leukemia protein has also been recently shown 
to regulate IP3 receptor activity and the mobilization of Ca2+ to the mitochondria 
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(Giorgi et al., 2010). Thus, lipid synthesis, mitochondrial homeostasis, Ca2+ 
transmission and apoptosis are all intimately connected at the ER-mitochondria 
interface. This implies the molecular scaffolds tethering ER to mitochondria are 
essential for maintaining these functions. The results described in this chapter which 
support a role for VAPB and PTPIP51 in regulating ER-mitochondria association thus 
have major relevance to a number of physiological processes.  
 
Finally, it will be important to assess the significance of altered ER-mitochondria 
contacts for human disease. Indeed, damage to ER-mitochondria associations and 
consequent alterations to lipid metabolism and Ca2+ transmission are now linked to 
neurodegenerative disorders such as Alzheimers’s disease and Parkinson’s disease 
(Area-Gomez et al., 2012; Cali et al., 2012; Zampese et al., 2011). This aspect is 
explored in more detail in the next chapter, where ER-mitochondria associations are 











CHAPTER 4: BOTH WILD-TYPE AND ALS 




As discussed in Chapter 1 (Section 1.4), changes to ER-mitochondria associations are 
predicted to have important effects on the neuronal homeostasis. The prolonged and 
excessive tightening of ER-mitochondria contacts will likely lead to increased Ca2+ 
signalling between the two organelles, mitochondria Ca2+ overload and induction of 
apoptosis (Csordas et al., 2006; Rowland and Voeltz, 2012). Conversely, the loosening 
of contacts may affect Ca2+-dependent regulation of ATP synthesis by mitochondria. 
This is likely to have a profound effect at synapses since mitochondria are enriched in 
this compartment and perform essential functions in maintaining ionic potential 
(Csordas et al., 2006; Rowland and Voeltz, 2012). 
 
This raises the intriguing possibility that human pathogenic processes target proteins at 
the MAM interface and ER-mitochondria associations. Indeed, a number of studies have 
focused attention on defective ER-mitochondria contacts and communication in 
neurodegenerative diseases (see for reviews (Rowland and Voeltz, 2012; Schon and 
Area-Gomez, 2010)).  
 
Alzheimer’s disease-associated presenilins have been shown to increase ER-
mitochondria contacts and induce alterations to both Ca2+ and lipid metabolism (Area-
Gomez et al., 2012; Zampese et al., 2011). Likewise,  Parkinson’s disease associated α-
synuclein has been shown to enhance ER-mitochondria interactions and increase 
mitochondrial Ca2+ levels (Cali et al., 2012). Moreover, pathogenic proteins associated 
with Huntington’s disease aberrantly interact with the IP3 receptors (Tang et al., 2003) 
and loss of IP3 receptor function is associated with some forms of spinocerebellar ataxia 
(van de Leemput et al., 2007). Finally, mutations in the gene encoding the ER-
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mitochondria tethering protein mitofusin-2 cause some forms of Charcot-Marie-Tooth 
disease (Barisic et al., 2008). 
 
Similar to other neurodegenerative diseases, a number of ALS associated proteins are 
located at the ER-mitochondria interface and can affect ER-mitochondria 
communication. Notably, VAPB is located in MAM and mutant VAPB causes familial 
ALS, disrupts ER structure and ER to mitochondria Ca2+ exchange (De Vos et al., 2012; 
Fasana et al., 2010; Kim et al., 2010a; Langou et al., 2010; Nishimura et al., 2004; 
Teuling et al., 2007; Tudor et al., 2010). A consequence of altered Ca2+ transmission at 
the MAM is impaired mitochondrial transport described in ALS mutant VAPB 
expressing neurons (Morotz et al., 2012). Mutant SOD1 and FUS also perturb ER 
structure and can induce ER stress and UPR (Farg et al., 2012; Saxena et al., 2009). In 
addition, ALS associated mutant SOD1 interacts with and damages VDAC1 (Israelson 
et al., 2010), an outer mitochondrial membrane Ca2+ channel closely associated to IP3 
receptors in the ER membrane (Rapizzi et al., 2002; Szabadkai et al., 2006). However, 
although ALS associated insults can disrupt ER-mitochondria communication, changes 
in physical associations between the two organelles have not yet been explored.  
 
In this chapter, the effect of wild-type and ALS mutant TDP-43 on ER-mitochondria 
associations was investigated. Accumulations of TDP-43 are a common pathological 
feature in a variety of neurodegenerative diseases including ALS (Arai et al., 2006; 
Neumann et al., 2006) and TARDBP mutationsare causative for familial forms of ALS 
(Sreedharan et al., 2008). Although normally located mostly in the nucleus, pathogenic 
TDP-43 translocates to the cytoplasm where it may induce local damage. Interestingly, 
the ER stress response coordinated at ER-mitochondria contact sites was recently found 
 130 
to be disrupted in TDP-43 transgenic rats (Tong et al., 2012).  
 
To further explore the role of TDP-43 at the ER-mitochondria interface, ER-
mitochondria associations were monitored by electron and light microscopy in NSC34 
motor neuron cells transfected with either wild-type or an ALS mutant TDP-43 (TDP-
43 M337V). In addition, the effect of expressing either wild-type or ALS mutant TDP-
43 on the VAPB-PTPIP51 interaction was quantified using both proximity ligation 
assays and immunoprecipitation assays. Finally, preliminary results are presented to 
determine the effects of expressing wild-type and ALS mutants of FUS and SOD1 on 
the VAPB-PTPIP51 interaction in immunoprecipitation experiments. 
 
As described in Chapter 3, NSC34 motor neuron cells were used for the electron 
microscopy studies and CV1 cells were used for the confocal light microscopy studies. 
For the immunoprecipitation studies, NSC34 cells were utilised. 
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4.2 Results 
4.2.1 Expression of wild-type and ALS mutant TDP-43 disrupt ER-mitochondria 
associations in electron microscopy studies using NSC34 cells 
To investigate the effect of TDP-43 on ER-mitochondria interactions, wild-type and 
familial ALS mutant TDP-43 were first transfected into NSC34 cells and ER-
mitochondria associations then quantified by electron microscopy. This involved 
capturing images of mitochondria in appropriately manipulated cells and then 
calculating the percentage of the mitochondrial surface closely apposed (less than 25 
nm) to ER. The quantification was performed using the ImageJ software 
(http://rsb.info.nih.gov/ij/) (see Section 2.2.3.3). 
 
First, cells were transfected with EGFP control vector, EGFP-TDP-43 or ALS mutant 
EGFP-TDP-43 M337V. Since these transient transfections achieved transfection 
efficiencies of only 30% to 50%, the EGFP tags were further utilized to isolate 
transfected cells using a BD® FACS Aria cell sorter. The cell sorting achieved over 
98% EGFP positive cells, which were further processed for the electron microscopy 
analyses (Figure 4.1). In control cells expressing EGFP alone, approximately 12% of 
the mitochondrial surface was closely associated with ER (Figure 4.2) and this was 
similar to that in cells expressing ECFP or treated with control siRNA (see Figures 3.1 
and 3.5). However, the expression of both wild-type and TDP-43 M337V led to 
significant, approximate 50% reductions in ER-mitochondria associations (Figure 4.2).  
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4.2.2 TDP-43 disrupts ER-mitochondria co-localization in confocal microscopy 
studies using CV1 cells 
For these investigations, CV1 cells were utilized due to their highly spread and flattened 
phenotype which facilitates immunofluorescent morphological analyses. As described 
in Chapter 3, ER was detected by immunostaining for the integral ER protein PDI and 
mitochondria were detected by immunostaining for TOM20. The co-localization of PDI 
and TOM20 was quantified using ICA and data presented as relative intensity 
correlation quotients (ICQ) (Li et al., 2004). ICA is a rigorous method for studying co-
localization of proteins by confocal microscopy which compares the scatter plots of two 
stains against the product of the pixel intensity difference for each of the two stains 
from their respective means.  
 
The cells were transfected with EGFP control vector, EGFP-TDP-43 or EGFP-TDP-43 
M337V and ER and mitochondria co-localization monitored by immunostaining. The 
transfection of EGFP-TDP-43 or EGFP-TDP-43 M337V both decreased co-localization 
of PDI and TOM20 (Figure 4.3) and this was consistent with the EM results (Figure 
4.2).  
 
4.2.3 TDP-43 does not affect expression of VAPB, PTPIP51 or mitofusin-2 
The finding that wild-type TDP-43 and TDP-43 M337V both disrupt ER-mitochondria 
interactions is consistent with the phenotypes seen in transgenic mice where expression 
of both wild-type and mutant TDP-43 all induce disease (Shan et al., 2010; Stallings et 
al., 2010; Wils et al., 2010; Xu et al., 2010). TDP-43 has been linked to mRNA 
metabolism and gene expression (Buratti and Baralle, 2012; Polymenidou et al., 2011; 
Tollervey et al., 2011). Therefore, it was enquired whether transfection of wild-type or 
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TDP-43 M337V influenced the expression of VAPB, PTPIP51 or mitofusin-2, a further 
protein that has been linked to ER-mitochondria associations. To do so, NSC34 cells 
transfected with control EGFP, EGFP-TDP-43 or EGFP-TDP-43 M337V were purified 
using a cell sorter via the EGFP fluorescent tag as described above. These purified cell 
populations were then analysed by immunoblotting for VAPB, PTPIP51 and mitofusin-
2. However, no differences in the expression of any of these proteins were detected in 
the different samples (Figure 4.4). Thus, the reduction in ER-mitochondria interactions 
seen in cells expressing wild-type TDP-43 or TDP-43 M337V is not due to changes in 
expression of VAPB, PTPIP51 or mitofusin-2. 
 
4.2.4 TDP-43 induced disruption of ER-mitochondria associations is accompanied 
by changes in VAPB-PTPIP51 interaction 
Since VAPB and PTPIP51 mediate ER-mitochondria associations and these 
associations are disrupted by TDP-43 expression, the influence of TDP-43 on the 
VAPB-PTPIP51 interaction was investigated. To do so, VAPB-PTPIP51 binding was 
first monitored using a proximity ligation assay (Soderberg et al., 2006) (see Section 
2.2.3.2). CV1 cells were transfected with EGFP control vector, wild-type EGFP-
TDP43, ALS mutant EGFP-TDP-43 M337V or EGFP-TDP-43 A382T and then probed 
with VAPB and PTPIP51 primary antibodies. The proximity of VAPB to PTPIP51 in 
these cells was then detected following labeling with secondary antibodies coupled to 
complementary oligonucleotides (one for each of the two primary antibodies). If the 
distance between the two antibody-coupled oligonucleotides is less than 40 nm, they 
hybridize and generate fluorescent signals.  
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To first test the specificity of the assay, one or both primary antibodies were omitted 
from the reaction in control untransfected cells and this resulted in no or very few 
proximity ligation signals (Figure 4.5). In agreement with previous studies using this 
assay to monitor the VAPB-PTPIP51 interaction (De Vos et al., 2012), robust positive 
signals were obtained when both the primary antibodies were used (Figure 4.5). 
Transfection of EGFP control vector did not significantly influence the numbers of 
proximity ligation signals compared to non-transfected cells (Figure 4.6). However, the 
numbers of proximity ligation signals were significantly reduced in cells transfected 
with either wild-type or two different ALS mutants of TDP-43 (Figure 4.6).  
 
The effect of TDP-43 on the VAPB-PTPIP51 interaction was also monitored using 
immunoprecipitation assays in cells transfected with EGFP control vector, wild-type 
EGFP-TDP-43 or four different ALS mutants of EGFP-TDP-43 (TDP-43 M337V, 
TDP-43 Q331K, TDP-43 A382T and TDP-43 G348C). PTPIP51 was 
immunoprecipitated from PTPIP51-HA co-transfected cells using the anti-HA antibody 
and the amounts of bound endogenous VAPB detected by immunoblotting. Expression 
of wild-type TDP-43 and four different ALS associated mutants of TDP-43 all reduced 
the amount of VAPB that was associated with PTPIP51 in these assays (Figure 4.7). 
Thus, expression of ALS associated TDP-43 disrupts ER-mitochondria interactions and 
this is associated with a decrease in the binding of VAPB to PTPIP51 as detected in two 
different assays (proximity ligation and immunoprecipitation assays). 
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4.2.5 ALS associated FUS but not SOD1 disrupts VAPB binding to PTPIP51 in 
immunoprecipitation assays 
The above studies demonstrated that ALS-associated TDP-43 disrupts ER-mitochondria 
interactions and that this is associated with a decrease in binding of VAPB to PTPIP51. 
To begin to investigate whether other insults associated with familial ALS might also 
disrupt binding of VAPB to PTPIP51, the effects of expressing wild-type and ALS 
mutants of FUS and SOD1 on the VAPB-PTPIP51 interaction was investigated in 
immunoprecipitation experiments. Cells were co-transfected with PTPIP51-HA and 
either EGFP control, wild-type EGFP-FUS, ALS mutants of EGFP-FUS, wild-type 
EGFP-SOD1 or ALS mutants of EGFP-SOD1. ALS mutants of FUS were FUS R521C, 
FUS R521G, FUS R521H, FUS R518K. ALS mutants of SOD1 were SOD1 G93A and 
SOD1 A4V. PTPIP51 was then immunoprecipitated using the HA tag and the amounts 
of co-immunoprecipitating endogenous VAPB detected by immunoblotting. 
 
Expression of wild-type and all four ALS mutants of FUS all reduced the amounts of 
VAPB associated with PTPIP51 in these assays (Figure 4.8). However, neither wild-
type nor ALS mutant SOD1 affected the amounts of VAPB that co-immunoprecipitated 
with PTPIP51 (Figure 4.9). Thus, ALS FUS, but not SOD1 disrupts the VAPB-
PTPIP51 interaction in a manner similar to that of TDP-43. 
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 Figure 4.1 FACS post-sorting analyses demonstrating purification of EGFP positive 
samples 
NSC34 cells transfected with EGFP control vector (A), EGFP-TDP-43 (B) or EGFP-
TDP-43 M337V (C) were sorted based on their EGFP tags. The scatter plots (A-a, B-a, 
C-a) illustrate high cell viability and low amounts of cell debris in the sorted population. 
The area charts (A-b, B-b, C-b) display an EGFP positive cell population (GFP+) 
distinct from the very few negative cells (GFP-). The tables (A-c, B-c, C-c) show the 
percentage of viable cells in the sorted population and the percentage of EGFP positive 
cells within the live population. 
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 Figure 4.2 Expression of wild type and ALS mutant TDP-43 reduce ER-mitochondria 
associations  
Representative electron micrographs of ER-mitochondria contacts in NSC34 cells 
transfected with control EGFP vector (CTRL), EGFP-TDP-43 or EGFP-TDP-43M337V 
as indicated. Scale bar is 100 nm. Arrowheads show ER-mitochondria contact sites. Bar 
chart shows % of mitochondrial surface closely apposed to ER in the different samples. 
Data were analysed by one-way ANOVA followed by Tukey’s multiple comparison 
test. n=34-40 cells and 483-747 mitochondria; error bars are SEM; ***p<0.001. 
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 Figure 4.3 Expression of wild type or ALS mutant TDP-43 reduce ER-mitochondria co-
localization  
Confocal immunostaining of CV-1 cells transfected with control EGFP vector (CTRL), 
EGFP-TDP-43 or EGFP-TDP-43-M337V and immunostained for ER (using mouse PDI 
antibody) and mitochondria (using rabbit TOM-20 antibody) as indicated. Zoom shows 
high magnification of boxed area with co-localized pixels. Scale bars=20 µm, 4 µm 
(zoom). Bar chart shows ICQ values (with EGFP control represented as 100%) in the 
different transfections. Data were analysed by one-way ANOVA with Tukey’s post-hoc 
test. n=36-49 cells; error bars are SEM; **p<0.01, ***p<0.001. 
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 Figure 4.4 Overexpression of wild-type or ALS associated mutant TDP-43 do not alter 
expression of VAPB, PTPIP51 or mitofusin-2 (MFN2) 
Immunoblots of NSC34 cells either untransfected (Un-T) or transfected with EGFP as a 
control (CTRL), EGFP-TDP-43 or EGFP-TDP-43 M337V. Transfected cells were 
purified via the EGFP tag using a cell sorter and the samples probed on immunoblots as 
indicated.  Tubulin is shown as a loading control.  
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 Figure 4.5 Specificity of the Duolink proximity ligation assay for VAPB and PTPIP51 
Non-transfected CV1 cells were labeled with no primary antibodies (No Abs), with 
VAPB antibody alone (VAPB Ab), with PTPIP51 antibody alone (PTPIP51 Ab) or with 
both VAPB and PTPIP51 antibodies (PTPIP51+VAPB). In agreement with previous 
studies (De Vos et al., 2012), omission of one or both of the primary antibodies 
produced no or very few proximity ligation signals. However, probing with both VAPB 
and PTPIP51 antibodies produced strong positive ligation signals. Scale bar is 40 µm. 
Bar charts show numbers of proximity signals/cell in the different transfections. Data 
were analysed by one-way ANOVA and Tukey’s post hoc test. n=30 cells; error bars 
are SEM, ***p<0.001. 
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 Figure 4.6 Expression of wild-type or ALS associated mutants of TDP-43 all reduce the 
interaction of VAPB with PTPIP51 in proximity ligation assays  
CV1 cells were transfected with either EGFP control vector (CTRL), EGFP-TDP-43, 
EGFP-TDP-43 M337V or EGFP-TDP-43 A382T and proximity ligation assays 
performed using rat anti-VAPB and rabbit anti-PTPIP51 primary antibodies. 
Representative cells transfected with EGFP, EGFP-TDP-43, EGFP-TDP43 M337V and 
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EGFP-TDP43 A382T are shown. Scale bar is 40 µm. Bar charts show relative % of 
proximity signals/cell in the different transfections. Data were analysed by one-way 
ANOVA and Tukey’s post hoc test. n=30 cells; error bars are SEM, ***p<0.001. 
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 Figure 4.7 Expression of wild-type or ALS associated mutants of TDP-43 (TDP-43 
Q331K, TDP-43 M337V, TDP-43 G348C and TDP-43 A382T) reduce the binding of 
VAPB to PTPIP51 in immunoprecipitation assays  
Cells were either mock transfected (Mock) or co-transfected with PTPIP51-HA and 
either EGFP control vector (CTRL) or wild type or ALS mutants of TDP-43. PTPIP51 
was immunoprecipitated using the HA-tag and the amounts of endogenous bound 
VAPB detected by immunoblotting. No signals were obtained for either VAPB or 
PTPIP51 in immunoprecipitations from mock transfected cells which demonstrates the 
specificity of the immunoprecipitations. Both inputs and immunoprecipitations (IP) are 
shown. Bar charts show relative levels of VAPB bound to PTPIP51 in the 
immunoprecipitations following quantification of signals from immunoblots. VAPB 
signals were normalized to immunoprecipitated PTPIP51-HA signals. Data were 
analysed by one-way ANOVA and Tukey’s post hoc test. n=5; error bars are SEM, 
*p<0.05, **p<0.01. 
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 Figure 4.8 Expression of wild-type or ALS associated mutants of FUS (FUS R521C, 
FUS R521G, FUS R521H and FUS R518K) reduce the binding of VAPB to PTPIP51 in 
immunoprecipitation assays  
Cells were either mock transfected (Mock) or co-transfected with PTPIP51-HA and 
either EGFP control vector (CTRL) or wild type or ALS mutants of FUS. PTPIP51 was 
immunoprecipitated using the HA-tag and the amounts of endogenous bound VAPB 
detected by immunoblotting. No signals were obtained for either VAPB or PTPIP51 in 
immunoprecipitations from mock transfected cells which demonstrates the specificity of 
the immunoprecipitations. Both inputs and immunoprecipitations (IP) are shown. Bar 
charts show relative levels of VAPB bound to PTPIP51 in the immunoprecipitations 
following quantification of signals from immunoblots. VAPB signals were normalized 
to immunoprecipitated PTPIP51-HA signals. Data were analysed by one-way ANOVA 
and Tukey’s post hoc test. n=5; error bars are SEM, *p<0.05, **p<0.01. 
 
 145 
 Figure 4.9 Expression of wild-type or ALS associated mutants of SOD1 (SOD1 G93A, 
SOD1 A4V) do not influence the binding of VAPB to PTPIP51 in immunoprecipitation 
assays  
Cells were either mock transfected (Mock) or co-transfected with PTPIP51-HA and 
either EGFP control vector (CTRL) or wild type or ALS mutants of SOD1. PTPIP51 
was immunoprecipitated using the HA-tag and the amounts of endogenous bound 
VAPB detected by immunoblotting. No signals were obtained for either VAPB or 
PTPIP51 in immunoprecipitations from mock transfected cells which demonstrates the 
specificity of the immunoprecipitations. Both inputs and immunoprecipitations (IP) are 
shown. Bar charts show relative levels of VAPB bound to PTPIP51 in the 
immunoprecipitations following quantification of signals from immunoblots. VAPB 
signals were normalized to immunoprecipitated PTPIP51-HA signals. Data were 
analysed by one-way ANOVA. n=3; error bars are SEM. 
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4.3 Discussion 
Abnormal accumulations of TDP-43 are a hallmark pathology in a number of 
neurodegenerative diseases including ALS and FTD (Arai et al., 2006; Neumann et al., 
2006). However, the molecular mechanisms by which defective TDP-43 metabolism 
might induce disease are not clear. Overexpression of both wild-type and familial ALS 
associated mutants of TDP-43 all induce disease in transgenic rodents (Shan et al., 
2010; Stallings et al., 2010; Swarup et al., 2011; Wils et al., 2010; Xu et al., 2010; Xu et 
al., 2011b; Zhou et al., 2010). Moreover, elevated TDP-43 expression has been 
observed in sporadic ALS patients (Kasai et al., 2009; Suzuki et al., 2010). Together, 
these findings suggest that overexpression of wild-type TDP-43 is pathogenic in ALS. 
  
The cellular targets of pathogenic TDP-43 are not fully understood but disruption to 
both mitochondria (Braun et al., 2011; Shan et al., 2010; Xu et al., 2010; Xu et al., 
2011b) and ER stress signaling pathways (Suzuki et al., 2011; Suzuki and Matsuoka, 
2012; Tong et al., 2012) have been described. These findings focus attention on the ER-
mitochondria axis. Moreover, several recent studies have implicated defective ER-
mitochondria contacts in some related neurodegenerative diseases including 
Alzheimer’s and Parkinson’s diseases (Area-Gomez et al., 2012; Cali et al., 2012; 
Zampese et al., 2011). 
 
In this chapter, both wild-type and ALS associated mutant TDP-43 were shown to 
reduce ER-mitochondria associations in both electron and confocal microscopy 
analyses. Moreover, the TDP-43-induced change in ER-mitochondria contacts was 
accompanied by decreases in VAPB-PTPIP51 interactions demonstrated in two 
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different assays. It thus seems likely that the effect of TDP-43 on ER-mitochondria 
associations involves a TDP-43-induced decrease in binding of VAPB to PTPIP51. 
 
In order to begin to determine whether other ALS-associated insults also influence ER-
mitochondria associations and the VAPB-PTPIP51 interaction, the effects of wild-type 
and ALS mutant FUS and SOD1 on VAPB-PTPIP51 binding was studied. This 
involved immunoprecipitation experiments similar to those performed for TDP-43. 
These experiments revealed that overexpression of both wild-type and ALS associated 
FUS decreased the VAPB-PTPIP51 interaction. Interestingly, expression of wild-type 
FUS (like wild-type TDP-43) is pathogenic in transgenic mice (Mitchell et al., 2012). 
By contrast, overexpression of wild-type or ALS mutant SOD1 did not influence the 
VAPB-PTPIP51 interaction. It appears that the effect of mutant SOD1 on the ER-
mitochondria axis and especially on the VAPB-PTPIP51 connection may be different to 
that of TDP-43 and FUS. However, SOD1 has been shown to damage VDAC1, a 
protein believed to contribute to ER-mitochondria associations (Israelson et al., 2010; 
Szabadkai et al., 2006). Therefore, it is possible that all these ALS insults perturb ER-
mitochondria associations, but the precise target for mutant SOD1 damage within MAM 
axis is different to TDP-43 and FUS. Clearly, future studies to quantify ER-
mitochondria associations in the presence of wild-type and ALS mutant FUS and SOD1 
using electron microscopy methods similar to those described in this thesis will help 
resolve these issues. 
  
The regulation of ER-mitochondria associations is fundamental to a number of 
physiological processes and both abnormal tightening or loosening of ER-mitochondria 
contacts are predicted to have detrimental effects to cells. In particular, excessive 
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tightening of contacts may sensitize mitochondria to Ca2+ overload leading to opening 
of the mitochondrial permeability transition pore and apoptosis (Hajnoczky et al., 2006; 
Szabadkai et al., 2006).  
 
By contrast, loosening of ER-mitochondria contacts will affect Ca2+-dependent 
regulation of the tricarboxylic acid cycle and ATP synthesis by mitochondria (Csordas 
et al., 2006; Rowland and Voeltz, 2012). Synaptic dysfunction is a key and early feature 
of ALS and the energy requirements of synapses are especially high; ATP is required to 
drive the pumps that maintain ionic potential at the synapse (Laughlin et al., 1998). 
Disruption to mitochondrial ATP synthesis is thus predicted to have particularly 
detrimental effects at the synapse. 
 
Another piece of evidence suggests that controlling the distance between ER and 
mitochondria can determine the rate of Ca2+ refilling in neighboring ER regions 
(Arnaudeau et al., 2001). Therefore, this raises the possibility that reduced ER-
mitochondria contacts might decrease intraluminal ER Ca2+, which in turn could affect 
proper protein folding, inducing ER stress and triggering the UPR (Lodish and Kong, 
1990; Zhang and Kaufman, 2008). In addition, close interorganellar contacts are 
essential in the early phases of ER stress and uncoupling mitochondria from ER renders 
cells more vulnerable to stress (Bravo et al., 2011). Indeed, chronic ER stress and UPR 
are common findings in ALS patients and represent some of the earliest pathogenic 
changes detected in this disease ((Kanekura et al., 2009) and see Section 1.3.7). Chronic 
unresolved UPR can trigger cell death programmes through the activation of C/EBP 
homologous protein or c-Jun N-terminal kinase and both these pathways have recently 
been found to be activated by TDP-43 (Suzuki and Matsuoka, 2012, 2013).  
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 Finally, detaching mitochondria from the ER membranes can prevent local Ca2+ uptake 
in regions with high Ca2+ concentrations, thus diminishing mitochondrial Ca2+ buffering 
and elevating intracellular Ca2+ levels. Indeed, delayed mitochondrial Ca2+ uptake and 
higher intracellular peaks have been described following ablation of proposed ER-
mitochondria tethering proteins VAPB, PTPIP51 or mitofusin-2 (de Brito and Scorrano, 
2008; De Vos et al., 2012). Elevated cytosolic Ca2+ could prove particularly disruptive 
in motor neurons, which have weak Ca2+ buffering systems in physiological conditions 
and rely heavier on their mitochondrial Ca2+ buffering capacity (see for review (von 
Lewinski and Keller, 2005)). Thus, diminished mitochondrial Ca2+ uptake combined 
with the increased glutamate activity previously described in ALS may further 
accelerate motor neuron demise. 
 
In summary, the results in this chapter reveal a novel pathogenic role for TDP-43 in 
decreasing ER-mitochondria associations via the VAPB-PTPIP51 interaction. This may 
perturb Ca2+ homeostasis and ATP production, therefore contributing to motor neuron 
degeneration. However, the mechanisms by which TDP-43 disrupts the VAPB-PTPIP51 
interaction are unclear; TDP-43 did not alter the expression of either VAPB or 
PTPIP51. A further possible route by which TDP-43 could influence the VAPB-
PTPIP51 binding might be via post-translational changes such as phosphorylation of 











CHAPTER 5: VAPB AND PTPIP51 
PHOSPHORYLATION AS A REGULATORY 




The results in Chapter 3 support a role for VAPB and PTPIP51 in mediating ER-
mitochondria associations. It is likely that ER-mitochondria interactions are dynamic 
and alter in response to physiological changes. The tightening of ER-mitochondria 
associations will increase Ca2+ and possibly phospholipid exchange between the two 
organelles. This may be required in situations of high energy demand since Ca2+ 
regulates the tricarboxylic acid cycle and ATP synthesis by mitochondria (Csordas et 
al., 2006; Rowland and Voeltz, 2012). However, prolonged and excessively close ER-
mitochondria associations are likely to promote mitochondrial Ca2+ overload, leading to 
opening of the permeability transition pore and apoptosis (Csordas et al., 2006; 
Rowland and Voeltz, 2012). As such, it is possible that cellular mechanisms controlling 
the levels of ER-mitochondria association involve modulation of the VAPB-PTPIP51 
interaction.  
 
Reversible phosphorylation is the most common posttranslational modification to 
proteins and is a potent mechanism for influencing protein function and also protein-
protein interactions. Indeed, a recent study investigating the interaction profile of 
PTPIP51 suggests that phosphorylation on tyrosine residues can influence its interaction 
with several binding partners such as 14-3-3β, Raf-1 and protein tyrosine phosphatase-
1B (PTP1B) (Brobeil et al., 2012). 
 
In order to properly examine the possibility that phosphorylation regulates the  
VAPB-PTPIP51 interaction, potential phosphorylation sites in both of these proteins 
first need to be identified. This will then facilitate the identification of kinases and 
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phosphatases that regulate VAPB and PTPIP51 phosphorylation and the experimental 
manipulation of VAPB/PTPIP51 phosphorylation state.  
 
In this chapter, the phosphoryalytion of PTPIP51 and VAPB was investigated. Firstly, 
mass spectrometric sequencing of PTPIP51 and VAPB was undertaken and several 
serine and threonine phosphorylation sites were identified in both proteins. Secondly, 
mutagenic approaches were used in which identified sites were altered to preclude 
phosphorylation or to mimic permanent phosphorylation. The effects of these mutations 
on VAPB-PTPIP51 binding was then studied in immunoprecipitation assays.  
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5.2 Results 
5.2.1 Purification of PTPIP51 by immunoprecipitation and separation on SDS-
PAGE 
To identify phosphorylation sites within PTPIP51, the first approach taken was to 
sequence the protein via mass spectrometry. Mass spectrometry is a powerful method to 
detect posttranslational modifications; the sensitivity and accuracy of this method 
allows analyses of amounts as little as 10 nanograms for individual proteins (Larsen et 
al., 2006). However, phosphorylation is usually present at sub-stoichiometric levels and 
the likelihood of finding such modification increases with a larger amount of starting 
material. Thus, HA-tagged PTPIP51 was exogenously expressed in cultured CHO cells 
by transfection in order to increase the amounts of protein available for the mass 
spectrometry analysis. High transfection efficiencies are usually achieved in CHO cells, 
which are often used to obtain high yields of transfected proteins including large scale 
production of pharmaceutical proteins (Omasa et al., 2010). The HA tag on the 
transfected PTPIP51 also enabled the purification of PTPIP51 by immunoprecipitation 
methods using an antibody directed against the HA epitope. 
 
Thus, HA-tagged PTPIP51 was transfected into CHO cells and purified by 
immunoprecipitation with anti-HA and separation on SDS-PAGE. As a control to 
demonstrate the specificity of the immunoprecipitation, control vector transfected CHO 
cells were subjected to immunoprecipitation with the same anti-HA antibody and 
immunoprecipitations from both samples were performed with no HA antibody. As 
shown in Figure 5.1A, a protein species corresponding to the correct size of PTPIP51 
was specifically detected in the PTPIP51 transfected CHO cell samples. Probing 
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immunoblots of the same samples confirmed that this species was PTPIP51 (Figure 5.1 
B) and mass spectrometry further confirmed this result (Figure 5.2). 
 
5.2.2 Identification of phosphorylation sites in PTPIP51 by mass spectrometry  
Following extraction of the PTPIP51-HA protein band from the SDS PAGE gels and 
trypsin digestion, the peptides mixture was subjected to LC/MS/MS as described in 
section 2.2.2.6. Tandem mass spectrometry analyses identified the band as PTPIP51 
with a sequence coverage of 58% (Figure 5.2A). Four phosphopeptides were identified 
(Figure 5.2B) and after amino acid sequencing of each phosphopeptide by MS/MS, 
phosphorylation was assigned to serine 44 (S44) (Figure 5.3), serine 46 (S46) (Figure 
5.4), serine 50 (S50) (Figure 5.5) and serine 212 (S212) (Figure 5.6). 
 
S44, S46 and S50 are located between the transmembrane domain and the coiled coil 
domain of PTPIP51. S212 is found between the coiled coil domain and the C-terminus 
of PTPIP51 (Figure 5.7). In the same region of the protein, two other phosphorylation 
sites (S221, S225) have been previously identified in a phosphoproteomics screen 
(Chen et al., 2009). Due to their close proximity to S212, all 6 phosphoserine residues 
were mutated. 
 
5.2.3 PTPIP51 is phosphorylated on tyrosine residue(s) 
Although the above mass spectrometry studies identified phosphorylation of PTPIP51 
on serine residues, no phosphorylation on tyrosines was detected. To assess whether 
PTPIP51 is also phosphorylated on tyrosine, a different strategy was chosen. This 
involved using the tyrosine phosphatase inhibitor pervanadate (Huyer et al., 1997) and 
an antibody that specifically detects proteins phosphorylated on tyrosine residues 
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(antibody 4G10). Pervanadate was used to inhibit tyrosine phosphatases as to induce 
tyrosine phosphorylation of proteins in CHO cells transfected with  
PTPIP51-HA. Phosphorylation on tyrosines was then detected with the 4G10 antibody. 
Thus, cells expressing transfected HA-tagged PTPIP51 were treated with pervanadate 
(as described in Section 2.2.4.1), lysed and PTPIP51 was immunoprecipitated with the 
anti-HA antibody. The immunoprecipitated material was analysed by immunoblotting 
with antibody 4G10 and anti-HA antibody. As shown in Figure 5.8, no signals from 
either antibody were detected in the absence of immunoprecipitating HA antibody 
demonstrating the specificity of the immunoprecipitations. Immunoprecipitated 
PTPIP51-HA from untreated cells did not react or reacted only weakly with antibody 
4G10 (seen following extended exposures of the immunoblots; Figure 5.8). However, in 
cells treated with pervanadate, a robust 4G10 signal was detected demonstrating that 
inhibition of tyrosine phosphatases drives increased phosphorylation of PTPIP51. 
 
The weak 4G10 reactivity under basal conditions (Figure 5.8) might explain the failure 
of the previous mass spectrometry experiments to identify phosphorylation of tyrosines 
in PTPIP51. Therefore the mass spectrometry analysis was repeated after treating the 
cells with pervanadate. Thus, PTPIP51-HA was exogenously expressed in cultured 
CHO cells, the cells treated with pervanadate and PTPIP51-HA protein 
immunoprecipitated using the anti-HA antibody. Following separation of proteins on 
SDS-PAGE (as in Figure 5.1), the samples were subjected to LC/MS/MS analyses. 
These identified the protein as PTPIP51 with a sequence coverage of 57% but no 
tyrosine phosphopeptides were detected. 
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5.2.4 Purification of VAPB by immunoprecipitation and separation on SDS-PAGE 
The same approach as for PTPTIP51 was used to identify phosphorylation sites in myc 
tagged VAPB. VAPB was transfected into CHO cells, purified by immunoprecipitation 
and SDS-PAGE and then sequenced by LC/MS/MS. 
 
As a control to demonstrate the specificity of the immunoprecipitation, control vector 
transfected CHO cells were subjected to immunoprecipitation with the same anti-myc 
antibody and immunoprecipitations from both samples were performed with no 
antibody. As shown in Figure 5.9A, a protein species corresponding to the correct size 
of VAPB was specifically detected in the transfected CHO cell samples. 
Immunoblotting of the same samples revealed this species was VAPB (Figure 5.9B) and 
mass spectrometry further confirmed this result (Figure 5.10). 
 
5.2.5 Identification of phosphorylation sites in VAPB by mass spectrometry  
Following extraction of the myc-VAPB protein band from the SDS PAGE gels and 
trypsin digestion, the peptide mixture was subjected to LC/MS/MS as described in 
section 2.2.2.5. Tandem mass spectrometry analyses identified the band as VAPB with 
sequence coverage of 54% (Figure 5.10A). Two phosphopeptides were identified 
(Figure 5.10B) and after amino acid sequencing of each phosphopeptide by MS/MS, 
phosphorylation was assigned to threonine 150 (T150) (Figure 5.11) and serine 158 
(S158) (Figure 5.12).  
 
T150 and S158 are located between the MSP domain and the coiled coil domain of 
VAPB (Figure 5.13). Although the mass spectrometry analyses identified 
phosphorylation of VAPB on serine and threonine residues, no phosphorylation on 
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tyrosines was detected. In the same region, previous mass spectrometry studies have 
identified other phosphorylation sites on serine residues (S146, S156, S159 and S160) 
(Christensen et al., 2010; Olsen et al., 2010; Weber et al., 2012; Wu et al., 2010). Thus 
all six identified sites were mutated for the immunoprecipitation analyses.  
 
5.2.6 Mutation of the PTPIP51 and VAPB phosphorylation sites does not affect the 
PTPIP51-VAPB interaction 
To investigate the role of PTPIP51 phosphorylation, mutants were generated and their 
ability to interact with VAPB was monitored in immunoprecipitation assays from 
transfected HEK293 cells. The previously identified phosphorylated residues in 
PTPIP51 were mutated to alanine to preclude phosphorylation or to aspartate to mimic 
permanent phosphorylation. There are many examples where replacing serines with a 
negatively charged residue such as an aspartate accurately mimics the effect of 
phosphorylation of the site (e.g. (Ackerley et al., 2003; Eidenmuller et al., 2000; 
Raingeaud et al., 1996)). 
 
The effect of phosphorylation mutants of PTPIP51 on binding to VAPB was monitored 
first. To achieve this, two sets of triple mutants were created: PTPIP51S44A/S46A/S50A, 
PTPIP51 S44D/S46D/S50D, PTPIP51S212A/S221A/S225A and PTPIP51 S212D/S221D/S225D. In addition, 
all six serine residues were mutated to alanine or aspartate respectively. PTPIP51 wild-
type (PTPIP51), PTPIP51S44A/S46A/S50A, PTPIP51S44D/S46D/S50D, PTPIP51S212A/S221A/S225A, 
PTPIP51S212D/S221D/S225D, PTPIP51S44A/S46A/S50A/S212A/S221A/S225A and PTPIP51 
S44D/S46D/S50D/S212D/S221D/S225D were separately transfected into HEK293 cells and 
specifically immunoprecipitated using the HA tag. PTPIP51wt, PTPIP51S44A/S46A/S50A, 
PTPIP51S44D/S46D/S50D, PTPIP51S212A/S221A/S225A, PTPIP51S212D/S221D/S225D, 
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PTPIP51S44A/S46A/S50A/S212A/S221A/S225A and PTPIP51 S44D/S46D/S50D/S212D/S221D/S225D all 
interacted equally well with endogenous VAPB in these assays and no signals for either 
PTPIP51 or VAPB were obtained from control transfected cells demonstrating the 
specificity of the immunoprecipitations (Figure 5.14). Thus, the interaction between 
transfected PTPIP51-HA and endogenous VAPB is not influenced by altering the 
identified phosphorylation sites in PTPIP51 to either preclude or mimic permanent 
phosphorylation.  
 
In order to investigate the role of VAPB phosphorylation, mutants were generated and 
their ability to interact with endogenous PTPIP51 was monitored in 
immunoprecipitation assays from transfected HEK293 cells. In the same way as for 
PTPIP51, the previously identified phosphorylated residues in VAPB were mutated to 
alanine to preclude phosphorylation or to aspartate to mimic permanent 
phosphorylation. Two sets of mutants were created that include the identified 
phosphorylated residues and the additional serine residues identified in VAPB by 
others: VAPBT150A/S158A, VAPBT150D/S158D, VAPBS146A/T150A/S156A/S158A/S159A/S160A and 
VAPBS146D/T150D/S156D/S158D/S159D/S160D. VAPB wild-type (VAPB), VAPBT150A/S158A, 
VAPBT150D/S158D, VAPBS146A/T150A/S156A/S158A/S159A/S160A and 
VAPBS146D/T150D/S156D/S158D/S159D/S160D were separately transfected into HEK293 cells and 
specifically immunoprecipitated using the myc tag. VAPBwt, VAPBT150A/S158A, 
VAPBT150D/S158D, VAPBS146A/T150A/S156A/S158A/S159A/S160A and 
VAPBS146D/T150D/S156D/S158D/S159D/S160D all interacted equally well with endogenous 
PTPIP51 in these assays and no signals for either PTPIP51 or VAPB were obtained 
from control transfected cells demonstrating the specificity of the immunoprecipitations 
(Figure 5.15). Thus, the interaction between transfected myc-VAPB and endogenous 
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PTPIP51 is not influenced by altering the identified phosphorylation sites in VAPB to 
either preclude or mimic permanent phosphorylation. Interestingly however, mutating 
all 6 identified phosphorylation sites to aspartate markedly slowed the migration of 
VAPB on SDS-PAGE (Figure 5.15). 
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 Figure 5.1 Purification of PTPIP51-HA by immunoprecipitation 
CHO cells were transfected with either control vector (CTRL) or PTPIP51-HA and 
transfected PTPIP51-HA was immunoprecipitated using anti-HA antibody. (A) shows 
Coomassie Blue stained gel. (B) shows immunoblot probed with anti-HA antibody to 
detect PTPIP51-HA. -Ab and +Ab refer to absence or presence of the anti-HA antibody 
in the immunoprecipitations. The positions of PTPIP51-HA and immunoglobulin heavy 
chain (Ig HC) of the anti-HA antibody are shown. Molecular mass markers are shown 



























Figure 5.2 Phosphorylation sites identified in PTPIP51  
(A) Sequence of human PTPIP51 with the MS/MS sequence coverage obtained after 
trypsin digestion shown as underlined. Four phosphorylation sites were identified (S44, 
S46, S50 and S212) which are highlighted. (B) PTPIP51 phosphopeptides obtained by 
MS/MS sequencing with their mass/charge (m/z) ratios. Phosphorylated residues are 
shown in bold and highlighted.  
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 Figure 5.3 Identification of PTPIP51 S44 as a phosphorylation site by LC/MS/MS 
Tandem MS/MS spectrum of the PTPIP51 phosphopeptide 
HGRSQSLPNSLDYTQTSDPGR (residues 41-61) fragment ion series after collision 
induced dissociation. The m/z of the fragment ions is plotted against intensity and the 
detected ions of the b- and y-ion collision series are indicated. The pattern of fragment 
ions produced localizes the phosphorylation site to S44 (highlighted in the peptide 
sequence) with b-ions identified from b(4). The mass difference between b(3) and b(4) 
and the release of phosphoric acid from b(4) (b(4)-H3PO4) are consistent with a 
phosphorylation on S44. 
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 Figure 5.4 Identification of PTPIP51 S46 as a phosphorylation site by LC/MS/MS 
Tandem MS/MS spectrum of the PTPIP51 phosphopeptide SQSLPNSLDYTQTSDPGR 
(residues 44-61) fragment ion series after collision induced dissociation. The m/z of the 
fragment ions is plotted against intensity and the detected ions of the b- and y-ion 
collision series are indicated. Diagnostic neutral loss of phosphoric acid (-H3PO4) from 
the parent ion is present at m/z 974.552+. The sequence tag from y(1-8) and y(11-15) 
provides strong evidence for the peptide sequence assignment and neutral loss from 
b(3), b(4), b(10) and b(15), but not b(2), localizes the phosphorylation site to S46 
(highlighted in the peptide sequence). Consecutively matched y- and b-ions without 
neutral loss indicate no phosphorylation of other potential sites (S44, S50, T54, T56 or 
S57). 
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 Figure 5.5 Identification of PTPIP51 S50 as a phosphorylation site by LC/MS/MS  
Tandem MS/MS spectrum of the PTPIP51 phosphopeptide SQSLPNSLDYTQTSDPGR 
(residues 44-61) fragment ion series after collision induced dissociation. The m/z of the 
fragment ions is plotted against intensity and the detected ions of the b- and y-ion 
collision series are indicated. Neutral loss from b(9), but not b(3) (S46) for the b-ion 
series and from y(12) but not y(5) (S57), y(6) (T56) or y(8) (T54) for the y-ion series 
localize the phosphorylation to S50 (highlighted in the peptide sequence).  
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 Figure 5.6 Identification of PTPIP51 S212 as a phosphorylation site by LC/MS/MS 
Tandem MS/MS spectrum of the PTPIP51 phosphopeptide 
KDSLDLEEEAASGASSALEAGGSSGLEDVLPLLQQADELHR (residues 210-250) 
fragment ion series after collision induced dissociation. The m/z of the fragment ions is 
plotted against intensity and the detected ions of the b- and y-ion collision series are 
indicated. The ion at m/z 1398.253+ corresponding to a neutral loss from the parent 
suggests phosphorylation of serine or threonine. Assignment of b(3-5) and b(9-11) and 
the loss of phosphate from b(3), but not b(2) localize the modification to S212 




Figure 5.7 Schematic representation of PTPIP51 structure showing positions of 
phosphorylation sites identified by mass spectrometry 
PTPIP51 encompasses an N-terminal transmembrane domain and a coiled coil domain. 
S44 S46 S50 S212 S221 S225 
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 Figure 5.8 PTPIP51 is phosphorylated on tyrosine residue(s)  
PTPIP51 is phosphorylated on tyrosine(s) in pervanadate-treated CHO cells. CHO cells 
were transfected with PTPIP51-HA and treated with either vehicle or the tyrosine 
phosphatase inhibitor pervanadate as indicated (- pervanadate; + pervanadate). 
PTPIP51-HA was immunoprecipitated using the anti-HA antibody and the samples 
were probed on immunoblots with anti-HA or phosphotyrosine antibody 4G10 as 
indicated. -Ab and +Ab refer to absence or presence of the anti-HA antibody in the 
immunoprecipitations. Signals for the PTPIP51-HA are only seen in the presence of 
immunoprecipitating HA antibody and treatment with pervanadate induced a strong 
PTPIP51 signal with antibody 4G10. 
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 Figure 5.9 Purification of myc-VAPB by immunoprecipitation 
CHO cells were transfected with either control vector (CTRL) or myc-VAPB and 
transfected myc-VAPB was immunoprecipitated using anti-myc antibody. (A) shows 
Coomassie Blue stained gel. (B) shows immunoblot probed with anti-myc antibody 
9B11 to detect myc-VAPB. -Ab and +Ab refer to absence or presence of the anti-myc 
antibody in the immunoprecipitations. The positions of myc-VAPB and 
immunoglobulin light chain (Ig LC) of the anti-myc antibody are shown. Molecular 









B   
Peptide sequence Residues m/z 
SLSSSLDDTEVK 156-167 680.79  
IISTTASKTETPIVSK 140-155 878.45 
 
Figure 5.10 Phosphorylation sites identified in VAPB  
(A) Sequence of VAPB with the MS/MS sequence coverage obtained after trypsin 
digestion shown as underlined. Two phosphorylation sites were identified (T150, S158) 
which are highlighted. (B) VAPB phosphopeptides obtained by MS/MS sequencing 
with their mass/charge (m/z) ratios. Phosphorylated residues are shown in bold and 
highlighted.  
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 Figure 5.11 Identification of VAPB T150 as a phosphorylation site by LC/MS/MS 
Tandem MS/MS spectrum of the VAPB phosphopeptide IISTTASKTETPIVSK 
(residues 140-155) fragment ion series after collision induced dissociation. The m/z of 
the fragment ions is plotted against intensity and the detected ions of the b- and y-ion 
collision series are indicated. The sequence tag of y-ions from y(6) to y(10) are 
identified with a neutral loss of phosphoric acid but not at y(5), therefore localizing the 
phosphorylation to T150 (highlighted in the peptide sequence). Further evidence for this 
localization is determined by neutral loss from the b(11) ion (-H3PO4) and not at other 
serine or threonine residues in the sequence.  
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 Figure 5.12 Identification of VAPB S158 as a phosphorylation site by LC/MS/MS 
 Tandem MS/MS spectrum of the VAPB phosphopeptide SLSSSLDDTEVK (residues 
156-167) fragment ion series after collision induced dissociation. The m/z of the 
fragment ions is plotted against intensity and the detected ions of the b- and y-ion 
collision series are indicated. A constant neutral loss from the parent ion is not 
identified but ions at b(4-6) show a neutral loss of phosphoric acid (-H3PO4). The y(10) 
ion with neutral loss also confirms localization of the phosphorylation to the serine 





Figure 5.13 Schematic representation of VAPB structure showing positions of 
phosphorylation sites identified by mass spectrometry 
VAPB encompasses three main domains: a major sperm protein (MSP) domain, a coiled 
coil domain and a transmembrane domain required for ER membrane localization. The 
MSP domain is positioned towards the N-terminus and the transmembrane domain is 
positioned towards the C-terminus of the protein. Threonine 150 (T150) and serine 158 
(S158) are located between the MSP domain and the coiled coil domain. In previous 
studies, other phosphorylation sites have also been identified in this region of the 
protein, including S146, S156, S159 and S160. 
            S156  
            S158 
  S146 S159  




 Figure 5.14 Mutation of PTPIP51 residues to alanine to preclude phosphorylation and 
aspartate to mimic permanent phosphorylation do not affect PTPIP51 binding to VAPB 
HEK293 cells were transfected with either control vector (CTRL), PTPIP51-HA wild-
type (PTPIP51), PTPIP51S44A/S46A/S50A, PTPIP51S44D/S46D/S50D, PTPIP51S212A/S221A/S225A, 
PTPIP51S212D/S221D/S225D, PTPIP51S44A/S46A/S50A/S212A/S221A/S225A or PTPIP51 
S44D/S46D/S50D/S212D/S221D/S225D and PTPIP51 immunoprecipitated using anti-HA to the HA 
epitope tag. Samples were probed on immunoblots for PTPIP51 using anti-HA and 
endogenous VAPB using antibody sk83. Samples of the input lysates and 
immunoprecipitates (IP) are shown. No VAPB signal was obtained from control vector 
transfected cells, which demonstrates the specificity of the immunoprecipitations. 
VAPB signals were normalized to immunoprecipitated PTPIP51-HA signals. Data were 
analysed by one-way ANOVA (n=3) and this revealed no differences between binding 
of wild-type or the phosphorylation mutants of PTPIP51 to VAPB. 
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 Figure 5.15 Mutation of VAPB residues to alanine to preclude phosphorylation and 
aspartate to mimic permanent phosphorylation does not affect VAPB binding to 
PTPIP51 
HEK293 cells were transfected with either control vector (CTRL), VAPB wild-type 
(VAPB), VAPBT150A/S158A, VAPBT150D/S158D, VAPBS146A/T150A/S156A/S158A/S159A/S160A or 
VAPBS146D/T150D/S156D/S158D/S159D/S160D and VAPB immunoprecipitated using anti-myc to 
the myc epitope tag. Samples were probed on immunoblots for VAPB using anti-myc 
and endogenous PTPIP51 using antibody FAM82A2. Samples of the input lysates and 
immunoprecipitates (IP) are shown. No PTPIP51 signal was obtained from control 
vector transfected cells, which demonstrates the specificity of the immunoprecipitations. 
PTPIP51 signals were normalized to immunoprecipitated myc-VAPB signals. Data 
were analysed by one-way ANOVA (n=3) and this revealed no differences between the 
binding of wild-type or the phosphorylation mutants of VAPB to PTPIP51. 
 175 
5.3 Discussion 
In this chapter, the role of phosphorylation in modulating the VAPB-PTPIP51 
interaction was investigated. For this purpose, VAPB and PTPIP51 were transfected 
into CHO cells and purified by immunoprecipitation and SDS-PAGE using the myc- or 
HA-tags. The proteins were then analyzed by mass spectrometry and this approach 
identified phosphorylated serine and threonine residues in both VAPB and PTPIP51. In 
addition, treating the cells with the tyrosine phosphatase inhibitor pervanadate revealed 
that tyrosine phosphorylation occurs in PTPIP51. However, the phosphorylated tyrosine 
residues were not identified via mass spectrometry. One reason for this may be that 
phosphorylation on tyrosines is a less common event than phosphorylation on serine or 
threonine residues. Indeed, phosphorylation of tyrosines accounts for only 1.8% of the 
total phosphoproteome (Olsen et al., 2006). Also, the low sequence coverage (57%) 
obtained in this experiment might have hampered the detection of phosphopeptides.  
 
To investigate how phosphorylation might influence the VAPB-PTPIP51 interaction, 
the identified serine and threonine residues in VAPB and PTPIP51 were mutated to 
either alanine to preclude phosphorylation, or to aspartate to mimic permanent 
phosphorylation. However, mutation of these sites did not affect binding of VAPB to 
PTPIP51 in immunoprecipitation assays. Interestingly, mutation of all 6 
phosphorylation sites in VAPB produced a marked shift in migration on SDS-PAGE. 
This might suggest that phosphorylation of some or all of these sites induces 
conformational changes to VAPB.  
 
The above results suggest that, at least on the sites manipulated here, phosphorylation of 
PTPIP51 or VAPB does not affect the VAPB-PTPIP51 interaction. However, recent 
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studies have identified other phosphorylation sites which were not investigated in this 
thesis (see www.phosphosite.org). These sites include residues T54, S149, S151, T152, 
S154, S155, S156, Y176 in PTPIP51 and residues S204, S206, S209, T214, S221 and 
T222 in VAPB. Therefore, the regulation of the VAPB-PTPIP51 interaction via 
phosphorylation cannot be excluded based solely on the data presented here. 
Interestingly, a recent study investigating the effects of PTPIP51 tyrosine 
phosphorylation on its interaction profile has found that phosphorylation of tyrosine 176 
increases the binding of PTPIP51 to PTP1B, 14-3-3β and Raf-1 (Brobeil et al., 2012). 
These results suggest that PTPIP51 phosphorylation on tyrosine residues might be an 
important target for modulating the interaction with binding partners. Further studies are 
needed to investigate the existence of additional tyrosine phosphorylation sites and 
whether they can regulate the interaction with VAPB.  
 
A further mechanism which might influence VAPB-PTPIP51 interactions involves the 
proteolytic cleavage of VAPB. Indeed, the MSP domain situated at the N-terminus of 
VAPB can be cleaved and secreted to modulate axon guidance and mitochondrial 
morphology (Gkogkas et al., 2011; Han et al., 2012; Tsuda et al., 2008). Since the N-
terminal domain of VAPB protrudes into the cytosol and is responsible for the 
interaction with PTPIP51, VAPB cleavage may also sever this connection and detach 
ER membranes from mitochondria.  
 
Therefore, it will be important to further investigate the mechanisms regulating VAPB 
proteolysis, its involvement in modulating VAPB-PTPIP51 interactions and ultimately 
the association of ER to mitochondria. Finally, considering that ER-mitochondria 
contact sites are disrupted in a number of neurodegenerative diseases (Area-Gomez et 
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al., 2012; Cali et al., 2012; Zampese et al., 2011) and see also results Chapter 4), 
deciphering the mechanisms that regulate VAPB-PTPIP51 control of ER-mitochondria 
















The studies in this thesis sought to gain insight into the role of VAPB and PTPIP51 in 
mediating ER-mitochondria associations. This was achieved by modulating VAPB 
and/or PTPIP51 expression and monitoring ER-mitochondria contacts by electron 
microscopy and confocal microscopy. Knockdown of VAPB or PTPIP51 using siRNA 
caused a decrease in ER-mitochondria associations, while overexpression of VAPB 
and/or PTPIP51 via transfection induced a significant increase in ER-mitochondria 
associations. The increase was particularly striking after co-expressing VAPB and 
PTPIP51 which caused ER and mitochondria to redistribute and form close associations 
over approximately 60% of the mitochondrial surface. These results, together with the 
finding that VAPB and PTPIP51 mediate Ca2+ transmission at the ER-mitochondria 
interface (De Vos et al., 2012) strongly support a role for VAPB and PTPIP51 in 
tethering ER to mitochondria. 
 
TDP-43 is a major component of pathological inclusions in most ALS and FTD cases 
(Arai et al., 2006; Neumann et al., 2006) and has also been linked to other 
neurodegenerative diseases (Chen-Plotkin et al., 2010). Moreover, mutations in 
TARDBP are responsible for a subset of familial ALS cases (Sreedharan et al., 2008). In 
this thesis, a variety of experimental approaches were used to explore the effect of wild-
type and ALS mutant TDP-43 on ER-mitochondria associations. This was initially 
achieved by overexpressing TDP-43 in cell lines and monitoring the ER-mitochondria 
contacts using electron and confocal microscopy. Interestingly, both wild-type and 
mutant TDP-43 reduced the amount of ER-mitochondria associations. Since diminished 
contact between the two organelles could be a consequence of reduced molecular tether 
expression, the levels of VAPB, PTPIP51 and mitofusin-2 were assessed in the presence 
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of wild-type and mutant TDP-43. However, TDP-43 did not change the expression of 
these proteins on immunoblots. 
 
TDP-43 toxicity could also target the interaction between VAPB and PTPIP51 to reduce 
ER-mitochondria contacts. Therefore, the VAPB-PTPIP51 interaction was investigated 
after overexpressing wild-type or four different ALS associated mutants of TDP-43 
(M337V, Q331K, A382T and G348C). Both wild-type and all TDP-43 mutants used 
decreased the VAPB-PTPIP51 interaction as assessed by proximity ligation and 
immunoprecipitation assays. To test whether other ALS-related insults target the 
VAPB-PTPIP51 interaction, immunoprecipitation experiments were also performed in 
the presence of wild-type or mutant FUS and SOD1. Similar to TDP-43, both wild-type 
and mutant FUS produced a decrease in the VAPB-PTPIP51 interaction. However, 
wild-type and mutant SOD1 did not have an effect on VAPB binding to PTPIP51. Thus, 
both TDP-43 and FUS disrupt the VAPB-PTPIP51 interaction and this could be the 
mechanism underlying the TDP-43-induced reduction in ER-mitochondria associations. 
 
It is likely that ER-mitochondria interactions are dynamic and change in response to 
physiological stimuli. To explore possible mechanisms regulating the VAPB-PTPIP51 
interactions, studies in this thesis sought to determine whether phosphorylation of 
VAPB and/or PTPIP51 influences their binding. This involved identifying 
phosphorylation sites via mass spectrometry. A number of serine and threonine 
phosphorylation sites in both VAPB and PTPIP51 were identified. Interestingly, 
treating the cells with the tyrosine phosphatase inhibitor pervanadate indicated that 
PTPIP51 was also phosphorylated on tyrosines, although no specific phosphotyrosine 
residues were identified. The VAPB-PTPIP51 interaction was investigated after 
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mutating these phosphorylated serine and threonine residues to preclude 
phosphorylation or to mimic permanent phosphorylation. However, none of the 
phosphorylation mutants altered VAPB binding to PTPIP51.  
 
6.2 Future directions 
The results presented in this thesis highlight VAPB and PTPIP51 as proteins that 
control ER-mitochondria associations and reveal a novel pathogenic mechanism for 
TDP-43 in disrupting ER-mitochondria contacts via the VAPB-PTPIP51 interaction. 
Some suggestions for future research directions are listed below. 
 
1. The effects of ALS-associated FUS and SOD1 on the VAPB-PTPIP51 interaction 
were investigated using biochemical approaches. The studies revealed that FUS but not 
SOD1 decreased binding of VAPB to PTPIP51. It would thus be useful to determine 
whether FUS and SOD1 affected ER-mitochondria association using the confocal and 
electron microscopy assays described in this thesis. Monitoring the ER-mitochondria 
associations in transgenic mouse models of TDP-43, FUS and SOD1 mediated ALS by 
electron microscopy would further support the data presented in this thesis. 
 
2. A mutation in VAPB involving a proline to serine substitution at position 56 (VAB 
P56S) causes familial ALS type-8 and this alters its binding to PTPIP51 (De Vos et al., 
2012). It would thus be interesting to compare ER-mitochondria associations in VAPB 
and VAPB P56S expressing cells using the assays described in this thesis. 
 
3. Alzheimer’s disease associated presenilins and Parkinson’s disease associated  
α-synuclein have been shown to increase ER-mitochondria associations (Area-Gomez 
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et al., 2012; Cali et al., 2012; Zampese et al., 2011). However, these results were 
generated using mainly confocal light microscopy studies. Using such light microscopy 
analyses to monitor ER-mitochondria interactions involving approximate 25 nm tethers 
has been criticized recently and shown to generate artefactual results (Cosson et al., 
2012). Indeed, a major review on MAM and ER-mitochondria interactions has 
suggested that electron microscopy analyses should be the preferred method for 
analyzing ER-mitochondria contacts (Rowland and Voeltz, 2012). The effects of 
presenilins and α-synuclein on ER-mitochondria contacts thus need to be re-evaluated 
using the sensitive electron microscopy assays described in this thesis. 
 
4. Expression of TDP-43 was shown to decrease ER-mitochondria interactions. Since 
these contacts regulate Ca2+ handling and Ca2+ exchange between ER and mitochondria, 
the effects of TDP-43 on cellular Ca2+ homeostasis need to be investigated. This would 
involve Fura-2 measurement of Ca2+ levels in appropriately transfected cells and also 
monitoring Ca2+ exchange between ER and mitochondria using approaches similar to 
those described in other studies (De Vos et al., 2012; Morotz et al., 2012). 
 
5. ER-mitochondria associations are believed to be involved in regulating ER stress and 
the UPR (Malhotra and Kaufman, 2011). It is also possible that ER-mitochondria 
associations impact upon the mitochondrial stress response (Malhotra and Kaufman, 
2011; Pellegrino et al., 2013). Moreover, VAPB is involved in mediating ER stress and 
the UPR (Amarilio et al., 2005; Chen et al., 2010; Gkogkas et al., 2008; Kanekura et al., 
2006; Langou et al., 2010; Suzuki et al., 2009). Thus, the effects of insults targeting 
VAPB-PTPIP51 interactions and ER-mitochondria associations (e.g. TDP-43) on ER 
and mitochondrial stress and the UPR should be investigated. 
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 6. Finally, the findings reported here and in other studies (Area-Gomez et al., 2012; Cali 
et al., 2012; Zampese et al., 2011) which show that insults associated with 
neurodegenerative diseases disrupt ER-mitochondria associations, highlight the ER-
mitochondria axis as a possible target for therapeutic intervention. Identifying small 
molecules that modulate the interaction may represent a new type of treatment for these 
diseases. The demonstration that VAPB and PTPIP51 represent some of the tethers that 
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